



Clinical Trials Appendix

Q3 2026 Results Update

30 October 2026



Pipeline at a glance

Across five focus therapy areas:

Oncology

BioPharmaceuticals

CVRM | R&I | Infectious Disease

Rare Disease

180

projects in our
development pipeline

20

new molecular entities
(NME) in our late-stage
pipeline

116

new molecular entities
(NME) or major lifecycle
management (LCM) projects
in Phase II or Phase III

45

regulatory approvals
in major markets
since FY 2025



Key upcoming pipeline catalysts: 2026 and 2027

Oncology BioPharmaceuticals Rare Disease

	H2 2026	H1 2027	H2 2027
Regulatory decision ^{1,2}	<p>Imfinzi muscle invasive bladder cancer (cis-ineligible/refusal) VOLGA</p> <p>Ultomiris IgAN I CAN (JP)</p> <p>Klygefa generalised myasthenia gravis PREVAIL (US, EU)</p>	<p>Calquence 1L MCL ECHO (CN)</p> <p>Enhertu high-risk HER2+ eBC DESTINY-Breast05 (JP)</p> <p>Baxfendy uncontrolled hypertension BaxHTN (EU, JP, CN)</p> <p>Breztri uncontrolled asthma KALOS/LOGOS (CN)</p> <p>tozorakimab COPD OBERON/TITANIA/PROSPERO</p> <p>Klygefa generalised myasthenia gravis PREVAIL (CN)</p> <p>Ultomiris IgAN I CAN (CN)</p> <p>efzimfotase alfa HPP MULBERRY/CHESTNUT/HICKORY</p>	<p>Calquence previously untreated CLL AMPLIFY (CN)</p> <p>Truqap PTEN-deficient mHSPC CAPItello-281 (CN)</p>
Key Phase III data readouts		<p>Datroway + Imfinzi NSQ/NSQ TROP2+ NSCLC (1L) AVANZAR</p> <p>Datroway +/- Tagrisso EGFRm NSCLC (2L) TROPION-Lung15</p> <p>Datroway NSQ/NSQ TROP2+ NSCLC (1L) TROPION-Lung07</p> <p>Imfinzi + oleclumab/monalizumab unresectable stage III NSCLC PACIFIC-9</p> <p>balci/dapa HF with renal impairment BalanceD-HF</p> <p>laroprovstat dyslipidemia AZURE-LDL/AZURE-HeFH</p> <p>laro/rosu dyslipidaemia with ASCVD/high risk of ASCVD reAZURE-PLUS</p> <p>zibo/dapa CKD and high proteinuria ZENITH</p> <p>Saphnelo lupus nephritis IRIS</p> <p>Saphnelo systemic sclerosis DAISY</p> <p>Saphnelo CLE LAVENDER</p>	<p>Datroway + Imfinzi TNBC with residual disease (post-neoadj) TROPION-Breast03</p> <p>Datroway + Imfinzi PD-L1 CPS ≥10 TNBC (1L) TROPION-Breast05</p> <p>Etcamah adj. switch HR+ HER2- early breast cancer CAMBRIA-1</p> <p>Imfinzi unresected Stage I/II NSCLC PACIFIC-4</p> <p>Truqap 1L early relapse/ET resistant advanced HR+ BC CAPItello-292</p> <p>puxi-sam B7-H4+ endometrial cancer (2-3L) Bluestar-Endometrial01</p> <p>rilvegostomig adj. BTC with curative intent ARTEMIDE-Biliary01</p> <p>saruparib HRRm and non-HRRm CSPC evoPAR-Prostate01</p> <p>volrustomig high-risk locally advanced cervical cancer eVOLVE-Cervical</p> <p>Baxfendy primary aldosteronism BaxPA</p> <p>laro/rosu Tx-naïve elevated LDL-C reAZURE-NAIVE</p> <p>tozorakimab LRTD TILIA</p>

Key upcoming pipeline catalysts are defined by a threshold of non-risk adjusted global peak year revenue expectations as of 27 July 2026.

1. Regulatory decision includes programmes under review in a major market. 2. Inclusion dependent on status of regulatory submission and/or submission acceptance in regions in which submission acceptance is granted.

As of 30 October 2026.

Appendix: [Glossary](#).



Clinical Trials Appendix: selected highlights

	Oncology	BioPharmaceuticals	Rare Disease
Approved medicines Key LCM	<i>Calquence</i>	<i>Airsupra</i>	<i>Klygefa</i> (gefurulimab)
	<i>Datroway</i>	<i>Baxfendy</i> (baxdrostat)	<i>Ultomiris</i>
	<i>Enhertu</i>	<i>Breztri</i>	
	<i>Etcamah</i> (camizestrant)	<i>Fasenra</i>	
	<i>Imfinzi/Imjudo</i>	<i>Tezspire</i>	
	<i>Lynparza</i>	<i>Saphnelo</i>	
	<i>Tagrisso</i>		
	<i>Truqap</i>		
Next-wave pipeline Registrational trials ongoing	puxitatug samrotecan B7-H4 TOP1i ADC	balcinrenone/dapagliflozin MR antagonist/modulator / SGLT2	clirarnitug TTR depleter
	rilegostomig PD-1/TIGIT bispecific mAb	baxdrostat/dapagliflozin ASI/SGLT2	efzimfotase alfa enzyme replacement therapy
	saruparib PARP1 inhibitor	elecoglipron oral GLP-1	eneboparatide PTH 1 agonist
	sonesitatug vedotin Claudin18.2 MMAE ADC	laroprovstat oral PSCK9	
	surovatamig CD19/CD3 TCE	laroprovstat/rosuvastatin oral PSCK9/HMG-CoA reductase inhibitor	
	torvutatug samrotecan FRα TOP1i ADC	zibotentan/dapagliflozin ETA receptor antagonist/SGLT2	
	volrustomig PD-1/CTLA-4 bispecific mAb	tozorakimab IL-33 ligand mAb	
	(225Ac) zadavotide guraxetan PSMA RC		
	AZD0120 BCMA/CD19 CAR-T		



Project movements since Q2 2026 update

New to Phase I	New to pivotal trial		New to registration
<p><u>NME</u> AZD0543 long-acting hMPV neutralising mAb prevention of hMPV respiratory disease</p> <p>AZD4045 BCMA UEC CAR-T multiple myeloma</p>	<p><u>NME</u> lenbelintide (AZD6234) selective amylin receptor agonist chronic weight management in overweight or obesity</p> <p><u>Additional indication</u> AZD0120 DURGA-6 CD19/BCMA CAR-T newly diagnosed multiple myeloma in transplant eligible patients</p> <p>balcinrenone/dapagliflozin MR antagonist/modulator + SGLT2 inhibitor advanced CKD</p> <p>elecglipton oral GLP-1 receptor agonist CKD</p> <p>elecglipton oral GLP-1 receptor agonist HFpEF</p> <p>elecglipton/dapagliflozin FDC oral GLP-1 receptor agonist / SGLT2 inhibitor CKD</p>	<p><u>Additional indication</u> elecglipton/dapagliflozin FDC oral GLP-1 receptor agonist / SGLT2 inhibitor HFpEF</p> <p>laroprovstat/rosuvastatin PCSK9 inhibitor / HMG-CoA reductase inhibitor dyslipidaemia</p> <p>saruparib + ADT +ARPI EvoPAR-Prostate05 PARP1 inhibitor + ADT + ARPI HRRm/non-HRRm mHSPC after Docetaxel or 177Lu-PSMA therapy</p> <p>torvutatug samrotecan + bevacizumab TREVI-OC-02 anti-FRα TOP1i ADC + VEGFi 1L HRD- adv ovarian cancer</p> <p>torvutatug samrotecan +/- bevacizumab TREVI-OC-03 anti-FRα TOP1i ADC +/- VEGFi 2L Cons PSR ovarian cancer</p>	<p><u>Lifecycle Management</u> Imfinzi + EV +/- Imjudo VOLGA PD-L1 mAb + nectin-4 targeting MMAE ADC +/- CTLA-4 mAb muscle invasive bladder cancer (cis-ineligible/refusal)</p> <p>Ultomiris paediatric anti-complement C5 mAb haematopoietic stem cell transplant-associated thrombotic microangiopathy</p>
New to Phase II			



Project movements since Q2 2026 update

Removed from Phase I	Removed from Phase II	Removed from Phase III	Approved /removed from registration
<p><u>NME</u> AZD2962 IRAK4 inhibitor haematological malignancies</p> <p>AZD8359 STEAP2 T-cell engager prostate cancer</p> <p>AZD8421 CDK2 inhibitor solid tumours</p> <p>AZD9750 AR PROTAC prostate cancer</p>		<p><u>Additional indication</u> volrustomig eVOLVE-Lung02 PD-1/CTLA-4 bispecific mAb 1L metastatic NSCLC</p> <p><u>Lifecycle management</u> Etcamah + palbociclib SERENA-4 ngSERD + CDK4/6i 1L HR+ HER2-advanced breast cancer</p> <p>Imfinzi +/- bevacizumab EMERALD-2 PD-L1 mAb +/- VEGFi adjuvant HCC</p> <p>Ultomiris AWAKE anti-complement C5 mAb delayed graft function</p>	<p><u>NME</u> Amlypave (anselamimab) CARES fibril-reactive mAb amyloid kappa light-chain amyloidosis</p> <p>Klygefa (gefurulimab) PREVAIL novel anti-C5, dual binding, nanobody generalised myasthenia gravis</p> <p><u>Lifecycle management</u> Ultomiris I CAN anti-complement C5 mAb immunoglobulin A nephropathy</p>



Q3 2026 Oncology new molecular entity¹ pipeline

Phase I 19 New Molecular Entities		Phase II 15 New Molecular Entities		Phase III 26 New Molecular Entities		
surovatamig CD19/CD3 TCE r/r B-cell non-Hodgkin lymphoma	AZD5492 CD20 TITAN T-cell engager haematology	IPH5201 + <i>Imfinzi</i> # CD39 mAb + PD-L1 mAb neoadjuvant/adjuvant NSCLC	volrustomig CANTOR PD-1/CTLA-4 bispecific mAb colorectal cancer (mCRC)	<i>Imfinzi</i> +/- oclumab +/- monalizumab PACIFIC-9# PD-L1 mAb +/- CD73 mAb +/- NKG2A mAb unresectable stage III NSCLC	torvutatug samrotecan +/- bevacizumab TREVI-OC-03 anti-FRα TOP1i ADC +/- VEGFi 2L Cons PSR ovarian cancer	saruparib + <i>Etcamah</i> EvoPAR-Breast01 PARP1i + ngSERD BRCA/PALB2m HR+ HER2- metastatic breast cancer
surovatamig SOUNDTRACK-E CD19/CD3 TCE mature B-cell malignancies	AZD5863 CLDN18.2/CD3 bispecific antibody solid tumours	puxitatug samrotecan B7-H4 TOP1i ADC solid tumours	volrustomig eVOLVE-01 PD-1/CTLA-4 bispecific mAb NSCLC	rilvegostomig ARTEMIDE-Lung03# PD-1/TIGIT bispecific mAb 1L PD-L1 TC ≥1% NSQ NSCLC	volrustomig eVOLVE-Cervical PD-1/CTLA-4 bispecific mAb high-risk locally advanced cervical cancer	sonesitatug vedotin + CTx +/- rilvegostomig CLARITY-Gastric02 CLDN18.2 MMAE ADC + CTx +/- PD-1/TIGIT bispecific mAb 1L CLDN18.2+ gastric cancer
AZD0240 KRAS G12D armoured TCR-T solid tumours	AZD6621 STEAP2 T-cell engager prostate cancer	rilvegostomig ARTEMIDE-01# PD-1/TIGIT bispecific mAb solid tumours	volrustomig eVOLVE-02 PD-1/CTLA-4 bispecific mAb cervical cancer, HNSCC, esophageal squamous cell carcinoma	rilvegostomig + CTx ARTEMIDE-Biliary01# PD-1/TIGIT bispecific mAb + CTx adjuvant biliary tract cancer	volrustomig eVOLVE-Meso PD-1/CTLA-4 bispecific mAb 1L unresectable malignant pleural mesothelioma	surovatamig SOUNDTRACK-D2 CD19/CD3 TCE 1L elderly DLBCL
AZD0516 STEAP2 TOP1i ADC prostate cancer	AZD6750 CD8-guided IL2 solid tumours	saruparib PARP1 inhibitor solid tumours	AZD0120 DURGA-1 CD19/BCMA CAR-T multiple myeloma	rilvegostomig + <i>Enhertu</i> ARTEMIDE-Gastric01# PD-1/TIGIT bispecific mAb + HER2 TOP1i ADC 1L HER2+ gastric cancer	AZD0120 DURGA-4 CD19/BCMA CAR-T relapsed/refractory multiple myeloma	torvutatug samrotecan + bevacizumab TREVI-OC-02 anti-FRα TOP1i ADC + VEGFi 1L HRD-adv ovarian cancer
AZD0754 STEAP2 CAR-T prostate cancer	AZD7003 GPC3 CAR-T hepatocellular carcinoma/squamous NSCLC	sonesitatug vedotin CLDN18.2 MMAE ADC solid tumours	AZD0305 GPC5D MMAE ADC r/r multiple myeloma	rilvegostomig ARTEMIDE-Lung04# PD-1/TIGIT bispecific mAb 1L PD-L1 ≥50% NSCLC	puxitatug samrotecan Bluestar-Endometrial01 B7-H4 TOP1i ADC 2-3L B7-H4+ endometrial cancer	torvutatug samrotecan TREVI-OC-01 anti-FRα TOP1i ADC 2-4L PRR ovarian cancer
AZD2284 STEAP2 actinium RC prostate cancer	AZD9793 GPC3 TITAN T-cell engager solid tumours	surovatamig SOUNDTRACK-B CD19/CD3 TCE B-cell non-Hodgkin lymphoma	AZD3470 PRMT5i classic Hodgkin lymphoma, solid tumours	saruparib + ADT + ARPI EvoPAR-Prostate05 PARP1 inhibitor + ADT + ARPI HRRm/non-HRRm mHSPC after Docetaxel or 177Lu-PSMA therapy	rilvegostomig + bevacizumab +/- <i>Imjudo</i> ARTEMIDE-HCC01# PD-1/TIGIT bispecific mAb + VEGFi +/- CTLA-4 mAb 1L HCC	volrustomig eVOLVE-HNSCC PD-1/CTLA-4 bispecific mAb unresected locally advanced HNSCC
AZD3632 MENIN inhibitor haematological malignancies	NT-112 KRAS G12D armoured TCR-T solid tumours	surovatamig SYRUS CD19/CD3 TCE B-cell acute lymphoblastic leukaemia	AZD9574 PARP1 inhibitor advanced solid malignancies	saruparib + NHA EvoPAR-Prostate01 PARP1i + NHA HRRm/non-HRRm mCSPC	rilvegostomig + CTx ARTEMIDE-Lung02# PD-1/TIGIT bispecific mAb + CTx 1L PD-L1 TC ≥1% SQ NSCLC	zadavotide guraxetan (AZD2265) VECTRA-01 PSMA actinium RC prostate cancer (mCRPC)
AZD4045 BCMA UEC CAR-T multiple myeloma	NT-175 TP53 R175H armoured TCR-T solid tumours	volrustomig PD-1/CTLA-4 bispecific mAb solid tumours		sonesitatug vedotin CLARITY-Gastric01 CLDN18.2 MMAE ADC 2L+ CLDN18.2+ gastric cancer	rilvegostomig ARTEMIDE-Biliary02# PD-1/TIGIT bispecific mAb metastatic biliary tract cancer	AZD0120 DURGA-6 CD19/BCMA CAR-T newly diagnosed multiple myeloma in transplant eligible patients
AZD4512 CD22 TOP1i ADC r/r B-cell non-Hodgkin lymphoma	JAB-23E73# pan-KRAS inhibitor solid tumours			surovatamig SOUNDTRACK-F1 CD19/CD3 TCE follicular lymphoma	saruparib + ADT +/- abiraterone EvoPAR-Prostate02 PARP1i + ADT +/- NHA localised/locally advanced BRCAm prostate cancer	
AZD4956 POLQ inhibitor solid tumours						

Under review
0 New Molecular Entities

Phase progressions based on first subject in achievement
 1. Includes additional indications for assets where the lead is not yet launched
 # Partnered and/or in collaboration
 As of 30 October 2026.
 Appendix: [Glossary](#).



Q3 2026 Oncology lifecycle management¹ pipeline

Phase I	Phase II	Phase III	Under review		
0 Projects	2 Projects	28 Projects	2 Projects		
	Imfinzi combinations NeoCOAST-2# PD-L1 mAb + novel ONC therapies resectable NSCLC	Calquence + R-CHOP ESCALADE BTKi + R-CHOP 1L DLBCL	Datroway +/-rilvegostomig TROPION-Urothelial04# TROP2 TOP1i ADC +/- PD-1/TIGIT bispecific mAb non-pCR adjuvant MIUC	Datroway TROPION-Lung17# TROP2 TOP1i ADC TROP2 QCS NMR+ non-squamous NSCLC 2L	Enhertu DESTINY-PanTumor03 (China)# HER2 TOP1i ADC HER2 expressing solid tumours
	Tagrisso combinations ORCHARD# EGFR TKI + multiple novel ONC therapies 2L EGFRm osimertinib-resistant NSCLC	Datroway + Imfinzi + CTx AVANZAR# TROP2 TOP1i ADC + PD-L1 mAb + CTx 1L NSQ/NSQ TROP2+ NSCLC	Imfinzi + Imjudo + TACE +/- lenvatinib EMERALD-3 PD-L1 mAb+CTLA4 mAb +/- chemoembolisation +VEGFi locoregional HCC	Imfinzi + SBRT PACIFIC-4 PD-L1 mAb + SBRT stage I/II NSCLC	Imfinzi + EV +/- Imjudo VOLGA PD-L1 mAb + nectin-4 targeting MMAE ADC +/- CTLA-4 mAb muscle invasive bladder cancer (cis-ineligible/refusal)
		Datroway + Imfinzi TROPION-Breast05# TROP2 TOP1i ADC + PD-L1 mAb 1L PD-L1 CPS ≥10 TNBC	Enhertu + rilvegostomig/pembrolizumab DESTINY-Endometrial01# HER2 TOP1i ADC + PD-1/TIGIT bispecific mAb/PD-1 mAb 1L HER2+ pMMR endometrial cancer	Datroway + Imfinzi TROPION-Breast04# TROP2 TOP1i ADC + PD-L1 mAb neo/adjuvant TNBC or HR-low/HER2- breast cancer	
		Datroway + pembrolizumab TROPION-Lung08# TROP2 TOP1i ADC + PD-1 mAb 1L PD-L1 TPS ≥50% NSQ NSCLC	Imfinzi + VEGF + TACE EMERALD-1 PD-L1 mAb +VEGFi +TACE locoregional HCC	Datroway + pembrolizumab TROPION-Lung07# TROP2 TOP1i ADC + PD-1 mAb 1L PD-L1 <50% NSQ NSCLC	
		Datroway + Tagrisso TROPION-Lung14# TROP2 TOP1i ADC + EGFR TKI 1L EGFRm NSCLC	Enhertu DESTINY-Lung04# HER2 TOP1i ADC 1L HER2m NSCLC	Tagrisso +/- CTx NeoADAURA EGFR TKI +/- CTx neoadjuvant stage II/III resectable EGFRm NSCLC	
		Datroway +/- Imfinzi TROPION-Breast03# TROP2 TOP1i ADC +/- PD-L1 mAb post-neoadjuvant TNBC with residual disease	Lynparza MONO-OLA1# PARPi 1L BRCAwt ovarian cancer	Datroway + rilvegostomig TROPION-Lung10# TROP2 TOP1i ADC + PD-1/TIGIT bispecific mAb 1L PD-L1 ≥50% NSQ NSCLC	
		Enhertu + rilvegostomig DESTINY-BTC01# HER2 TOP1i ADC + PD-1/TIGIT bispecific mAb 1L HER2+ biliary tract cancer	Tagrisso ADAURA2 EGFR TKI EGFRm NSCLC stage Ia2-Ia3 following complete tumour resection	Truqap + Faslodex + palbociclib CAPItello-292 AKTi + SERD + CDK4/6 1L early relapse/ET resistant advanced HR+ breast cancer	
		Enhertu DESTINY-Endometrial02# HER2 TOP1i ADC adjuvant endometrial cancer	Etcamah CAMBRIA-1 ngSERD adjuvant switch HR+ HER2- early breast cancer	Datroway + Tagrisso TROPION-Lung15# TROP2 TOP1i ADC + EGFR TKI 2L EGFRm NSCLC	
		Etcamah +/- abemaciclib CAMBRIA-2 ngSERD + CDK4/6i adjuvant HR+ HER2- early breast cancer	Imfinzi + Imjudo + SoC NILE PD-L1 mAb + CTLA-4 mAb + SoC 1L urothelial cancer		
		Imfinzi + CRT KUNLUN PD-L1 mAb + CRT locally advanced ESCC	Tagrisso + Orpathys SAFFRON# EGFR TKI +METi advanced EGFRm NSCLC		

Phase progressions based on first subject in achievement

1. Includes significant lifecycle management projects and parallel indications for assets beyond Phase III

Partnered and/or in collaboration

As of 30 October 2026.

Appendix: [Glossary](#).



Q3 2026 BioPharmaceuticals new molecular entity¹ pipeline

Phase I

13 New Molecular Entities

surovatamig
CD19/CD3 TCE B-cell driven
autoimmune disease

AZD3974
anti-inflammatory and anti-fibrotic
mechanism cirrhosis

AZD0120 AURORA
CD19/BCMA CAR-T autoimmune
diseases

AZD4063
PLN R14del dilated cardiomyopathy

AZD0120 PHOENIX
CD19/BCMA CAR-T systemic lupus
erythematosus

AZD4248
NNMT inhibitor cardiorenal disease

AZD0120 ZENITH
CD19/BCMA CAR-T multiple sclerosis

AZD4916
healthy volunteers

AZD0543
long-acting hMPV neutralising mAb
prevention of hMPV respiratory disease

AZD4954
Lp(a) inhibitor dyslipidaemia

AZD1043
ActRII mAb obesity

AZD5492
CD20 TITAN T-cell engager systemic
lupus erythematosus

AZD1613
PAPPA-1 mAb ADPKD

Phase II

15 New Molecular Entities

opemalirsén
podocyte health nephropathy

AZD5148
anti-clostridioides difficile TcdB mAb
reduction of C.diff recurrence

sunakiment (AZD8630)#
inhaled TSLP Fab asthma

AZD5462#
RXFP1 agonist heart failure

surovatamig CLEAR-AbKD
CD19/CD3 TCE antibody-mediated
kidney disease

AZD6793
IRAK4 inhibitor COPD

tozorakimab
IL-33 mAb asthma

AZD7760
mAb combination targeting S aureus
virulence factors prevention of Staph
aureus infection

AZD0292
pseudomonas Psl-PcrV bispecific mAb
bronchiectasis

AZD7798
humanised monoclonal antibody
targets T-cells subset Crohn's disease

AZD1163
anti-PAD2/4 bispecific antibody
rheumatoid arthritis

AZD8965
inhibition of arginase enzyme idiopathic
pulmonary fibrosis

AZD2389
anti-fibrotic mechanism metabolic
dysfunction-associated steatohepatitis

AZD9550 + AZD6234
GLP-1R glucagon dual agonist +
selective amylin agonist obesity

AZD4144
NLRP3 cardiorenal disease

Phase III

14 New Molecular Entities

balcinrenone/dapagliflozin
MR antagonist/modulator + SGLT2
inhibitor heart failure with CKD

elecglipton/dapagliflozin FDC
oral GLP-1 receptor agonist / SGLT2
inhibitor HFpEF

balcinrenone/dapagliflozin
MR antagonist/modulator + SGLT2
inhibitor advanced CKD

elecglipton/dapagliflozin FDC
oral GLP-1 receptor agonist / SGLT2
inhibitor CKD

elecglipton
oral GLP-1 receptor agonist weight
management

laroprovstat AZURE
PCSK9 dyslipidaemia

elecglipton
oral GLP-1 receptor agonist T2D

laroprovstat/rosuvastatin
PCSK9 inhibitor / HMG-CoA reductase
inhibitor dyslipidaemia

elecglipton
oral GLP-1 receptor agonist HFpEF

lenbelintide (AZD6234)
selective amylin receptor agonist
chronic weight management in
overweight or obesity

elecglipton
oral GLP-1 receptor agonist CKD

tozorakimab TILIA
IL-33 mAb severe viral lower respiratory
tract disease

elecglipton/dapagliflozin FDC
oral GLP-1 receptor agonist / SGLT2
inhibitor T2D

zibotentan/dapagliflozin
endothelin A receptor
antagonist/SGLT2i CKD with high
proteinuria

Under review

1 New Molecular Entity

tozorakimab OBERON TITANIA
PROSPERO MIRANDA
IL-33 mAb COPD

Phase progressions based on first subject in achievement

1. Includes additional indications for assets where the lead is not yet launched

Partnered and/or in collaboration

As of 30 October 2026.

Appendix: [Glossary](#).



Q3 2026 BioPharmaceuticals lifecycle management¹ pipeline

Phase I 0 Projects	Phase II 0 Projects	Phase III 11 Projects	Under review 0 Projects
		Baxfendy BaxPA aldosterone synthase inhibitor primary aldosteronism	Saphnelo JASMINE# type I IFN receptor mAb myositis
		Baxfendy/dapagliflozin aldosterone synthase inhibitor and reversible inhibitor of SGLT2 CKD	Saphnelo LAVENDER# type I IFN receptor mAb cutaneous lupus erythematosus
		Baxfendy/dapagliflozin aldosterone synthase inhibitor and reversible inhibitor of SGLT2 prevention of heart failure	Tezspire CROSSING# TSLP mAb eosinophilic esophagitis
		Breztri/Trixeo THARROS# LABA/LAMA/ICS cardiopulmonary outcomes trial in COPD	Tezspire EMBARK, JOURNEY# TSLP mAb chronic obstructive pulmonary disease
		Saphnelo DAISY# type I IFN receptor mAb systemic sclerosis	Wainua# ligand-conjugated antisense ATTR-cardiomyopathy
		Saphnelo IRIS# type I IFN receptor mAb lupus nephritis	

Phase progressions based on first subject in achievement

1. Includes significant lifecycle management projects and parallel indications for assets beyond Phase III

Partnered and/or in collaboration

As of 30 October 2026.

Appendix: [Glossary](#).



Q3 2026 Rare Disease pipeline¹

Phase I 5 Projects	Phase II 3 Projects	Phase III 2 Projects	Under review 2 Projects
ALXN2080 oral factor D healthy participants	cevolisiran (ALXN2030) CONCORD siRNA targeting complement C3 antibody mediated rejection	cliramitug DepleTTR-CM# TTR deleter transthyretin amyloid cardiomyopathy	efzimfotase alfa Hickory (301), Mulberry (305), Chestnut (303) next generation TNSALP ERT hypophosphatasia
ALXN2230 healthy participants	tarperprumig I TRANSCEND anti-properdin (complement factor P), dual-binding, nanobody ANCA-associated vasculitis	eneboparatide CALYPSO parathyroid hormone receptor 1 hypoparathyroidism	Ultomiris anti-complement C5 mAb haematopoietic stem cell transplant-associated thrombotic microangiopathy
ALXN2350 DCMRestore AAV gene therapy BAG3-associated dilated cardiomyopathy	ALXN1920 AUTUMN kidney-targeted factor H fusion protein primary membranous nephropathy		
AZD0120 ALACRITY CD19/BCMA CAR-T amyloid light-chain amyloidosis			
AZD1390 ATM inhibitor glioblastoma			

Phase progressions based on first subject in achievement
1. Includes new molecular entities and significant lifecycle management projects
Partnered and/or in collaboration
As of 30 October 2026.
Appendix: [Glossary](#).



Active designations in our pipeline

6	3	12	3	18
Priority Review	Breakthrough / PRIME ¹ / Sakigake ²	Fast Track	Qualified Infectious Disease product	Orphan
tozorakimab COPD (US)	AZD0292 Psl-PcrV N3YNCFBE (EU)	AZD0292 Psl-PcrV N3YNCFBE (US)	AZD0292 Psl-PcrV N3YNCFBE (US)	<i>Saphnelo</i> myositis JASMINE (US)
<i>Enhertu</i> HER2 expressing solid tumours DESTINY-PanTumor03 (CN)	<i>Tezspire</i> COPD EMBARK, JOURNEY (US)	AZD4144 acute kidney injury (US)	AZD5148 C. difficile mAb - Prevention of Recurrence (US)	<i>Saphnelo</i> systemic sclerosis DAISY (US)
<i>Imfinzi</i> + EV +/- <i>Imjudo</i> MIBC Cis-Ineligible VOLGA (US)	tozorakimab severe viral LRTD TILIA (CN)	AZD7760 Staph aureus mAbs-Hemodialysis (US)	AZD7760 prevention of Staph aureus infection (US)	<i>Saphnelo</i> systemic sclerosis DAISY (JP)
clirimitug DepleTTR-CM (JP)		balci/dapa HF with CKD (US)		<i>Tezspire</i> EoE CROSSING (US)
efzimfotase alfa s.c. HPP (US)		opemalirsens AMKD (US)		surovatamig + R FL 1L SOUNDTRACK-F1 (EU)
<i>Ultomiris</i> immunoglobulin A nephropathy I CAN (CN)		tozorakimab COPD (US)		surovatamig rr ALL 3L+ SYRUS (US)
		tozorakimab severe viral LRTD (US)		surovatamig rr ALL 3L+ SYRUS (EU)
		<i>Wainua</i> ATTR-Cardiomyopathy (US)		AZD1390 Glioblastoma (US)
		<i>Orpathys</i> + <i>Tagrisso</i> NSCLC SAFFRON (US)		clirimitug DepleTTR-CM (US)
		clirimitug DepleTTR-CM (US)		clirimitug DepleTTR-CM (EU)
		efzimfotase alfa s.c. HPP (US)		clirimitug DepleTTR-CM (JP)
		eneboparatide HypoPT (US)		efzimfotase alfa s.c. HPP (US)
				efzimfotase alfa s.c. HPP (EU)
				efzimfotase alfa s.c. HPP (JP)
				eneboparatide HypoPT (EU)
				eneboparatide HypoPT (US)
				<i>Ultomiris</i> HSCT-TMA ALXN1210-TM-313 (US)
				<i>Ultomiris</i> HSCT-TMA ALXN1210-TM-313 (JP)

ACCELERATED APPROVAL, these regulations allowed medicines for serious conditions that addressed an unmet medical need to be approved based on a surrogate endpoint

BREAKTHROUGH DESIGNATION is a process designed to expedite the development and review of medicines which may demonstrate substantial improvement over available therapy. 1PRIME is a scheme launched by the EMA to enhance support for the development of medicines that target an unmet medical need. 2SAKIGAKE is aimed at early introduction of innovative medicines, medical devices, etc. that are initially developed in Japan

FAST TRACK is a process designed to facilitate the development, and expedite the review of medicines to treat serious conditions and fill an unmet medical need

PRIORITY REVIEW DESIGNATION is the US FDA's goal to take action on an application within 6 months

ORPHAN DRUG DESIGNATION, intended for treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 patients in the US, or that affect more than 200,000 patients but are not expected to recover the costs of developing and marketing a treatment drug

QUALIFIED INFECTIOUS DISEASE PRODUCT designation confers particular advantages, including priority review by the US Food and Drug Administration (FDA) and fast-track designation, which can accelerate development of a product, as well as an additional five years' market exclusivity if a product is licensed.



Oncology




BioPharmaceuticals



Rare Disease





Oncology

Approved medicines
and late-stage pipeline



Calquence (BTK inhibitor)

Blood cancers

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III AMPLIFY (ACE-CL-311) NCT03836261	Previously untreated CLL	981	<ul style="list-style-type: none"> Arm 1: <i>Calquence</i> + venetoclax Arm 2: <i>Calquence</i> + venetoclax + obinutuzumab Arm 3: FCR or BR 	<ul style="list-style-type: none"> Primary endpoint: PFS (IRC) (Arm 1 vs. Arm 3) Secondary endpoints: PFS (IRC) (Arm 2 vs. Arm 3) and PFS (INV) (Arm 1 vs. Arm 3; Arm 2 vs. Arm 3) 	<ul style="list-style-type: none"> FPCD: Q1 2019 LPCD: Q3 2023 Data readout: Q3 2024 Primary endpoint met
Phase III ECHO (ACE-LY-308) NCT02972840	Previously untreated MCL	634	<ul style="list-style-type: none"> Arm 1: <i>Calquence</i> + bendamustine + rituximab Arm 2: bendamustine + rituximab 	<ul style="list-style-type: none"> Primary endpoint: PFS by Lugano Classification for NHL Secondary endpoints: IA, PFS, ORR, DoR, time to response and OS 	<ul style="list-style-type: none"> FPCD: Q2 2017 LPCD: Q1 2023 Data readout: Q2 2024 Primary endpoint met
Phase III ESCALADE NCT04529772	DLBCL	600	<ul style="list-style-type: none"> Arm 1: <i>Calquence</i> + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone Arm 2: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone 	<ul style="list-style-type: none"> Primary endpoint: PFS 	<ul style="list-style-type: none"> FPCD: Q1 2021 Data anticipated: H1 2027
Phase II TrAVeRse NCT05951959	Treatment-naïve MCL	100	<ul style="list-style-type: none"> Open-label, single-arm trial <i>Calquence</i> + venetoclax + rituximab 	<ul style="list-style-type: none"> Primary endpoint: MRD-negative CR at end of induction 	<ul style="list-style-type: none"> FPCD: Q1 2024 Data anticipated: >2027



Datroway (datopotamab deruxtecan, TROP2 ADC)

Breast cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase III TROPION-Breast02 NCT05374512 Partnered (Daiichi Sankyo)	Locally recurrent inoperable or metastatic TNBC not candidates for IO	644	<ul style="list-style-type: none"> Open-label, randomised trial Arm 1: <i>Datroway</i> Arm 2: investigator's choice of chemotherapy (paclitaxel, nab-paclitaxel, carboplatin, capecitabine, eribulin mesylate) 	<ul style="list-style-type: none"> Primary endpoints: PFS (BICR) and OS Secondary endpoints: PFS (INV), ORR, DoR, PK parameters and ADA 	<ul style="list-style-type: none"> FPCD: Q2 2022 LPCD: Q2 2024 Data readout: Q4 2025 Dual primary endpoints met
Phase III TROPION-Breast03 NCT05629585 Partnered (Daiichi Sankyo)	Stage I-III TNBC without pathological complete response following neoadjuvant therapy	1174	<ul style="list-style-type: none"> Open-label, randomised trial Arm 1: <i>Datroway</i> + <i>Imfinzi</i> Arm 2: <i>Datroway</i> Arm 3: investigator's choice of therapy (capecitabine, pembrolizumab, or capecitabine + pembrolizumab) 	<ul style="list-style-type: none"> Primary endpoint: iDFS Secondary endpoints: DDFS, OS, PK parameters and ADA 	<ul style="list-style-type: none"> FPCD: Q4 2022 LPCD: Q4 2024 Data anticipated: H2 2027
Phase III TROPION-Breast04 NCT06112379 Partnered (Daiichi Sankyo)	Perioperative triple-negative or HR-low/HER2-negative breast cancer	1902	<ul style="list-style-type: none"> Open-label, randomised Arm 1: <i>Datroway</i> + <i>Imfinzi</i> Arm 2: pembrolizumab + chemotherapy 	<ul style="list-style-type: none"> Primary endpoint: EFS Secondary endpoints: pCR, OS, DDFS and safety 	<ul style="list-style-type: none"> FPCD: Q4 2023 LPCD: Q3 2025 Data anticipated: >2027
Phase III TROPION-Breast05 NCT06103864 Partnered (Daiichi Sankyo)	Patients with PD-L1-positive locally recurrent inoperable or metastatic TNBC	625	<ul style="list-style-type: none"> Open-label, randomised Arm 1: <i>Datroway</i> + <i>Imfinzi</i> Arm 2: investigator's choice of chemotherapy in combination with pembrolizumab (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin) Arm 3: <i>Datroway</i> 	<ul style="list-style-type: none"> Primary endpoint: PFS (BICR) Secondary endpoints: OS, PFS (INV), ORR, DoR, DCR and safety 	<ul style="list-style-type: none"> FPCD: Q4 2023 Data anticipated: H2 2027



Datroway (datopotamab deruxtecan, TROP2 ADC)

NSCLC

Trial	Population	Patients	Design	Endpoints	Status
Phase III AVANZAR NCT05687266	1L locally advanced/metastatic NSCLC without actionable genomic alterations	1350	<ul style="list-style-type: none"> Randomised, open-label Arm 1: <i>Datroway</i> + <i>Imfinzi</i> + platinum-based CTx Arm 2: pembrolizumab + platinum-based CTx 	<ul style="list-style-type: none"> Primary endpoints: PFS and OS in NSQ TROP2 NMR+ and NSQ ITT 	<ul style="list-style-type: none"> FPCD: Q1 2023 Data anticipated: H1 2027
Phase III TROPION-Lung07 NCT05555732 Partnered (Daiichi Sankyo)	1L PD-L1 TC <50% locally advanced/metastatic NSCLC without actionable genomic alterations	1170	<ul style="list-style-type: none"> Randomised, open-label Arm 1: <i>Datroway</i> + pembrolizumab + platinum-based CTx Arm 2: <i>Datroway</i> + pembrolizumab Arm 3: pembrolizumab + pemetrexed + platinum-based CTx 	<ul style="list-style-type: none"> Primary endpoints: PFS and OS in NSQ ITT and NSQ TROP2 NMR+ for both doublet and triplet 	<ul style="list-style-type: none"> FPCD: Q1 2023 LPCD: Q4 2025 Data anticipated: H1 2027
Phase III TROPION-Lung08 NCT05215340 Partnered (Daiichi Sankyo)	1L PD-L1 TC ≥50% locally advanced/metastatic non-squamous NSCLC without actionable genomic alterations	740	<ul style="list-style-type: none"> Randomised, open-label Arm 1: <i>Datroway</i> + pembrolizumab Arm 2: pembrolizumab 	<ul style="list-style-type: none"> Primary endpoints: PFS and OS Key secondary endpoints: PFS and OS in TROP2 NMR+ population 	<ul style="list-style-type: none"> FPCD: Q1 2022 Data anticipated: H1 2027
Phase III TROPION-Lung10 NCT06357533 Partnered (Daiichi Sankyo)	1L PD-L1 TC ≥50% locally advanced/metastatic non-squamous NSCLC without actionable genomic alterations	675	<ul style="list-style-type: none"> Randomised, open-label Arm 1: <i>Datroway</i> + rilvegostomig Arm 2: rilvegostomig Arm 3: pembrolizumab 	<ul style="list-style-type: none"> Primary endpoints: PFS and OS in TROP2 NMR+ Secondary endpoints: PFS and OS in the ITT population, ORR, DoR, PFS2, PRO 	<ul style="list-style-type: none"> FPCD: Q2 2024 Data anticipated: >2027
Phase III TROPION-Lung14 NCT06350097 Partnered (Daichii Sankyo)	1L <i>EGFR</i> m locally advanced/metastatic NSCLC	582	<ul style="list-style-type: none"> Randomised, open-label study Arm 1: <i>Tagrisso</i> + <i>Datroway</i> Arm 2: <i>Tagrisso</i> monotherapy 	<ul style="list-style-type: none"> Primary endpoint: PFS by BICR Secondary endpoints: OS, PFS (INV), ORR, DoR, DCR, PFS of CNS met. patients, PFS2; safety, PK parameters and immunogenicity 	<ul style="list-style-type: none"> FPCD: Q2 2024 Data anticipated: >2027
Phase III TROPION-Lung15 NCT06417814 Partnered (Daiichi Sankyo)	2L <i>EGFR</i> m locally advanced / metastatic <i>EGFR</i> m NSCLC (disease progressed on prior <i>Tagrisso</i>)	744	<ul style="list-style-type: none"> Open-label, randomised trial Arm 1: <i>Datroway</i> + <i>Tagrisso</i> Arm 2: <i>Datroway</i> Arm 3: Platinum-based CTx 	<ul style="list-style-type: none"> Primary endpoints: PFS (BICR) monotherapy vs CTx, PFS (BICR) combination vs CTx Secondary endpoints: OS, CNS PFS, PFS (Inv.), PFS2, ORR, DoR, DCR, TTR, safety and PRO 	<ul style="list-style-type: none"> FPCD: Q4 2024 Data anticipated: H1 2027



Datroway (datopotamab deruxtecan, TROP2 ADC)

NSCLC

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III TROPION-Lung17 NCT07291037 Partnered (Daiichi Sankyo)	TROP2 QCS NMR+ non-squamous NSCLC 2L	400	<ul style="list-style-type: none"> Randomized, double blind, placebo-controlled Arm A: Datopotamab deruxtecan monotherapy Arm B: Docetaxel monotherapy 	<ul style="list-style-type: none"> PFS by BICR and OS 	<ul style="list-style-type: none"> FPCD: Q4 2025 Data anticipated: >2027
Phase I TROPION-Lung02 NCT04526691 Partnered (Daiichi Sankyo)	Advanced or metastatic NSCLC	145	<ul style="list-style-type: none"> Open-label, two-part (dose escalation and dose expansion), sequential assignment <i>Datroway</i> + pembrolizumab +/- platinum chemotherapy 	<ul style="list-style-type: none"> Primary endpoints: DLT and safety Secondary endpoints: ORR, DoR, PFS, OS, PK parameters and ADA 	<ul style="list-style-type: none"> FPCD: Q4 2020 LPCD: Q2 2023 Data readout: Q4 2024
Phase I TROPION-Lung04 NCT04612751 Partnered (Daiichi Sankyo)	Advanced or metastatic NSCLC	155	<ul style="list-style-type: none"> Open-label, two-part (dose escalation, dose expansion), sequential assignment <i>Datroway</i> + <i>Imfinzi</i> +/- platinum chemotherapy Cohort 1 & 2: <i>Datroway</i> + <i>Imfinzi</i> Cohort 3 & 4: <i>Datroway</i> + <i>Imfinzi</i> + carboplatin Cohort 4a: <i>Datroway</i> + <i>Imfinzi</i> + carboplatin (SQ 1L only) Cohort 5 & 6: <i>Datroway</i> + rilvegostomig Cohort 7 & 8: <i>Datroway</i> + rilvegostomig + carboplatin Cohort 9 & 10: <i>Datroway</i> + volrustomig + carboplatin Cohort 11: <i>Datroway</i> + volrustomig 	<ul style="list-style-type: none"> Primary endpoints: DLT and safety Secondary endpoints: ORR, DoR, PFS, OS, PK parameters and ADA 	<ul style="list-style-type: none"> FPCD: Q1 2021 Data readout: Q3 2026

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



Datroway (datopotamab deruxtecan, TROP2 ADC)

Other cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase III TROPION-Urothelial04 NCT07720284 Partnered (Daiichi Sankyo)	High-risk muscle Invasive urothelial carcinoma at high risk of recurrence following radical resection	915	<ul style="list-style-type: none"> Global, randomised, open label trial Arm 1: <i>Datroway</i> + rilvegostomig Arm 2: <i>Datroway</i> Arm 3: SoC 	<ul style="list-style-type: none"> Primary endpoint: DFS (INV) Secondary endpoints: DFS (BICR), OS 	<ul style="list-style-type: none"> FPCD: Q3 2026 Data anticipated: >2027
Phase II TROPION-PanTumor03 NCT05489211 Partnered (Daiichi Sankyo)	Endometrial cancer, gastric cancer, mCRPC, ovarian cancer, CRC, bladder cancer and BTC	606	<ul style="list-style-type: none"> Sub-study 1 (endometrial cancer); Sub-study 1a: <i>Datroway</i> monotherapy Sub-study 2 (gastric cancer); Sub-study 2a: <i>Datroway</i> + capecitabine Sub-study 2b: <i>Datroway</i> + 5-fluorouracil Sub-study 3 (mCRPC); Sub-study 3a: <i>Datroway</i> (post-NHA) Sub-study 3c: <i>Datroway</i> + prednisone/prednisolone Sub-study 4 (ovarian cancer); Sub-study 4a: <i>Datroway</i> Sub-study 4a (expansion): <i>Datroway</i> PSR/PRR (2-3L) Sub-study 4c: <i>Datroway</i> + carboplatin + bevacizumab PSR (2-3L) Sub-study 5 (CRC); Sub-study 5a1: <i>Datroway</i> (TROP2+ 3L+) Sub-study 5a2: <i>Datroway</i> (TROP2+ 2L+) Sub-study 5b: <i>Datroway</i> + 5-FU/leucovorin or capecitabine + bevacizumab (TROP2+ 1L) Sub-study 6 (bladder); Sub-study 6d: <i>Datroway</i> (2L+) Sub-study 6b: 1L cis-ineligible/2L <i>Datroway</i> + rilvegostomig (1L) Sub-study 6c: post-pembro/EV - <i>Datroway</i> + carbo/cisplatin (2L) Sub-Study 6E: 1L <i>Datroway</i> + rilvegostomig Sub-study 7 (BTC) Sub-study 7a: TROP2+ <i>Datroway</i> (2L+) 	<ul style="list-style-type: none"> Primary endpoints: ORR and safety 	<ul style="list-style-type: none"> FPCD: Q3 2022 Data anticipated: H2 2027



Datroway (datopotamab deruxtecan, TROP2 ADC)

Other cancers

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II TROPION-PanTumor02 NCT05460273 Partnered (Daiichi Sankyo)	NSCLC and TNBC and other solid tumours in Chinese patients	119	<ul style="list-style-type: none"> Single-arm, multi-cohort trial with no blinding <i>Datroway</i> China only 	<ul style="list-style-type: none"> Primary endpoint: ORR Secondary endpoints: DoR, DCR, BOR, TTR, PFS and OS 	<ul style="list-style-type: none"> FPCD: Q3 2022 LPCD: Q2 2023 Data readout: Q2 2024
Phase I TROPION-PanTumor01 NCT03401385 Partnered (Daiichi Sankyo)	Subjects with advanced solid tumours: NSCLC, TNBC, HR+ breast cancer, HER2-negative gastric/GEJ, oesophageal, urothelial, SCLC, CRPC, PDAC, HNSCC, HR+ HER2-low breast cancer and HER2-positive breast cancer	890	<ul style="list-style-type: none"> Open-label, two-part (dose escalation, dose expansion), sequential assignment <i>Datroway</i> US and Japan 	<ul style="list-style-type: none"> Primary endpoints: DLT and safety Secondary endpoints: PK parameters, anti-tumour activity and ADA 	<ul style="list-style-type: none"> FPCD: Q1 2018 LPCD: Q4 2025 Data anticipated: H2 2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



Enhertu (trastuzumab deruxtecan, HER2 ADC)

Breast cancer

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III DESTINY-Breast05 NCT04622319 Partnered (Daiichi Sankyo)	High-risk HER2-positive with residual invasive breast cancer following neoadjuvant therapy	1600	<ul style="list-style-type: none"> Randomised, open-label, parallel assignment Arm 1: <i>Enhertu</i> Arm 2: ado-trastuzumab emtansine 	<ul style="list-style-type: none"> Primary endpoint: IDFS Secondary endpoints: DFS, OS, DRFI and BMFI 	<ul style="list-style-type: none"> FPCD: Q4 2020 Data readout: Q3 2025 Primary endpoint met
Phase III DESTINY-Breast09 NCT04784715 Partnered (Daiichi Sankyo)	HER2-positive, metastatic breast cancer with no prior therapy for advanced or metastatic disease	1157	<ul style="list-style-type: none"> Randomised, parallel assignment Arm 1: <i>Enhertu</i> + placebo Arm 2: <i>Enhertu</i> + pertuzumab Arm 3: SoC 	<ul style="list-style-type: none"> Primary endpoint: PFS Secondary endpoints: OS, DoR and ORR 	<ul style="list-style-type: none"> FPCD: Q2 2021 Data readout: Q2 2025 Primary endpoint met for <i>Enhertu</i> + pertuzumab arm Data anticipated for <i>Enhertu</i> monotherapy arm: H1 2027
Phase III DESTINY-Breast11 NCT05113251 Partnered (Daiichi Sankyo)	High-risk HER2-positive early non-metastatic breast cancer	927	<ul style="list-style-type: none"> Randomised, open-label, parallel assignment Arm 1: <i>Enhertu</i> Arm 2: <i>Enhertu</i> followed by THP Arm 3: doxorubicin and cyclophosphamide followed by THP 	<ul style="list-style-type: none"> Primary endpoint: pCR Secondary endpoints: EFS, IDFS and OS 	<ul style="list-style-type: none"> FPCD: Q4 2021 Data readout: Q2 2025 Primary endpoint met

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



Enhertu (trastuzumab deruxtecan, HER2 ADC)

Gastric cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase III DESTINY-Gastric04 NCT04704934 Partnered (Daiichi Sankyo)	HER2-positive gastric cancer or GEJ adenocarcinoma patients who have progressed on or after a trastuzumab-containing regimen and have not received any additional systemic therapy	490	<ul style="list-style-type: none"> Open-label, randomised, parallel group assignment Arm 1: <i>Enhertu</i> Arm 2: SoC chemotherapy 	<ul style="list-style-type: none"> Primary endpoint: OS Secondary endpoints: ORR, DoR, PFS, DCR and safety 	<ul style="list-style-type: none"> FPCD: Q2 2021 Data readout: Q1 2025
Phase III DESTINY-Gastric05 NCT06731478 Partnered (Daiichi Sankyo)	1L HER2-positive locally advanced or metastatic gastric cancer or GEJ adenocarcinoma	726	<ul style="list-style-type: none"> Arm A (CPS ≥ 1): <i>Enhertu</i> + 5-FU or capecitabine + pembrolizumab Arm B (CPS ≥ 1): <i>Enhertu</i> + 5-FU or capecitabine + cisplatin or oxaliplatin + pembrolizumab Arm C (CPS < 1): <i>Enhertu</i> + 5-FU or capecitabine Arm D (CPS < 1): ToGA 	<ul style="list-style-type: none"> Primary endpoint: PFS (BICR) in ITT Secondary endpoints: OS, ORR, PFS (INV), DoR, safety and PRO 	<ul style="list-style-type: none"> FPCD: Q1 2025 Data anticipated: >2027
Phase Ib/II DESTINY-Gastric03 NCT04379596 Partnered (Daiichi Sankyo)	Metastatic or unresectable HER2+ GC, GEJ and oesophageal adenocarcinoma	450	<ul style="list-style-type: none"> Open-label, parallel assignment Part 1: HER2+ patients with ≥ 2L following trastuzumab containing therapy to determine recommended Phase II combination dose Parts 2,3,4,5: Previously untreated metastatic or unresectable GC Arm 2A (HER2+): standard chemotherapy Arm 2B (HER2+): <i>Enhertu</i> monotherapy Arm 2C (HER2+): <i>Enhertu</i> with chemotherapy Arm 2D (HER2+): <i>Enhertu</i> with chemotherapy and pembrolizumab Arm 2E (HER2+): <i>Enhertu</i> and pembrolizumab Arm 2F (HER2+): <i>Enhertu</i>, chemotherapy and pembrolizumab Arm 3A (HER2+): <i>Enhertu</i>, chemotherapy and volrustomig Arm 3B (HER2low): <i>Enhertu</i>, chemotherapy and volrustomig Arm 4A (HER2+): <i>Enhertu</i>, chemotherapy and rilvegostomig Arm 4B (HER2low): <i>Enhertu</i>, chemotherapy and rilvegostomig Arm 5 (HER2low): <i>Enhertu</i>, chemotherapy and volrustomig (priming dose) 	<ul style="list-style-type: none"> Part 1: Primary endpoint: safety and tolerability, RP2D Secondary endpoints: ORR Part 2, 3, 4, 5: Primary endpoint: ORR Secondary endpoints: DCR, DoR, PFS, OS, safety, PK/ADA (<i>Enhertu</i>, Imfinzi, volrustomig, rilvegostomig), response by local vs central HER2 	<ul style="list-style-type: none"> FPCD: Q2 2020 Data anticipated: H2 2027



Enhertu (trastuzumab deruxtecan, HER2 ADC)

Other cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase III DESTINY-BTC01 NCT06467357 Partnered (Daiichi Sankyo)	Advanced treatment-naïve HER2-expressing BTC	620	<ul style="list-style-type: none"> Arm A: <i>Enhertu</i> + rilvegostomig Arm B: <i>Enhertu</i> Arm C: gemcitabine and cisplatin + <i>Imfinzi</i> 	<ul style="list-style-type: none"> Primary endpoint: OS Secondary endpoint: OS (ITT), PFS (BICR and INV), ORR (BICR and INV), DoR (INV) Safety, PRO 	<ul style="list-style-type: none"> FPCD: Q3 2024 Data anticipated: >2027
Phase III DESTINY-Endometrial01 NCT06989112 Partnered (Daiichi Sankyo)	Stage III, Stage IV, or recurrent, histologically-confirmed endometrial cancer	600	<ul style="list-style-type: none"> Open label, randomized, global Arm A: <i>Enhertu</i> + rilvegostomig Arm B: <i>Enhertu</i> + pembrolizumab Arm C: carboplatin/paclitaxel + pembrolizumab 	<ul style="list-style-type: none"> Primary: PFS (BICR) in ITT Secondary: OS, PFS (Investigator), ORR 	<ul style="list-style-type: none"> FPCD: Q2 2025 Data anticipated: >2027
Phase III DESTINY-Endometrial02 NCT07022483 Partnered (Daiichi Sankyo)	HER2-expressing (IHC 3+/2+) endometrial cancer	710	<ul style="list-style-type: none"> Randomised, open label, parallel assignment Arm 1: <i>Enhertu</i> +/- radiotherapy Arm 2: SoC chemotherapy +/- radiotherapy 	<ul style="list-style-type: none"> Primary endpoints: DFS ITT (BICR or pathology) Secondary endpoints: OS ITT, DFS ITT (INV), DDFS 	<ul style="list-style-type: none"> FPCD: Q4 2025 Data anticipated: >2027
Phase III DESTINY-Lung04 NCT05048797 Partnered (Daiichi Sankyo)	HER2-mutated, unresectable, locally advanced/metastatic NSCLC	454	<ul style="list-style-type: none"> Randomised, parallel group assignment Arm 1: <i>Enhertu</i> Arm 2: SoC (platinum, pemetrexed and pembrolizumab) 	<ul style="list-style-type: none"> Primary endpoint: PFS Secondary endpoints: OS, CNS-PFS, PFS (INV), ORR, DoR, safety, PK parameters, ADA, PRO-tolerability and PRO- pulmonary symptoms 	<ul style="list-style-type: none"> FPCD: Q4 2021 Data readout: Q3 2026 Primary endpoint met
Phase III DESTINY-Lung06 NCT06899126 Partnered (Daiichi Sankyo)	Locally advanced unresectable or metastatic NSCLC, no prior systemic treatment for advanced/metastatic disease, HER2-overexpressing and PD-L1 TPS <50% without AGA	686	<ul style="list-style-type: none"> Arm A: <i>Enhertu</i> + pembrolizumab Arm B: pembrolizumab + pemetrexed + platinum CTx (cisplatin or carboplatin) 	<ul style="list-style-type: none"> Primary endpoint: PFS by BICR Secondary endpoint: OS, PFS (INV), ORR per RECIST v1.1, DoR, safety and tolerability, PROs 	<ul style="list-style-type: none"> FPCD: Q4 2025 Data anticipated: >2027
Phase III DESTINY-Ovarian01 NCT06819007 Partnered (Daiichi Sankyo)	HER2-expressing (IHC 3+/2+/1+) advanced high-grade epithelial ovarian cancer	582	<ul style="list-style-type: none"> Daiichi Sankyo unilateral trial Phase 3, open label, randomised Arm 1: <i>Enhertu</i> + bevacizumab Arm 2: bevacizumab 	<ul style="list-style-type: none"> Primary: PFS (BICR) in IHC 2+/3+ Secondary: PFS (BICR) in ITT (3/2/1+), OS IHC 2+/3+, OS ITT 	<ul style="list-style-type: none"> FPCD: Q2 2025 Data anticipated: >2027



Enhertu (trastuzumab deruxtecan, HER2 ADC)

Other cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase II DESTINY-PanTumor03 NCT06271837 Partnered (Daiichi Sankyo)	HER2 expressing tumours	127	<ul style="list-style-type: none"> Non-randomised single group assignment <i>Enhertu</i> China only 	<ul style="list-style-type: none"> Primary endpoint: ORR Secondary endpoints: DoR, DCR, PFS, OS, safety and tolerability, PK 	<ul style="list-style-type: none"> FPCD: Q3 2024 Data readout: Q1 2026
Phase Ib DESTINY-Lung03 NCT04686305 Partnered (Daiichi Sankyo)	HER2-overexpressing, unresectable and/or metastatic NSCLC Part 1: 2L/3L advanced Parts 2/3/4/5: 1L advanced	244	<ul style="list-style-type: none"> Non-randomised, parallel group assignment Part 1: to determine recommended combination dose 3 arms combine <i>Enhertu</i> with SoC chemotherapies (cisplatin, carboplatin or pemetrexed) and <i>Imfinzi</i>; Arm 1D: <i>Enhertu</i> monotherapy arm Part 2: to assess efficacy of the selected combinations with chemotherapies (cisplatin, carboplatin or pemetrexed) and <i>Imfinzi</i> not initiated Part 3 (2 arms): dose confirmation to assess safety and efficacy with volrustomig and volrustomig and chemotherapy (carboplatin) Part 4 (2 arms): dose confirmation to assess safety and efficacy with rilvegostomig and rilvegostomig and chemotherapy (carboplatin) Part 5: to evaluate priming approach (<i>Enhertu</i>+ volrustomig (500mg) followed by 250mg until progression) 	<ul style="list-style-type: none"> Primary endpoint: safety and RP2D Secondary endpoints: ORR, DoR, DCR, PFS, OS and PK parameters 	<ul style="list-style-type: none"> FPCD: Q4 2021 Data anticipated: H2 2027
Phase I/II DESTINY-PanTumor02 NCT04482309 Partnered (Daichii Sankyo)	HER2-expressing tumours	477	<ul style="list-style-type: none"> Non-randomised, single group assignment <i>Enhertu</i> 	<ul style="list-style-type: none"> Primary endpoint: ORR Secondary endpoints: DoR, DCR, PFS and OS 	<ul style="list-style-type: none"> FPCD: Q4 2020 Data readout: Q3 2023
Phase I Enhertu SubQ NCT07015697 Partnered (Daiichi Sankyo)	Part 1: pre-treated mBC Part 2: HER2-low mBC	76	<ul style="list-style-type: none"> Non-randomised, sequential assignment Part 1: Dose escalation, subcutaneous <i>Enhertu</i> with hyaluronidase co-mixed Part 2: Expansion, subcutaneous <i>Enhertu</i> with hyaluronidase co-mixed flat dose 	<ul style="list-style-type: none"> Part 1: DLT incidence, safety, PK Part 2: Primary endpoint: PK; Secondary endpoints: ORR, safety, tolerability 	<ul style="list-style-type: none"> FPCD: Q4 2025 Data anticipated: >2027



Etcamah (camizestrant, next-generation oral SERD)

Breast cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase III CAMBRIA-1 NCT05774951	ER+/HER2-negative early breast cancer patients who completed definitive locoregional therapy and standard adjuvant ET for at least 2 years and up to 5 years	4300	<ul style="list-style-type: none"> Arm 1: <i>Etcamah</i> Arm 2: continue standard ET of investigator's choice 	<ul style="list-style-type: none"> Primary endpoint: IBCFS Secondary endpoints: IDFS, DRFS and OS 	<ul style="list-style-type: none"> FPCD: Q1 2023 Data anticipated: H2 2027
Phase III CAMBRIA-2 NCT05952557	ER+/HER2-negative early breast cancer with intermediate-high or high risk of recurrence that has completed definitive locoregional therapy and have no evidence of disease	5500	<ul style="list-style-type: none"> Arm 1: <i>Etcamah</i> ± abemaciclib Arm 2: standard endocrine therapy of investigator's choice (aromatase inhibitors [exemestane, letrozole, anastrozole] or tamoxifen) ± abemaciclib 	<ul style="list-style-type: none"> Primary endpoint: IBCFS Secondary endpoints: IDFS, DRFS and OS 	<ul style="list-style-type: none"> FPCD: Q4 2023 LPCD: Q3 2026 Data anticipated: >2027
Phase III SERENA-4 NCT04711252	HR+ HER2-negative advanced breast cancer	1370	<ul style="list-style-type: none"> Randomised, double-blind, comparative trial Arm 1: <i>Etcamah</i> + palbociclib Arm 2: anastrozole + palbociclib 	<ul style="list-style-type: none"> Primary endpoint: PFS Secondary endpoints: OS and PFS2 	<ul style="list-style-type: none"> FPCD: Q1 2021 LPCD: Q4 2023 Data readout: Q3 2026 Primary endpoint not met
Phase III SERENA-6 NCT04964934	HR+ HER2-negative advanced breast cancer	312	<ul style="list-style-type: none"> Randomised, double-blind, comparator trial Arm 1: <i>Etcamah</i> + palbociclib or abemaciclib or ribociclib Arm 2: anastrozole or letrozole + palbociclib or abemaciclib or ribociclib 	<ul style="list-style-type: none"> Primary endpoint: PFS Secondary endpoint: OS and PFS2 	<ul style="list-style-type: none"> FPCD: Q3 2021 LPCD: Q3 2024 Data readout: Q1 2025 Primary endpoint met



Imfinzi (durvalumab, PD-L1 mAb)

Gastrointestinal cancers

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III EMERALD-1 NCT03778957	Locoregional HCC	710	<ul style="list-style-type: none"> Arm 1: TACE in combination with <i>Imfinzi</i> Arm 2: TACE in combination with <i>Imfinzi</i> + bevacizumab Arm 3: TACE in combination with placebo 	<ul style="list-style-type: none"> Primary endpoint: PFS (Arm 2 vs. Arm 3) Secondary endpoints: PFS (Arm 1 vs. Arm 3) and OS 	<ul style="list-style-type: none"> FPCD: Q1 2019 LPCD: Q3 2021 Data readout: Q4 2023 Primary endpoint met
Phase III EMERALD-3 NCT05301842	Locoregional HCC	725	<ul style="list-style-type: none"> Arm 1: <i>Imfinzi</i> + <i>Imjudo</i> + TACE + lenvatinib Arm 2: <i>Imfinzi</i> + <i>Imjudo</i> + TACE Arm 3: TACE 	<ul style="list-style-type: none"> Primary endpoint: PFS Secondary endpoint: OS 	<ul style="list-style-type: none"> FPCD: Q2 2022 LPCD: Q4 2024 Data readout: Q1 2026 Primary endpoint met
Phase III KUNLUN NCT04550260	Locally advanced, unresectable ESCC	640	<ul style="list-style-type: none"> Arm 1: <i>Imfinzi</i> + definitive CRT Arm 2: placebo + definitive CRT 	<ul style="list-style-type: none"> Primary endpoint: PFS Secondary endpoint: OS 	<ul style="list-style-type: none"> FPCD: Q4 2020 LPCD: Q3 2023 Data anticipated: H2 2027
Phase III MATTERHORN-CN NCT07877818	Resectable GC/GEJC	140	<ul style="list-style-type: none"> Arm 1: <i>Imfinzi</i> + FLOT Arm 2: Placebo + FLOT China only 	<ul style="list-style-type: none"> Primary endpoint: pCR Secondary endpoints: EFS, OS 	<ul style="list-style-type: none"> Data anticipated: >2027 Initiating

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



Imfinzi (durvalumab, PD-L1 mAb)

Lung cancer

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III PACIFIC-4 NCT03833154	Unresected Stage I/II NSCLC	662	<ul style="list-style-type: none"> Arm 1: <i>Imfinzi</i> i.v. Q4W with definitive SBRT Arm 2: placebo with definitive SBRT 	<ul style="list-style-type: none"> Primary endpoint: PFS Secondary endpoint: OS 	<ul style="list-style-type: none"> FPCD: Q2 2019 Data anticipated: H2 2027
Phase III PACIFIC-9 NCT05221840 Partnered (Innate Pharma)	Patients with locally advanced (Stage III), unresectable NSCLC who have not progressed following platinum-based CRT	1051	<ul style="list-style-type: none"> Arm 1: <i>Imfinzi</i> + oleclumab Arm 2: <i>Imfinzi</i> + monalizumab + placebo Arm 3: <i>Imfinzi</i> + placebo 	<ul style="list-style-type: none"> Primary endpoint: PFS Secondary endpoints: OS, ORR, DoR, PFS2 and TFST 	<ul style="list-style-type: none"> FPCD: Q2 2022 Data anticipated: H1 2027
Phase II NeoCOAST-2 NCT05061550 Partnered (Innate Pharma)	Early-stage, resectable NSCLC (Stage II to Stage IIIA)	630	<ul style="list-style-type: none"> Open-label trial Arm 1: <i>Imfinzi</i> + oleclumab + platinum doublet chemotherapy Arm 2: <i>Imfinzi</i> + monalizumab + platinum doublet chemotherapy Arm 3: volrustomig + platinum doublet chemotherapy Arm 4: <i>Datroway</i> + single agent platinum chemotherapy Arm 5: AZD0171 + platinum doublet chemotherapy Arm 6: rilvegostomig + platinum doublet chemotherapy Arm 7: <i>Datroway</i> + rilvegostomig + single agent platinum chemotherapy 	<ul style="list-style-type: none"> Primary endpoints: pCR and safety 	<ul style="list-style-type: none"> FPCD: Q2 2022 Data anticipated: >2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



Imfinzi (durvalumab, PD-L1 mAb)

Other cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase III NILE NCT03682068	1L bladder cancer	1246	<ul style="list-style-type: none"> Arm 1: <i>Imfinzi</i> + <i>Imjudo</i> + SoC Arm 2: <i>Imfinzi</i> + SoC Arm 3: SoC 	<ul style="list-style-type: none"> Primary endpoint: OS 	<ul style="list-style-type: none"> FPCD: Q4 2018 LPCD: Q2 2021 Data readout: Q2 2026 Primary endpoint met
Phase III POTOMAC NCT03528694	Non-muscle-invasive bladder cancer	1018	<ul style="list-style-type: none"> Arm 1: BCG (induction + maintenance) Arm 2: <i>Imfinzi</i> + BCG (induction only) Arm 3: <i>Imfinzi</i> + BCG (induction + maintenance) 	<ul style="list-style-type: none"> Primary endpoint: DFS 	<ul style="list-style-type: none"> FPCD: Q2 2018 LPCD: Q4 2020 Data readout: Q2 2025 Primary endpoint met
Phase III VOLGA NCT04960709	Muscle-invasive bladder cancer ineligible to cisplatin	712	<ul style="list-style-type: none"> Arm 1: <i>Imfinzi</i> + <i>Imjudo</i> + enfortumab vedotin Arm 2: <i>Imfinzi</i> + enfortumab vedotin Arm 3: SoC cystectomy 	<ul style="list-style-type: none"> Primary endpoint: EFS Secondary endpoints: OS, pCR, safety 	<ul style="list-style-type: none"> FPCD: Q4 2021 LPCD: Q1 2025 Data readout: Q2 2026 Primary endpoint met
Phase II BEGONIA NCT03742102	1L mTNBC	243	<ul style="list-style-type: none"> Arm 1: <i>Imfinzi</i> + paclitaxel Arm 2: <i>Imfinzi</i> + paclitaxel + <i>Truqap</i> Arm 5: <i>Imfinzi</i> + paclitaxel + oleclumab Arm 6: <i>Imfinzi</i> + <i>Enhertu</i> Arm 7: <i>Imfinzi</i> + <i>Datroway</i> Arm 8: <i>Imfinzi</i> + <i>Datroway</i> (PD-L1-high) 	<ul style="list-style-type: none"> Primary endpoints: safety and tolerability Secondary endpoints: ORR, PFS, DoR, OS, PK and ADA 	<ul style="list-style-type: none"> FPCD: Q1 2019 Data readout: Q2 2025
Phase I IMFINZI-subQ NCT07391670	Part 1: Solid tumours - NSCLC, limited-stage SCLC or HCC Part 2: unresectable HCC	40	<ul style="list-style-type: none"> Part 1 (dose finding): subcutaneous <i>Imfinzi</i>, 2 planned dose levels (DL1 and DL2) Part 2 (dose expansion): subcutaneous <i>Imfinzi</i>, dose based on Part 1 	<ul style="list-style-type: none"> Primary endpoint: AUC and Ctrough of subcutaneous <i>Imfinzi</i> Secondary endpoints: Safety, AUClast, Cmax, tmax, terminal elimination half-life, CL(/F), VZ(/F), Cavg, serum concentration of <i>imfinzi</i> 	<ul style="list-style-type: none"> Data anticipated: H2 2027



Lynparza (PARP inhibitor)

Ovarian, endometrial and breast cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase III MONO-OLA1 NCT04884360	BRCAwt advanced ovarian cancer, 1L maintenance	366	<ul style="list-style-type: none"> Global trial – 12 countries Arm 1: <i>Lynparza</i> BID 24-month duration Arm 2: placebo BID 24-month duration 	<ul style="list-style-type: none"> Primary endpoints: PFS (BRCAwt HRD-positive) and PFS (BRCAwt) Secondary endpoints: OS, TFST and PFS2 	<ul style="list-style-type: none"> FPCD: Q3 2021 LPCD: Q1 2024 Data readout: Q3 2026 Primary endpoints met
Phase II OlympiaN NCT05498155	HER2 negative BRCAm neoadjuvant breast cancer	50	<ul style="list-style-type: none"> Non-randomised 2 cohort study Cohort A: lower-risk population receive neoadjuvant <i>Lynparza</i> monotherapy for 4-6 cycles Cohort B: higher-risk population receive neoadjuvant <i>Lynparza</i> + <i>Imfinzi</i> for 4-6 cycles 	<ul style="list-style-type: none"> Primary endpoint: pCR (central review) Secondary endpoints: pCR (local pathology review), RCB, percentage change in tumour volume, EFS, safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q4 2022 LPCD: Q2 2024 Data readout: Q3 2025 Primary endpoint met



Tagrisso (highly-selective, irreversible *EGFR* inhibitor)

NSCLC

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III ADAURA2 NCT05120349	Adjuvant <i>EGFR</i> m NSCLC Stage IA2 to IA3 following complete tumour resection	380	<ul style="list-style-type: none"> Arm 1: <i>Tagrisso</i> Arm 2: placebo 	<ul style="list-style-type: none"> Primary endpoint: DFS Secondary endpoints: DFS rate, OS, OS rate and QoL 	<ul style="list-style-type: none"> FPCD: Q2 2022 LPCD: Q4 2024 Data anticipated: >2027
Phase III NeoADAURA NCT04351555	Neoadjuvant <i>EGFR</i> m NSCLC	351	<ul style="list-style-type: none"> Arm 1: placebo + pemetrexed/carboplatin or pemetrexed/cisplatin Arm 2: <i>Tagrisso</i> + pemetrexed/carboplatin or pemetrexed/cisplatin Arm 3: <i>Tagrisso</i> 	<ul style="list-style-type: none"> Primary endpoint: mPR Secondary endpoints: cPR, EFS, DFS and OS 	<ul style="list-style-type: none"> FPCD: Q1 2021 LPCD: Q4 2023 Data readout: Q4 2024 Primary endpoint met
Phase III SAFFRON NCT05261399 Partnered (HUTCHMED)	Locally advanced or metastatic <i>EGFR</i> m, MET-overexpressed and/or amplified NSCLC progressed on first- or second-line treatment with <i>Tagrisso</i>	324	<ul style="list-style-type: none"> Arm 1: <i>Tagrisso</i> + <i>Orpathys</i> Arm 2: pemetrexed with either cisplatin or carboplatin 	<ul style="list-style-type: none"> Primary endpoint: PFS Secondary endpoints: OS, ORR, PK, DCR and DoR 	<ul style="list-style-type: none"> FPCD: Q3 2022 Data readout: Q3 2026 Primary endpoint met
Phase III SANOVO NCT05009836 Partnered (HUTCHMED)	1L <i>EGFR</i> m, MET+ locally advanced or metastatic NSCLC	320	<ul style="list-style-type: none"> Arm 1: <i>Tagrisso</i> + <i>Orpathys</i> Arm 2: <i>Tagrisso</i> + placebo 	<ul style="list-style-type: none"> Primary endpoint: PFS 	<ul style="list-style-type: none"> FPCD: Q3 2021 Data readout: Q3 2026 Primary endpoint met
Phase II ORCHARD NCT03944772	Advanced <i>EGFR</i> m NSCLC patients who have progressed on first-line <i>Tagrisso</i> treatment	247	<ul style="list-style-type: none"> Modular design platform trial: Module 1: <i>Tagrisso</i> + <i>Orpathys</i> (cMET) Module 2: <i>Tagrisso</i> + gefitinib (<i>EGFR</i>m) Module 3: <i>Tagrisso</i> + necitumumab (<i>EGFR</i>m) Module 4: carboplatin + pemetrexed + <i>Imfinzi</i> Module 5: <i>Tagrisso</i> + alectinib (ALK) Module 6: <i>Tagrisso</i> + selpercatinib (RET fusion) Module 7: <i>Imfinzi</i> + etoposide + carboplatin or cisplatin Module 8: <i>Tagrisso</i> + pemetrexed + carboplatin or cisplatin Module 9: <i>Tagrisso</i> + <i>Koselugo</i> Module 10: <i>Tagrisso</i> + <i>Datroway</i> No intervention: observational cohort 	<ul style="list-style-type: none"> Primary endpoint: ORR Secondary endpoints: PFS, DoR, OS, safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q3 2019 LPCD: Q4 2023 Data readout: Q4 2025



Truqap (capivasertib, AKT inhibitor)

Breast cancer and prostate cancer

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III CAPitello-281 NCT04493853	De novo PTEN deficient metastatic hormone sensitive prostate cancer	1012	<ul style="list-style-type: none"> Double-blind, randomised, comparative trial Arm 1: <i>Truqap</i> + abiraterone Arm 2: placebo + abiraterone 	<ul style="list-style-type: none"> Primary endpoint: rPFS 	<ul style="list-style-type: none"> FPCD: Q3 2020 LPCD: Q1 2024 Data readout: Q4 2024 Primary endpoint met
Phase Ib/III CAPitello-292 NCT04862663	1L early relapse/endocrine-resistant locally advanced (inoperable) or metastatic HR+/HER2-negative breast cancer	793	<ul style="list-style-type: none"> Double-blind, randomised, comparative trial Arm 1: <i>Truqap</i> + palbociclib + <i>Faslodex</i> Arm 2: placebo + palbociclib + <i>Faslodex</i> 	<ul style="list-style-type: none"> Primary endpoint: PFS 	<ul style="list-style-type: none"> FPCD: Q2 2021 Data anticipated: H2 2027



(225Ac) zadavotide guraxetan (AZD2265, PSMA radioconjugate)

Approved medicines
Late-stage development
Early development

Prostate cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase III VECTRA-01 NCT07611110	PSMA-positive mCRPC post-ARPI, -taxane, and -Pluvicto (or other PSMA-directed beta-emitting radioconjugate)	670	<ul style="list-style-type: none"> Multicentre, randomised controlled trial Arm 1: zadavotide guraxetan Arm 2: standard of care (investigator's choice of cabazitaxel, ARPI switch, or radium-223) 	<ul style="list-style-type: none"> Primary endpoints: rPFS, OS Secondary endpoints: PFS, PSA50, PSA90, ORR, DoR, SSE-FS, PK, safety/tolerability 	<ul style="list-style-type: none"> FPCD: Q2 2026 Data anticipated: >2027
Phase II AlphaBreak NCT06402331 Partnered (Fusion)	PSMA-positive mCRPC previously treated with lutetium-PSMA therapy	110	<ul style="list-style-type: none"> Open-label, randomised, multi-centre trial 	<ul style="list-style-type: none"> Primary endpoints: PSA50 and safety 	<ul style="list-style-type: none"> FPCD: Q2 2024 Data anticipated: H2 2026
Phase II PROSPECTOR NCT07590934	Metastatic prostate cancer	152	<ul style="list-style-type: none"> Multicentre, open-label and platform trial evaluating multiple anti-cancer agents in participants with metastatic prostate cancer Platform trial will comprise a series of substudies. Each substudy will follow a 2-part structure: part A: Dose escalation, part B: Dose optimisation/expansion zada-gu + palacaparib zada-gu docetaxel 	<ul style="list-style-type: none"> Primary endpoint: Safety and tolerability Secondary endpoints: Efficacy, PK 	<ul style="list-style-type: none"> FPCD: Q3 2026 Data anticipated: >2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



puxitatug samrotesan (AZD8205, B7-H4 TOP1i ADC)

Solid tumours

Approved medicines

Late-stage development

Early development

Oncology

Trial	Population	Patients	Design	Endpoints	Status
Phase III Bluestar-Endometrial01 NCT07044336	2-3L B7-H4 selected endometrial cancer	700	<ul style="list-style-type: none"> Randomised, single-open label Arm 1: puxitatug samrotesan 2.4mg/kg Q3W Arm 2: docetaxel/paclitaxel 	<ul style="list-style-type: none"> Primary endpoints: PFS, OS Secondary endpoints: ORR, DoR, PFS2, TFST, TSST, TDT 	<ul style="list-style-type: none"> FPCD: Q4 2025 Data anticipated: H2 2027
Phase I/II BLUESTAR NCT05123482	Breast cancer, ovarian cancer, endometrial cancer, squamous NSCLC	370	<ul style="list-style-type: none"> Open-label dose escalation and expansion trial Sub-study 1: puxitatug samrotesan monotherapy Sub-study 2: puxitatug samrotesan + rilvegostomig Sub-study 4: puxitatug samrotesan + rilvegostomig + AZD9574 	<ul style="list-style-type: none"> Primary endpoints: AE, SAE, DLTs, changes in lab and preliminary efficacy parameters Secondary endpoints: ORR, DCR, DoR, PFS, OS, PK parameters and ADA 	<ul style="list-style-type: none"> FPCD: Q1 2022 Data anticipated: H1 2027

CVRM

R&I

Infectious Diseases

Rare Disease



rilvegostomig (PD-1/TIGIT bispecific mAb)

Gastrointestinal cancers

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III ARTEMIDE-Biliary01 NCT06109779 Partnered (Compugen)	Adjuvant BTC with curative intent	750	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled, multicentre trial Arm 1: rilvegostomig + investigator's choice of CTx (capecitabine, S-1 (tegafur/gimeracil/oteracil) or gemcitabine/cisplatin) Arm 2: placebo + investigator's choice of CTx (capecitabine, S-1 (tegafur/gimeracil/oteracil) or gemcitabine/cisplatin) 	<ul style="list-style-type: none"> Primary endpoint: RFS Secondary endpoint: OS 	<ul style="list-style-type: none"> FPCD: Q4 2023 LPCD: Q1 2026 Data anticipated: H2 2027
Phase III ARTEMIDE-Biliary02 NCT07221253 Partnered (Compugen)	1L advanced BTC	1100	<ul style="list-style-type: none"> Randomised, open label, global, multicentre Arm 1: rilvegostomig + gemcitabine/cisplatin Arm 2: <i>Imfinzi</i> + gemcitabine/cisplatin 	<ul style="list-style-type: none"> Primary endpoint: OS Secondary endpoints: PFS, ORR, DoR 	<ul style="list-style-type: none"> FPCD: Q4 2025 Data anticipated: >2027
Phase III ARTEMIDE-Gastric01 NCT06764875 Partnered (Compugen)	HER2-positive PD-L1 CPS ≥ 1 locally advanced or metastatic gastric or GEJ adenocarcinoma	840	<ul style="list-style-type: none"> Randomised, multicentre Arm A: rilvegostomig + <i>Enhertu</i> + fluoropyrimidine Arm B: trastuzumab + CTx + pembrolizumab Arm C: trastuzumab + chemotherapy + rilvegostomig 	<ul style="list-style-type: none"> Primary endpoints: PFS, OS Secondary endpoints: ORR, DoR 	<ul style="list-style-type: none"> FPCD: Q1 2025 Data anticipated: >2027
Phase III ARTEMIDE-HCC01 NCT06921785 Partnered (Compugen)	Advanced HCC not amenable to curative therapy or locoregional therapy	1220	<ul style="list-style-type: none"> Randomised, open-label, multicentre, global trial Arm A: <i>Imjudo</i>, rilvegostomig + bevacizumab Arm B: rilvegostomig + bevacizumab Arm C: atezolizumab + bevacizumab 	<ul style="list-style-type: none"> Primary endpoint: OS Secondary endpoints: PFS, ORR, DoR 	<ul style="list-style-type: none"> FPCD: Q2 2025 Data anticipated: >2027
Phase IIb GEMINI-Gastric NCT05702229 Partnered (Compugen)	Gastric cancer	360	<ul style="list-style-type: none"> Open-label gastric platform trial Sub-study 1: volrustomig + XELOX or FOLFOX Sub-study 2: rilvegostomig + XELOX or FOLFOX Sub-study 3: sonestatug vedotin + volrustomig plus fluorouracil or capecitabine Sub-study 4: sonestatug vedotin + fluorouracil or capecitabine with or without rilvegostomig 	<ul style="list-style-type: none"> Primary endpoints: safety and efficacy (ORR and PFS6) Secondary endpoints: DoR, OS, PK, ADA and safety 	<ul style="list-style-type: none"> FPCD: Q1 2023 Data anticipated: >2027
Phase IIb GEMINI-PeriOp Gastric NCT07069712 Partnered (Compugen)	Gastroesophageal adenocarcinoma	250	<ul style="list-style-type: none"> Open-label platform study Substudy 1: sonestatug vedotin + rilvegostomig and 5-FU or capecitabine Substudy 2: <i>Enhertu</i> + rilvegostomig and 5-FU or capecitabine Substudy 3: rilvegostomig + FLOT chemotherapy 	<ul style="list-style-type: none"> Primary endpoints: safety, pCR rate 	<ul style="list-style-type: none"> FPCD: Q3 2025 Data anticipated: >2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



rilvegostomig (PD-1/TIGIT bispecific mAb)

Lung cancer

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III ARTEMIDE-Lung02 NCT06692738 Partnered (Compugen)	1L PD-L1 TC ≥1% squamous NSCLC	1160	<ul style="list-style-type: none"> Randomised, double-blind, multicentre Arm 1: rilvegostomig + platinum-based CTx followed by maintenance rilvegostomig Arm 2: pembrolizumab + platinum-based CTx followed by maintenance pembrolizumab 	<ul style="list-style-type: none"> Primary endpoints: PFS, OS Secondary endpoint: OS, ORR, DoR 	<ul style="list-style-type: none"> FPCD: Q4 2024 Data anticipated: >2027
Phase III ARTEMIDE-Lung03 NCT06627647 Partnered (Compugen)	1L PD-L1 TC ≥1% non-squamous NSCLC	1160	<ul style="list-style-type: none"> Randomised, double-blind, multicentre trial Arm 1: rilvegostomig + platinum-based CTx followed by maintenance rilvegostomig monotherapy + pemetrexed Arm 2: pembrolizumab + platinum-based CTx followed by maintenance pembrolizumab monotherapy + pemetrexed in maintenance 	<ul style="list-style-type: none"> Primary endpoints: PFS and OS Secondary endpoints: OS, ORR and DoR 	<ul style="list-style-type: none"> FPCD: Q4 2024 Data anticipated: >2027
Phase III ARTEMIDE-Lung04 NCT06868277 Partnered (Compugen)	1L PD-L1 TC ≥50% NSCLC	830	<ul style="list-style-type: none"> Randomised, double-blind, multicentre Arm A: rilvegostomig Arm B: pembrolizumab 	<ul style="list-style-type: none"> Primary endpoints: PFS, OS Secondary endpoints: ORR, DoR 	<ul style="list-style-type: none"> FPCD: Q3 2025 Data anticipated: >2027
Phase II LIBRA NCT07098338 Partnered (Daiichi Sankyo)	Locally advanced or metastatic NSCLC Sub-study 1- 1L non-AGA, PD-L1 ≥50% Sub-study 2 - 1L non-AGA, PD-L1 1-49% Sub-study 3 - 2L AGA+	278	<ul style="list-style-type: none"> Non-randomised, sequential assignment, open label trial Sub-study 1: rilvegostomig ± ramucirumab, i.v. Sub-study 2: rilvegostomig + ramucirumab, i.v. Sub-study 3: <i>Datroway</i> + ramucirumab ± rilvegostomig, i.v. 	<ul style="list-style-type: none"> Primary endpoints: safety and ORR Secondary endpoints: BOR, PFS, DCR, DoR, OS, PK parameters and ADA 	<ul style="list-style-type: none"> FPCD: Q3 2025 Data anticipated: >2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



rilvegostomig (PD-1/TIGIT bispecific mAb)

Lung cancer

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II ALTAIR NCT06996782	Advanced or metastatic NSCLC	116	<ul style="list-style-type: none"> Part A (safety run in): rilvegostomig + platinum-based CTx +/- ramucirumab Part B (dose expansion): rilvegostomig + platinum-based CTx +/- ramucirumab 	<ul style="list-style-type: none"> Primary endpoints: safety and tolerability, RP2D, DLT (Part A), ORR (Part B) Secondary endpoints: DoR, TTR, DCR, PFS, OS, PK measures, ORR (Part A) 	<ul style="list-style-type: none"> FPCD: Q4 2025 Data anticipated: >2027
Phase I/II ARTEMIDE-01 NCT04995523 Partnered (Compugen)	NSCLC	211	<ul style="list-style-type: none"> Global, open-label, dose escalation and dose expansion trial Part A: dose escalation in CPI-experienced stage III (unresectable) & stage IV NSCLC patients with rilvegostomig i.v. monotherapy Part B: dose expansion in CPI-experienced stage III (unresectable) & stage IV NSCLC patients with rilvegostomig i.v. monotherapy Part C: dose expansion in CPI-naïve stage IV NSCLC patients with rilvegostomig i.v. monotherapy Part D: randomised dose expansion in CPI-naïve stage IV NSCLC patients with rilvegostomig i.v. monotherapy Part E: dose expansion in treatment-naïve stage IV squamous NSCLC patients with rilvegostomig i.v. monotherapy 	<ul style="list-style-type: none"> Primary endpoints (Part A): safety, RP2D and MTD Primary endpoints (Part B): safety and efficacy (ORR) Primary endpoints (Part C): safety and efficacy (ORR) Primary endpoints (Part D): safety and efficacy (ORR) Primary endpoints (Part E): safety and efficacy (ORR) Secondary endpoints: PK parameters, PD (receptor occupancy), efficacy (DCR, DoR, DRR, PFS) 	<ul style="list-style-type: none"> FPCD: Q4 2021 LPCD: Q1 2026 Data anticipated: H2 2026
Phase I ARTEMIDE-subQ NCT07161414 Partnered (Compugen)	Solid tumours	40	<ul style="list-style-type: none"> Part 1 (dose finding): subcutaneous rilvegostomig, 2 planned dose levels (DL1, DL2) Part 2: (dose confirmation): subcutaneous rilvegostomig, dose selected in Part 1 	<ul style="list-style-type: none"> Primary endpoint: AUCtau Secondary endpoint: safety, Ctrough, Cavg, serum rilvegostomig concentration 	<ul style="list-style-type: none"> FPCD: Q4 2025 Data anticipated: H2 2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



rilvegostomig (PD-1/TIGIT bispecific mAb)

Solid tumours

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase IIb GEMINI-Hepatobiliary NCT05775159 Partnered (Compugen)	HCC, BTC	294	<ul style="list-style-type: none"> Open-label platform trial HCC sub-study: <ul style="list-style-type: none"> Cohort 1A: volrustomig monotherapy Cohort 1B: volrustomig + bevacizumab Cohort 1C: volrustomig + lenvatinib Cohort 1D: volrustomig + rilvegostomig + bevacizumab Cohort 1E: rilvegostomig + bevacizumab BTC sub-study: <ul style="list-style-type: none"> Cohort 2A: rilvegostomig + gemcitabine + cisplatin Cohort 2B: volrustomig + gemcitabine + cisplatin 	<ul style="list-style-type: none"> Primary endpoints (HCC sub-study): safety and efficacy (ORR) Primary endpoints (BTC sub-study): safety and efficacy (PFS6) Secondary endpoints: DoR, OS, PK and ADA 	<ul style="list-style-type: none"> FPCD: Q2 2023 Data anticipated: H2 2027



saruparib (AZD5305, PARP1 inhibitor)

Solid tumours

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III EvoPAR-Breast01 NCT06380751	BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative advanced breast cancer	788	<ul style="list-style-type: none"> Randomised, open-label trial Arm 1: saruparib + <i>Etcamah</i> Arm 2: physician's choice CDK4/6i + physician's choice ET Arm 3: physician's choice CDK4/6i + <i>Etcamah</i> Arm 4: saruparib + ET (CoC) 	<ul style="list-style-type: none"> Primary endpoint: PFS (BICR) Secondary endpoints: PFS and OS 	<ul style="list-style-type: none"> FPCD: Q3 2024 Data anticipated: >2027
Phase III EvoPAR-Prostate01 NCT06120491	HRRm and non-HRRm mHSPC	1898	<ul style="list-style-type: none"> Randomised, placebo-controlled trial Arm 1: saruparib + physician's choice NHA (abiraterone, darolutamide or enzalutamide) Arm 2: placebo + physician's choice NHA (abiraterone, darolutamide or enzalutamide) 	<ul style="list-style-type: none"> Primary endpoint: rPFS Secondary endpoints: OS and PFS2 	<ul style="list-style-type: none"> FPCD: Q4 2023 LPCD: Q3 2026 Data anticipated: H2 2027
Phase III EvoPAR-Prostate02 NCT06952803	High-risk BRCaM prostate cancer patients (adjuvant setting)	700	<ul style="list-style-type: none"> Randomised, double-blind trial Cohort A: <ul style="list-style-type: none"> Arm 1: saruparib + ADT Arm 2: placebo + ADT Cohort B: <ul style="list-style-type: none"> Arm 1: saruparib + ADT + abiraterone + prednisolone/prednisone Arm 2: placebo + ADT + abiraterone + prednisolone/prednisone 	<ul style="list-style-type: none"> Primary: Metastasis-free survival Key secondary: OS 	<ul style="list-style-type: none"> FPCD: Q2 2026 Data anticipated: >2027
Phase III EvoPAR-Prostate05 NCT07711002	HRRm and non-HRRm mHSPC	1330	<ul style="list-style-type: none"> Randomised, placebo-controlled trial Arm 1: saruparib + ADT + ARPI Arm 2: placebo + ADT + ARPI 	<ul style="list-style-type: none"> Primary endpoint: rPFS by Investigator Secondary endpoints: OS 	<ul style="list-style-type: none"> Data anticipated: >2027
Phase I/IIa PETRA NCT04644068	Advanced solid tumours	702	<ul style="list-style-type: none"> Modular, open-label, multi-centre dose escalation and expansion trial Module 1: saruparib Module 2: saruparib + paclitaxel Module 3: saruparib + carboplatin +/- paclitaxel Module 4: saruparib + <i>Enhertu</i> Module 5: saruparib + <i>Datroway</i> Module 6: saruparib + <i>Etcamah</i> 	<ul style="list-style-type: none"> Primary endpoints: safety, tolerability and PK parameters Secondary endpoint: efficacy 	<ul style="list-style-type: none"> FPCD: Q4 2020 LPCD: Q3 2025 Data anticipated: H2 2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



saruparib (AZD5305, PARP1 inhibitor)

Solid tumours

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase I/IIa PETRANHA NCT05367440	Metastatic prostate cancer	175	<ul style="list-style-type: none">Multi-arm, open-label, non-randomised, multi-centre trialArm 1: saruparib + enzalutamideArm 2: saruparib + abiraterone acetateArm 3: saruparib + darolutamideArm 4: saruparib + apalutamide	<ul style="list-style-type: none">Primary endpoints: safety and tolerabilitySecondary endpoints: PK parameters and efficacy	<ul style="list-style-type: none">FPCD: Q2 2022LPCD: Q3 2025Data anticipated: >2027
Phase I ASCERTAIN NCT05938270	Newly diagnosed prostate cancer	120	<ul style="list-style-type: none">Open-label, randomised, multi-centre trial	<ul style="list-style-type: none">Primary endpoint: effects of treatment on γH2AX changeSecondary endpoints: safety and tolerability, impact on surgical feasibility and change in Ki67	<ul style="list-style-type: none">FPCD: Q3 2023LPCD: Q2 2026Data readout: Q3 2026

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



sonesitug vedotin (AZD0901, CLDN18.2 MMAE ADC)

Solid tumours

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III CLARITY-Gastric01 NCT06346392	2L+ advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2	594	<ul style="list-style-type: none"> Multi-centre, open-label, sponsor-blinded, randomised trial Arm 1: sonesitug vedotin dose level 1 via i.v. infusion treatment Arm 2: sonesitug vedotin dose level 2 via i.v. infusion treatment Arm 3: investigator's choice CTx 	<ul style="list-style-type: none"> Primary endpoints: PFS and OS Secondary endpoints: OS, PFS for 3L+, ORR, ORR for 3L+, DoR, MMAE, safety and tolerability, PK parameters and prevalence of ADAs 	<ul style="list-style-type: none"> FPCD: Q2 2024 LPCD: Q2 2026 Data readout: Q3 2026 Primary endpoint met
Phase III CLARITY-Gastric02 NCT07431281	1L advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2	2130	<ul style="list-style-type: none"> Cohort 1: <ul style="list-style-type: none"> sonesitug vedotin in combination with rilvegostomig and capecitabine sonesitug vedotin in combination with nivolumab and capecitabine SoC nivolumab plus capecitabine plus oxaliplatin (CAPOX) or folinic acid, 5-fluorouracil, and oxaliplatin (FOLFOX) Cohort 2: <ul style="list-style-type: none"> sonesitug vedotin in combination with capecitabine CAPOX or FOLFOX alone or in combination with zolbetuximab 	<ul style="list-style-type: none"> Primary endpoints: PFS (Cohort 1 and Cohort 2) and OS (Cohort 1) Secondary endpoints: OS (Cohort 2); ORR, DoR, PK, Immunogenicity, safety & tolerability 	<ul style="list-style-type: none"> FPCD: Q1 2026 Data anticipated: >2027
Phase II CLARITY-PanTumour01 NCT06219941	Locally advanced unresectable or metastatic solid tumours expressing CLDN18.2	224	<ul style="list-style-type: none"> Open-label, multi-centre trial Sub-study 1: sonesitug vedotin monotherapy (gastric cancer) Sub-study 2: sonesitug vedotin and anti-cancer agents (pancreatic cancer) Sub-study 3: sonesitug vedotin monotherapy (BTC) 	<ul style="list-style-type: none"> Primary endpoints: AEs, SAEs and ORR Secondary endpoints: OS, PFS, DoR, DCR, PK parameters and prevalence of ADAs 	<ul style="list-style-type: none"> FPCD: Q1 2024 Data anticipated: H1 2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



surovatamig (CD19/CD3 T-cell engager)

Haematologic malignancies

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III SOUNDTRACK-D2 NCT07215585	B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma (elderly)	420	<ul style="list-style-type: none"> Multi-centre, randomised Safety run-in Arm 1: R-mini-CHOP followed by surovatamig Arm 2: R-mini-CHOP 	<ul style="list-style-type: none"> Primary: PFS Key secondary: OS 	<ul style="list-style-type: none"> Data anticipated: >2027
Phase III SOUNDTRACK-F1 NCT06549595	Previously untreated follicular lymphoma	1015	<ul style="list-style-type: none"> Multi-centre, randomised, open-label trial Arm 1: rituximab + surovatamig followed by observation Arm 2: rituximab + surovatamig followed by maintenance AZD0486 Arm 3: Investigator's choice of RCHOP/RCVP/BR followed by standard of care maintenance or observation 	<ul style="list-style-type: none"> Co-Primary endpoints: PFS and ORR Secondary endpoint: CR 	<ul style="list-style-type: none"> FPCD: Q3 2024 Data anticipated: >2027
Phase I/III SOUNDTRACK-C1 NCT07509151	Chronic lymphocytic leukaemia/small lymphocytic lymphoma with unmutated IGHV	400	<ul style="list-style-type: none"> Safety run-in: surovatamig Dose 1 and 2 subcutaneous injection Randomised, open-label: Arm A: surovatamig subcutaneous injection consolidation post-SoC induction therapy Arm B: Observation post-SoC induction therapy 	<ul style="list-style-type: none"> Primary endpoint (safety run in): safety and tolerability Primary endpoint (Phase III): PFS Secondary endpoints (Phase III): ORR, CR, DoR, OS, PK 	<ul style="list-style-type: none"> FPCD: Q2 2026 Data anticipated: >2027
Phase II SOUNDTRACK-B NCT06526793	B-cell non-Hodgkin lymphoma, follicular lymphoma and diffuse large B-cell lymphoma	270	<ul style="list-style-type: none"> Multi-centre, single-arm, open-label trial Module 1: follicular lymphoma Module 2 diffuse large B-cell lymphoma 	<ul style="list-style-type: none"> Primary endpoint: ORR Secondary endpoints: DoR, CR and PFS 	<ul style="list-style-type: none"> FPCD: Q4 2024 Data anticipated: H2 2027
Phase I/IIb SYRUS NCT06137118	R/R B-ALL	255	<ul style="list-style-type: none"> Multi-centre, open-label, single-arm dose escalation and dose optimisation trial 	<ul style="list-style-type: none"> Ph1 primary endpoints: DLT, and safety Ph2 primary endpoint: CR Secondary endpoints: ORR, DoR, CR rate at any time during trial, EFS, OS, subsequent alloSCT, CR MRD-negative rate, PK parameters and ADA 	<ul style="list-style-type: none"> FPCD: Q1 2024 Data anticipated: >2027
Phase I/II SOUNDTRACK-E NCT06564038	Mature B-cell malignancies (chronic lymphocytic leukaemia/small lymphocytic leukaemia, mantle-cell lymphoma, and large B-cell lymphoma)	408	<ul style="list-style-type: none"> Multi-centre, open-label trial Sub-study 1 (RR CLL/SLL): surovatamig in IV or SC Sub-study 2 (RR MCL): surovatamig in IV or SC Sub-study 3 (RR LBCL): surovatamig IV + R-CHOP 	<ul style="list-style-type: none"> Primary endpoints: DLT and safety Secondary endpoints: ORR, CR rate, DoR, Cmax, AUC, Cmin, Tmax, Ctrough, half-life of AZD0486, clearance of AZD0486 and ADA 	<ul style="list-style-type: none"> FPCD: Q1 2025 Data anticipated: >2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



surovatamig (CD19/CD3 T-cell engager)

Haematologic malignancies

Trial	Population	Patients	Design	Endpoints	Status
Phase I NCT04594642	R/R B-cell non-Hodgkin lymphoma	317	<ul style="list-style-type: none">Multi-centre, open-label, dose escalation and dose expansion trial	<ul style="list-style-type: none">Primary endpoints: safety and tolerability, MTD and/or RP2D and PK parametersSecondary endpoints: clinical activity of AZD0486 monotherapy and ADA titers for AZD0486 monotherapy	<ul style="list-style-type: none">FPCD: Q1 2021Data anticipated: >2027



torvutatug samrotecan (torvu-sam, AZD5335, anti-FR α TOP1i ADC)

Ovarian cancer, solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase III TREVI-OC-01 NCT07218809	Previously treated FR α -expressing platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer	1100	<ul style="list-style-type: none"> Randomised, open-label FRα-high cohort: <ul style="list-style-type: none"> Arm 1: torvu-sam Arm 2: mirvetuximab soravtansine FRα-low cohort: <ul style="list-style-type: none"> Arm 1: torvu-sam Arm 2: investigator's choice single-agent CTx 	<ul style="list-style-type: none"> Primary endpoint: PFS Secondary endpoint: OS, ORR, safety & tolerability, HRQoL 	<ul style="list-style-type: none"> FPCD: Q2 2026 Data anticipated: >2027
Phase III TREVI-OC-02 NCT07851025	HRD-negative advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer	950	<ul style="list-style-type: none"> Randomised, open-label trial Arm 1: torvu-sam + bevacizumab Arm 2: bevacizumab 	<ul style="list-style-type: none"> Primary endpoint: PFS Secondary endpoints: OS, PFS2, TFST, TSST, HRQoL, safety and tolerability 	<ul style="list-style-type: none"> Data anticipated: >2027 Initiating
Phase III TREVI-OC-03 NCT07816666	Platinum-sensitive relapsed advanced, epithelial ovarian, fallopian tube, or primary peritoneal cancer following completion of second-line or third-line chemotherapy	600	<ul style="list-style-type: none"> Randomised, open-label trial Arm 1: torvu-sam +/- bevacizumab Arm 2: SoC (observation or bevacizumab) 	<ul style="list-style-type: none"> Primary Endpoint: PFS Secondary Endpoints: OS, PFS2, TFST, TSST, HRQoL, safety & tolerability 	<ul style="list-style-type: none"> Data anticipated: >2027 Initiating
Phase I/II FONTANA NCT05797168	Advanced solid tumour malignancies	602	<ul style="list-style-type: none"> Module 1: torvu-sam monotherapy Module 2: torvu-sam + saruparib Module 3: torvu-sam + bevacizumab Module 4: torvu-sam + carboplatin +/- bevacizumab Module 5: torvu-sam + palacaparib +/- bevacizumab Module 6: torvu-sam + pembrolizumab +/- palacaparib 	<ul style="list-style-type: none"> Primary endpoints: safety and tolerability Secondary endpoints: efficacy and PK parameters 	<ul style="list-style-type: none"> FPCD: Q3 2023 Data anticipated: >2027
Phase I NCT07402915	Ovarian, primary peritoneal, or fallopian tube cancer	32	<ul style="list-style-type: none"> Open-label, fixed sequence study; torvu-sam/torvu-sam + itraconazole 	<ul style="list-style-type: none"> Primary endpoint: PK Secondary endpoints safety and tolerability, efficacy 	<ul style="list-style-type: none"> FPCD: Q1 2026 Data anticipated: H2 2027



volrustomig (PD-1/CTLA-4 bispecific mAb)

Solid tumours

Approved medicines
Late-stage development
Early development

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease

Trial	Population	Patients	Design	Endpoints	Status
Phase III eOLVE-Cervical NCT06079671	High-risk locally advanced cervical cancer with no progression following platinum-based cCRT	800	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled, multi-centre trial Arm 1: volrustomig Arm 2: placebo 	<ul style="list-style-type: none"> Primary endpoint: PFS (INV, ITT) Secondary endpoints: OS, ORR, DoR 	<ul style="list-style-type: none"> FPCD: Q4 2023 Data anticipated: H2 2027
Phase III eOLVE-HNSCC NCT06129864	Unresected locally advanced HNSCC	1145	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled, multicentre trial Arm 1: volrustomig Arm 2: observational 	<ul style="list-style-type: none"> Primary endpoint: PFS (BICR, PD-L1 expressing tumours) Secondary endpoints: PFS (BICR, ITT), landmark PFS, OS (PD-L1 expressing tumours), landmark OS and OS (ITT) 	<ul style="list-style-type: none"> FPCD: Q1 2024 Data anticipated: >2027
Phase III eOLVE-Lung02 NCT05984277	1L PD-L1 <50% mNSCLC	895	<ul style="list-style-type: none"> Double-arm randomised, open-label trial Arm 1: volrustomig + CTx Arm 2: pembrolizumab + CTx 	<ul style="list-style-type: none"> Primary endpoints: OS and PFS (PD-L1 < 1%) Secondary endpoints: PFS (ITT), ORR and DoR . . 	<ul style="list-style-type: none"> FPCD: Q4 2023 Trial discontinued due to efficacy
Phase III eOLVE-Meso NCT06097728	1L unresectable malignant pleural mesothelioma	863	<ul style="list-style-type: none"> Double-arm, randomised, open-label trial Arm 1: volrustomig + CTx Arm 2: CTx or nivolumab + ipilimumab 	<ul style="list-style-type: none"> Primary endpoint: OS Secondary endpoints: PFS, landmark OS, landmark PFS and ORR 	<ul style="list-style-type: none"> FPCD: Q4 2023 Data anticipated: >2027
Phase IIb eOLVE-01 NCT06448754	Metastatic NSCLC	194	<ul style="list-style-type: none"> Platform, randomised, open-label, multicentre, global trial Substudy 1: mNSCLC (non-squamous) Arm 1A: volrustomig dose regimen 1 + CTx Arm 1B: volrustomig dose regimen 2 + CTx Substudy 2: mNSCLC (non-squamous or squamous) Arm 2A: volrustomig dose regimen 2 + ramucirumab + CTx 	<ul style="list-style-type: none"> Primary endpoints: safety, & tolerability, ORR Secondary endpoints: DCR, DoR, PFS, OS 	<ul style="list-style-type: none"> FPCD: Q3 2024 Data anticipated: H2 2027



volrustomig (PD-1/CTLA-4 bispecific mAb)

Solid tumours

Approved medicines
Late-stage development
Early development

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease

Trial	Population	Patients	Design	Endpoints	Status
Phase II CANTOR NCT06792695	Metastatic colorectal cancer	80	<ul style="list-style-type: none"> Platform, randomised, open-label, multicentre, global trial Arm A: volrustomig + FOLFIRI + bevacizumab Arm B: FOLFIRI + bevacizumab 	<ul style="list-style-type: none"> Primary endpoints: PFS, safety Secondary endpoints: OS, ORR, DCR, DoR 	<ul style="list-style-type: none"> FPCD: Q1 2025 Data anticipated: H1 2027
Phase II eVOLVE-02 NCT06535607	Advanced/metastatic solid tumours	257	<ul style="list-style-type: none"> Platform, multicentre trial Sub-study 1: volrustomig monotherapy in cervical cancer Sub-study 2: volrustomig monotherapy in head and neck squamous cell carcinoma Sub-study 3: volrustomig + CTx in head and neck squamous cell carcinoma Sub-study 4: volrustomig + CTx in esophageal squamous cell carcinoma Sub-study 5: volrustomig monotherapy in unresectable pleural mesothelioma 	<ul style="list-style-type: none"> Primary endpoints: ORR and safety Secondary endpoints: DoR, PFS, TTR, OS, DCR, PK parameters and immunogenicity 	<ul style="list-style-type: none"> FPCD: Q3 2024 Data anticipated: >2027
Phase Ib NCT04522323	Advanced renal cell carcinoma	67	<ul style="list-style-type: none"> Open-label, dose escalation and dose expansion trial Arm 1: volrustomig + axitinib Arm 2: volrustomig + lenvatinib 	<ul style="list-style-type: none"> Primary endpoints (escalation): safety, MTD, RP2D, tolerability and anti-tumour activity of combination (ORR) Secondary endpoints: PK parameters, ADA and anti-tumour activity (PFS, OR, DoR, DCR, TTR, OS) 	<ul style="list-style-type: none"> FPCD: Q3 2020 LPCD: Q2 2023 Data readout: Q2 2026
Phase I NCT03530397	Advanced solid tumours	400	<ul style="list-style-type: none"> Open-label, dose escalation and dose expansion trial Dose escalation: volrustomig i.v. Dose expansion: volrustomig i.v. as monotherapy and + CTx Arm 1: volrustomig i.v. Arm 2: volrustomig i.v., pemetrexed + carboplatin Arm 3: pembrolizumab, pemetrexed + carboplatin Arm 4: volrustomig i.v., taxane (paclitaxel or nab-paclitaxel) + carboplatin 	<ul style="list-style-type: none"> Primary endpoints (escalation): safety and tolerability, MTD, OBD and HPDD Primary endpoint (expansion): antitumour activity based on ORR Secondary endpoints: PK parameters, ADA, tumoural baseline PD-L1, anti-tumour activity (OR, DoR, DCR, PFS, OS) 	<ul style="list-style-type: none"> FPCD: Q2 2018 LPCD: Q4 2023 Data readout: Q1 2026



AZD0120 (autologous anti-CD19 and anti-BCMA CAR-T)

Blood cancers

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III DURGA-4 NCT07391657	Relapsed/refractory multiple myeloma	508	<ul style="list-style-type: none"> Randomised, multicentre, controlled, open-label, global trial Arm A: AZD0120 Arm B: Standard regimens (DKd, DPd, PVd or Kd) 	<ul style="list-style-type: none"> Primary: PFS, MRD negativity rate at 9 months Secondary: CRR, ORR, OS 	<ul style="list-style-type: none"> FPCD: Q1 2026 Data anticipated: >2027
Phase III DURGA-5 NCT07764978	Newly diagnosed multiple myeloma transplant-ineligible (NDMM TNI)	750	<ul style="list-style-type: none"> Randomised, multicentre, controlled, open-label, global trial Arm A: AZD0120 Arm B: Standard regimens (Isa-VRD or DRd) 	<ul style="list-style-type: none"> Primary: PFS, MRD negativity rate at 9 months Secondary: CRR, ORR, OS 	<ul style="list-style-type: none"> FPCD: Q2 2026 Data anticipated: >2027
Phase III DURGA-6 NCT07735637	Newly diagnosed multiple myeloma (transplant-eligible)	750	<ul style="list-style-type: none"> Randomised, multicentre, controlled, open-label, global trial Arm A: AZD0120 followed by a maximum of 2 years lenalidomide monotherapy maintenance treatment Arm B: ASCT followed by a maximum of 2 years lenalidomide monotherapy maintenance treatment 	<ul style="list-style-type: none"> Primary: PFS, MRD negative CRR Secondary: CRR, ORR, OS, DoR, safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q3 2026 Data anticipated: >2027
Phase II DURGA-3 NCT06235229	Relapsed/refractory multiple myeloma	20	<ul style="list-style-type: none"> Open-label, multi-centre, non-randomised trial Phase II dose expansion China only 	<ul style="list-style-type: none"> Primary endpoint (Phase Ib): safety and tolerability measures Secondary endpoints (Phase Ib): PK parameters Primary endpoint (Phase II): ORR Secondary endpoints (Phase II): PFS, OS, MRD, DoR, TTR 	<ul style="list-style-type: none"> FPCD: Q3 2025 LPD: Q2 2026 Data anticipated: >2027
Phase I/II DURGA-1 NCT05850234	Relapsed/refractory multiple myeloma	232	<ul style="list-style-type: none"> Open-label, single-arm, multi-centre trial 	<ul style="list-style-type: none"> Primary endpoints: ORR Secondary endpoints: DoR, PFS, OS, MRD negative rate, AEs 	<ul style="list-style-type: none"> FPCD: Q3 2023 Data anticipated: H2 2027
Phase I DURGA-2 NCT07073547	Newly diagnosed multiple myeloma, early relapsed or primary refractory multiple myeloma	40	<ul style="list-style-type: none"> Open-label, single-arm, multi-centre trial 	<ul style="list-style-type: none"> Primary endpoints: incidence of AEs, SAEs and DLTs Secondary endpoints: ORR, CRR, DoR, TTR, MRD negative status at 9 months, AEs and PK parameters 	<ul style="list-style-type: none"> FPCD: Q3 2025 Data anticipated: H2 2026

Oncology


CVRM

R&I

Infectious Diseases

Rare Disease





Oncology

Early-stage development



IPH5201 (CD39 mAb)

Solid tumours

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase I NCT04261075 Partnered (Innate Pharma)	Advanced solid tumours	57	<ul style="list-style-type: none">Open-label, dose escalation trial to determine MTD of IPH5201 as monotherapy, or in combination with <i>Imfinzi</i> +/- oleclumabPart 1: IPH5201 monotherapy dose escalation to MTDPart 2: IPH5201 + <i>Imfinzi</i> dose escalation to MTDPart 3: IPH5201 + <i>Imfinzi</i> + oleclumab dose escalation to MTDRoute of administration: i.v.Global trial – US and EU	<ul style="list-style-type: none">Primary endpoints: AE, SAE and DLTSecondary endpoints: OR, DC, PK parameters and ADA	<ul style="list-style-type: none">FPCD: Q1 2020LPCD: Q2 2022Data readout: Q2 2023

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



JAB-23E73 (pan-KRAS inhibitor)

Solid tumours

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase Ib/III NCT07640295 Partnered (Jacobio)	1L metastatic PDAC harbouring KRAS gene alterations	80	<ul style="list-style-type: none"> JAB-23E73 + nab-paclitaxel + gemcitabine Phase 1b: multicentre, open-label study to determine RP3D China only 	<ul style="list-style-type: none"> Primary endpoints (Phase Ib): DLT, safety and tolerability Secondary endpoints (Phase Ib): efficacy, PK 	<ul style="list-style-type: none"> FPCD: Q3 2026 Data anticipated: >2027
Phase I/IIa NCT06973564 Partnered (Jacobio)	Advanced solid tumours with KRAS alteration	294	<ul style="list-style-type: none"> Non-randomised, open-label Phase 1a dose escalation Phase 1b dose expansion/optimisation Phase 2a indication expansion 	<ul style="list-style-type: none"> Primary endpoints: safety and tolerability, RP2D, preliminary efficacy Secondary endpoints: Efficacy, PK 	<ul style="list-style-type: none"> FPCD: Q2 2025 Data anticipated: H2 2027
Phase I/IIa NCT06959615 Partnered (Jacobio)	Advanced solid tumours with KRAS alteration	334	<ul style="list-style-type: none"> Multicentre, non-randomised, open-label China only study Phase 1: Dose escalation Phase IIa: Dose expansion 	<ul style="list-style-type: none"> Primary endpoints: DLT, ORR Secondary endpoints: safety and tolerability, PK, efficacy 	<ul style="list-style-type: none"> FPCD: Q4 2024 Data anticipated: H2 2026

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



NT-112 (KRAS G12D specific TCR-T)

Solid tumours

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase I NCT06218914	Unresectable, advanced/metastatic NSCLC, colorectal adenocarcinoma, pancreatic adenocarcinoma, endometrial Cancer or any other solid tumour histology positive for KRAS G12D variant mutation and HLA-C*08:02 positive, HLA-A* 11:01 or HLA-A* 11:02	108	<ul style="list-style-type: none">Open-label, adult, single-arm, multi-centre trial with dose escalation and expansionArm 1: NT-112 (autologous, engineered T Cells targeting KRAS G12D)Arm 2: AZD0240 (autologous, engineered T Cells targeting KRAS G12D)	<ul style="list-style-type: none">Primary endpoints: incidence of DLTs, TEAEs and SAEsSecondary endpoints: ORR per RECIST v.1.1, BOR, DoR, CBR (CR, PR, SD), TTR, PFS and OS	<ul style="list-style-type: none">FPCD: Q1 2024LPCD: Q3 2026Data anticipated: H2 2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



NT-175 (TP53 R175H armoured TCR-T)

Solid tumours

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase I NCT05877599	Unresectable, advanced, and/or metastatic solid tumours positive for HLA-A*02:01 and TP53 R175H mutation	45	<ul style="list-style-type: none">Open-label, single-arm, multi-centre trial with dose escalation and dose expansion components	<ul style="list-style-type: none">Primary endpoint: Incidence of DLTs, TEAEs and SAEsSecondary endpoints: ORR per RECIST v.1.1, BOR, DoR, CBR (CR, PR, SD), TTR, PFS and OS	<ul style="list-style-type: none">FPCD: Q3 2023Data anticipated: >2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



palacaparib (AZD9574, PARP1-sel BBB inhibitor)

Solid tumours

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase I/IIa CERTIS-1 NCT05417594	Advanced solid malignancies	695	<ul style="list-style-type: none"> Modular, open-label, multi-centre dose escalation and expansion trial Module 1: AZD9574 monotherapy Module 2: AZD9574 + temozolomide Module 3: [11C]AZ14193391 + AZD9574 or [11C]AZ14193391 + AZD9574 + temozolomide Module 4: AZD9574 + <i>Enhertu</i> Module 5: AZD9574 + <i>Datroway</i> 	<ul style="list-style-type: none"> Primary endpoints: safety and tolerability of AZD9574 as monotherapy and in combination with anti-cancer agents, determination of PARP1 occupancy in brain by AZD9574 at examined doses and plasma concentration and evaluation of safety of radioligand [11C]AZ14193391 Secondary endpoints: PK parameters and efficacy of AZD9574 as monotherapy and in combination with anti-cancer agents 	<ul style="list-style-type: none"> FPCD: Q3 2022 Data anticipated: >2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



vemzatatug vedotin (AZD0305, GPRC5D MMAE ADC)

Blood cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II NCT06106945	R/R multiple myeloma	226	<ul style="list-style-type: none">Open-label, dose escalation and dose expansion trialPhase I: AZD0305 in monotherapy or in combination with other anticancer agents, prescribed at specified dose levelsPhase II: AZD0305 monotherapy prescribed as RP2D	<ul style="list-style-type: none">Primary endpoints: occurrence of dose-limiting toxicities and incidence and severity of AEs and SAEsSecondary endpoints: ORR, DoR, PFS, OS, PK parameters and immunogenicity	<ul style="list-style-type: none">FPCD: Q4 2023Data anticipated: H2 2027



AZD0516 (STEAP2 ADC)

Prostate cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II SEACLIFF NCT07181161	mCRPC	177	<ul style="list-style-type: none">Open-label multi-centre, modular dose escalation and dose optimisation trial	<ul style="list-style-type: none">Primary endpoint: safety and tolerabilitySecondary endpoints: efficacy, PK and immunogenicity	<ul style="list-style-type: none">FPCD: Q4 2025Data anticipated: >2027



AZD0754 (STEAP2 dnTGFβRII-armoured CAR-T)

Solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II APOLLO NCT06267729	mCRPC with prior NHA and taxane exposure	60	<ul style="list-style-type: none">Open-label, single-arm, multi-centre trial with dose escalation and dose expansion components	<ul style="list-style-type: none">Primary endpoints (Phase I): DLT, AEs (including AESI and SAEs), determination of recommended dose for expansion phaseSecondary endpoints (Phase I): PSA related changes (PSA50, PSA90), radiological assessment according to RECIST v1.1 and PCWG3 (ORR, BOR, DRR, DCR, TTR, rPFS, OS), PK parameters (Cmax, Tmax, Tlast, AUC)	<ul style="list-style-type: none">FPCD: Q2 2024Data anticipated: H2 2027



AZD2284 (STEAP2 radioconjugate)

Prostate cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase I NCT06879041	mCRPC	134	<ul style="list-style-type: none">Part A (imaging):Part A (cold antibody exploration, optimal dosing exploration): AZD2284 +/- AZD2275Part A (expansion): prevalence of PSMA and STEAP2 expression by imagingPart B (therapeutic):Part B (actinium-225 dose escalation): AZD2284 dose escalation informed by Part APart B (expansion cohorts 1, 2): AZD2284	<ul style="list-style-type: none">Primary endpoints: safety and tolerabilitySecondary endpoints: anti-tumour activity, PK parameters and immunogenicity	<ul style="list-style-type: none">FPCD: Q1 2025Data anticipated: H2 2027



AZD2962 (IRAK4 inhibitor)

Blood cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase I NCT07064122	Haematologic neoplasms	7	<ul style="list-style-type: none">Modular, open-label, multicentreAZD2962 dose escalation	<ul style="list-style-type: none">Primary endpoints: DLT, AEs, duration of exposure, relative dose intensitySecondary endpoints: OR, DoR, TTR, OS, time to progression, PK measures	<ul style="list-style-type: none">FPCD: Q4 2025Trial discontinued due to strategic portfolio prioritisation



AZD3470 (PRMT5 inhibitor)

Solid tumours and blood cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II PRIMAVERA NCT06137144	R/R haematologic malignancies	110	<ul style="list-style-type: none"> Modular Phase I/II open-label dose escalation and expansion trial Module 1 – Part A (dose escalation): AZD3470 monotherapy Module 1 – Part B (dose expansion/optimisation): AZD3470 monotherapy Module 1 - Cohort 2 (consolidation above 50 yrs in 1L cHL): AZD3470 monotherapy Module 1 - Cohort 3 (r/r PTCL): AZD3470 monotherapy Module 2 - Cohort 1 (2L+ cHL): AZD3470 + pembrolizumab 	<ul style="list-style-type: none"> Primary endpoints: safety and tolerability Secondary endpoints: PK parameters and clinical efficacy 	<ul style="list-style-type: none"> FPCD: Q1 2024 Data anticipated: H1 2027
Phase I/II PRIMROSE NCT06130553	MTAP-deficient advanced solid tumours	334	<ul style="list-style-type: none"> Open-label, multicentre Module 1 (dose escalation): AZD3470 Module 2: <i>Datroway</i> + AZD3470 vs <i>Datroway</i> in 2L+ NSQ NSCLC 	<ul style="list-style-type: none"> Module 1: FTiH safety, PK parameters and efficacy Module 2: Efficacy and safety 	<ul style="list-style-type: none"> FPCD: Q1 2024 Data anticipated: H2 2027



AZD3632 (menin inhibitor)

Blood cancers

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II MOMENTUM NCT07155226	R/RAML, ALL and HR MDS with KMT2Ar, NPM1m, or other genotypes associated with homeobox (HOX) overexpression	84	<ul style="list-style-type: none">Module 1 (dose escalation): AZD3632Module 2: AZD3632 + posaconazole	<ul style="list-style-type: none">Primary endpoints: safety and tolerabilitySecondary endpoints: preliminary efficacy (CR, CRh, TTR, DoR, TI, EFS, OS), PK parameters	<ul style="list-style-type: none">FPCD: Q1 2026Data anticipated: >2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



AZD4045 (allogeneic BCMA-targeting Universal Effector Cell (UEC))

Haematology

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II NCT07681596	Relapsed/refractory multiple myeloma	101	<ul style="list-style-type: none">Modular, open-label, multicentre trialArm A: AZD4045Arm B: AZD4045 + daratumumab + aldesleukin	<ul style="list-style-type: none">Primary: safety and tolerability, DLTSecondary: efficacy, PK	<ul style="list-style-type: none">FPCD: Q3 2026Data anticipated: >2027



AZD4512 (CD22 TOP1i ADC)

Blood cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II ALLight NCT07109219	Acute Lymphoblastic Leukemia	83	<ul style="list-style-type: none"> Modular phase I/II, open-label multi-centre study Module 1 (dose escalation): AZD4512 Module 2 (dose expansion): AZD4512 	<ul style="list-style-type: none"> Module 1: <ul style="list-style-type: none"> Primary endpoints: safety Secondary endpoints: PK, safety, ORR, DoR, EFS, OS Module 2: <ul style="list-style-type: none"> Primary endpoints: ORR, safety Secondary endpoints: DoR, EFS, OS, PK, safety 	<ul style="list-style-type: none"> FPCD: Q4 2025 Data anticipated: >2027
Phase I/II Lumi-NHL NCT07123454	Relapsed/refractory B-cell Non-Hodgkin Lymphoma	120	<ul style="list-style-type: none"> Module 1: AZD4512 	<ul style="list-style-type: none"> Primary endpoints: safety measures Secondary endpoints: ORR, CR, DoR, PFS, OS 	<ul style="list-style-type: none"> FPCD: Q4 2025 Data anticipated: >2027



AZD4956 (POLQ inhibitor)

Solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II PARTHENON NCT07446855	HRRm solid tumours	180	<ul style="list-style-type: none">Module 1: AZD4956 monotherapyModule 2: AZD4956 + saruparibEach module may further contain 2 parts Part A (dose escalation/dose finding) and Part B (dose expansion)	<ul style="list-style-type: none">Primary endpoints: safety and tolerabilitySecondary: PFS, ORR, DoR,BOR	<ul style="list-style-type: none">FPCD: Q1 2026Data anticipated: >2027



AZD5492 (CD20 TITAN TCE)

Blood cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase I TITANIUM NCT06542250	Relapsed/refractory B-Cell malignancies	176	<ul style="list-style-type: none">Module 1: AZD5492 monotherapy	<ul style="list-style-type: none">Primary endpoints: safety and tolerabilitySecondary endpoints: preliminary efficacy (ORR, CRR, DoR, PFS, OS), PK parameters and immunogenicity	<ul style="list-style-type: none">FPCD: Q3 2024Data anticipated: >2027



AZD5863 (CLDN18.2 CD3 bispecific antibody)

Solid tumours

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II NCT06005493	Advanced or metastatic Claudin 18.2-expressing solid tumours	392	<ul style="list-style-type: none">Part A: AZD5863 dose escalationPart B: AZD5863 dose expansion	<ul style="list-style-type: none">Primary endpoints (Part A): safety and tolerabilityPrimary endpoints (Part B): safety, tolerability and preliminary anti-tumour activitySecondary endpoints: preliminary anti-cancer activity, PK parameters and immunogenicity	<ul style="list-style-type: none">FPCD: Q4 2023Data anticipated: >2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



AZD6621 (STEAP2 T-cell engager)

Prostate cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II ACTIVATED-4-PC NCT07192614	mCRPC	52	<ul style="list-style-type: none">Open-label, multi-centre, modular designPart A: (dose escalation): AZD6621Part B: (dose expansion): AZD6621	<ul style="list-style-type: none">Primary: safety, tolerabilitySecondary: efficacy, PK, immunogenicity	<ul style="list-style-type: none">FPCD: Q4 2025Data anticipated: >2027



AZD6750 (CD8 guided IL-2)

Solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II NCT07115043	Select advanced or metastatic solid tumours	120	<ul style="list-style-type: none">Open-label, dose escalation and expansion studyModule 1: AZD6750 monotherapyModule 2: AZD6750 + rilvegostomig	<ul style="list-style-type: none">Primary endpoints: Safety and efficacy measuresSecondary endpoints: PK/PD parameters, immunogenecity, efficacy	<ul style="list-style-type: none">FPCD: Q3 2025Data anticipated: >2027



AZD7003 (GPC3 CAR-T)

Hepatocellular carcinoma (HCC)

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase I STARLIGHT NCT06590246	GPC3-positive advanced/recurrent HCC	121	<ul style="list-style-type: none"> Open-label, single-arm, multicentre trial Part A1 (dose escalation): AZD7003 Part A2 (dose expansion): AZD7003 Part B: will not be opened China only 	<ul style="list-style-type: none"> Primary endpoints (Part A): DLT, AEs (including AESI and SAEs), determination of recommended dose for expansion phase Secondary endpoints (Part B): ORR per RECIST v. 1.1, TTR, DCR, DRR, BoR, DoR, PFS and OS; PK parameters (Cmax, Tmax, Tlast, AUC) 	<ul style="list-style-type: none"> FPCD: Q4 2024 Data anticipated: H1 2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



AZD8359 (STEAP2 T-cell engager)

Prostate cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II CRIUS-1 NCT07529717	Prostate cancer	42	<ul style="list-style-type: none">Open-label, multi-centre, modular designPart A (dose escalation): AZD8359Part B (dose expansion): AZD8359	<ul style="list-style-type: none">Primary: safety, tolerabilitySecondary: efficacy, PK, immunogenicity	<ul style="list-style-type: none">FPCD: Q2 2026Trial discontinued due to strategic portfolio prioritisation



AZD8421 (CDK2 inhibitor)

Breast cancer

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II CYCAD-1 NCT06188520	ER+ HER2-negative advanced breast cancer	204	<ul style="list-style-type: none">Module 1: AZD8421Module 2: AZD8421+ <i>Etcamah</i> + one or more of abemaciclib or ribociclib or palbociclib	<ul style="list-style-type: none">Primary endpoints: safety and tolerabilitySecondary endpoints: PK parameters	<ul style="list-style-type: none">FPCD: Q4 2023Trial discontinued due to strategic portfolio prioritisation

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



AZD9750 (AR PROTAC)

Prostate cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II ANDROMEDA NCT07336446	Metastatic prostate cancer	300	<ul style="list-style-type: none">Open-label, multicenterModule 1, Part A (dose escalation): AZD9750Module 1, Part B (dose optimisation and expansion): AZD9750Module 2, Part A (dose escalation): AZD9750 + saruparibModule 2, Part B (dose expansion): AZD9750 + saruparib	<ul style="list-style-type: none">Primary endpoints: safety and tolerability, clinical efficacy (Part B)	<ul style="list-style-type: none">FPCD: Q1 2026LPCD: Q2 2026Trial discontinued due to PK/PD



AZD9793 (GPC3 TITAN T-cell engager)

Solid tumours

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II RHEA-1 NCT06795022	Metastatic solid tumours	304	<ul style="list-style-type: none">Open label, non randomised, multi-centre, dose escalation and expansionModule 1: intravenous AZD9793Module 2: subcutaneous AZD9793	<ul style="list-style-type: none">Primary endpoint: safety and tolerabilitySecondary endpoints: ORR, BOR, DRR, DoR, TTR, PFS, OS, PK parameters	<ul style="list-style-type: none">Data anticipated: >2027

Oncology


CVRM

R&I

Infectious Diseases

Rare Disease





BioPharmaceuticals

Approved medicines
and late-stage pipeline

Baxfendy (baxdrostat, selective aldosterone synthase inhibitor)

Hypertension

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III Bax24 NCT06168409	Patients with resistant hypertension on three or more antihypertensive medications	218	<ul style="list-style-type: none"> Arm 1: <i>Baxfendy</i> 2mg QD Arm 2: placebo QD 	<ul style="list-style-type: none"> Primary endpoint: effect of <i>Baxfendy</i> vs. placebo on ambulatory 24-hour average systolic blood pressure at Week 12 	<ul style="list-style-type: none"> FPCD: Q2 2024 LPCD: Q2 2025 Data readout: Q4 2025 Primary endpoint met
Phase III BaxAsia NCT06344104	Patients with uncontrolled hypertension on two or more antihypertensive medications including patients with resistant hypertension	326	<ul style="list-style-type: none"> Arm 1: <i>Baxfendy</i> 1mg QD Arm 2: <i>Baxfendy</i> 2mg QD Arm 3: placebo QD 	<ul style="list-style-type: none"> Primary endpoint: effect of <i>Baxfendy</i> vs. placebo on seated systolic blood pressure at Week 12 Secondary endpoints: effect of <i>Baxfendy</i> vs. placebo on seated systolic blood pressure at 8 weeks after randomised withdrawal, safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q2 2024 LPCD: Q1 2025 Data readout: Q1 2026 Primary endpoint met
Phase III BaxHTN NCT06034743	Patients with uncontrolled hypertension on two or more antihypertensive medications including patients with resistant hypertension	796	<ul style="list-style-type: none"> Arm 1: <i>Baxfendy</i> 1mg QD Arm 2: <i>Baxfendy</i> 2mg QD Arm 3: placebo QD 	<ul style="list-style-type: none"> Primary endpoint: effect of <i>Baxfendy</i> vs. placebo on seated systolic blood pressure at Week 12 Secondary endpoints: effect of <i>Baxfendy</i> vs. placebo on seated systolic blood pressure at 8 weeks after randomised withdrawal, safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q1 2024 LPCD: Q1 2025 Data readout: Q3 2025 Primary endpoint met
Phase I NCT06657105	Healthy volunteers	22	<ul style="list-style-type: none"> Arm1: <i>Baxfendy</i> 2mg and ethinyl estradiol/levonorgestrel 0.06/0.3mg 	<ul style="list-style-type: none"> Primary endpoints: AUCinf, AUClast and Cmax 	<ul style="list-style-type: none"> FPCD: Q4 2024 LPCD: Q4 2024 Data readout: Q2 2025

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



Baxfendy (baxdrostat, selective aldosterone synthase inhibitor)

Primary aldosteronism

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III BaxPA NCT07007793	Primary aldosteronism	250	<ul style="list-style-type: none"> Multicentre, randomised, double-blind, placebo-controlled, parallel-group Arm 1: baxdrostat QD Arm 2: placebo QD 	<ul style="list-style-type: none"> Primary endpoints: change from baseline in seated systolic blood pressure and achieving normalisation of the renin angiotensin aldosterone system at week 8 	<ul style="list-style-type: none"> FPCD: Q3 2025 LPCD: Q3 2026 Data anticipated: H2 2027
Phase II SPARK NCT04605549	Patients with primary aldosteronism	18	<ul style="list-style-type: none"> Arm 1: <i>Baxfendy</i> 2-8mg QD US only 	<ul style="list-style-type: none"> Primary endpoints: safety and tolerability in patients with PA at doses from 2 to 8mg per day for 12 weeks and the reduction in SBP patients with PA after 12 weeks Secondary endpoints: reduction in DBP as a function of dose in patients with PA after 12 weeks of treatment, change in serum potassium and requirement for potassium supplementation and change in serum sodium and requirement for fluid or mineral replacement 	<ul style="list-style-type: none"> FPCD: Q3 2022 LPCD: Q2 2023 Data readout: Q1 2025



Wainua (eplontersen, ligand-conjugated antisense)

ATTR

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III CARDIO-TTRansform NCT04136171 Partnered (Ionis Pharmaceuticals, Inc.)	Hereditary or wild-type transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)	1438	<ul style="list-style-type: none"> Arm 1: <i>Wainua</i> s.c. Arm 2: placebo 	<ul style="list-style-type: none"> Primary endpoints: composite outcome of CV mortality and recurrent CV clinical events at Week 140 Secondary endpoints: 6MWT, KCCQ, CV events and CV mortality, all cause mortality, composite outcome of CV mortality and recurrent CV clinical events in subgroup of patients treated with tafamidis at baseline 	<ul style="list-style-type: none"> FPCD: Q1 2020 Data readout: Q3 2026 Primary endpoint not met
Phase III EPIC-ATTR NCT06194825	Hereditary or wild-type transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)	64	<ul style="list-style-type: none"> Arm 1: <i>Wainua</i> s.c. Q4W Arm 2: placebo China only 	<ul style="list-style-type: none"> Primary endpoint (at week 24): percent change from baseline in serum TTR concentration Secondary endpoints: PK, immunogenicity, disease biomarkers (NT pro-BNP, hsTnT) 	<ul style="list-style-type: none"> FPCD: Q4 2023 Data readout: Q2 2026 Primary endpoint met
Phase III NEURO-TTRansform NCT04136184 Partnered (Ionis Pharmaceuticals, Inc.)	Hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)	168	<ul style="list-style-type: none"> Arm 1: <i>Wainua</i> s.c. Arm 2: inotersen s.c. 	<ul style="list-style-type: none"> Primary endpoints (at Week 35): change from baseline in mNIS+7 and percent change from baseline in TTR concentration Secondary endpoint (Week 35): changes from baseline in Norfolk QoL Primary endpoints (at Week 66): change from baseline in mNIS+7, change from baseline in the Norfolk QoL-DN Questionnaire and percent change from baseline in TTR concentration 	<ul style="list-style-type: none"> FPCD: Q1 2020 LPCD: Q3 2023 Data readout: Q2 2022 Co-primary endpoints met at Week 35 and Week 66
Phase II ATTRiumph NCT07608354	Transthyretin amyloid cardiomyopathy (ATTR-CM)	326	<ul style="list-style-type: none"> Randomised, double-blind, multicentre trial Arm A: <i>Wainua</i> + clirmitug Arm B: <i>Wainua</i> + placebo 	<ul style="list-style-type: none"> Primary endpoint: cardiopulmonary exercise test peak VO2 at week 52 Secondary endpoints: extracellular volume, KSSQ-CSS, NT-proBNP 	<ul style="list-style-type: none"> Trial discontinued due to strategic portfolio prioritisation

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



balcinrenone/dapagliflozin (MR antagonist/modulator + SGLT2 inhibitor)

Heart failure, CKD

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III BalanceD-CKD NCT07624305	Patients with CKD Stage 3b and 4	2800	<ul style="list-style-type: none"> Randomised, double-blind, double-dummy, parallel-group, active-controlled, event-driven trial Arm 1: balcinrenone/dapagliflozin 15mg/10mg Arm 2: dapagliflozin 10mg 	<ul style="list-style-type: none"> Primary endpoint: Time from randomisation to first occurrence of CV death, death from kidney failure, kidney failure, sustained 50% or greater decline in eGFR, and heart failure event Secondary endpoints: Time from randomisation to first occurrence of CV death, death from kidney failure, kidney failure and sustained 50% or greater decline in eGFR; change from baseline in urinary albumin to creatinine ratio to Week 24; time from randomisation to first occurrence of CV death or heart failure event; time from randomisation to CV death; time from randomisation to death from any cause 	<ul style="list-style-type: none"> FPCD: Q3 2026 Data anticipated: >2027
Phase III BalanceD-HF NCT06307652	Heart failure patients with renal impairment (eGFR 20-60 ml/min) with heart failure event within the last 6 months	3850	<ul style="list-style-type: none"> Randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven trial Arm 1: balcinrenone/dapagliflozin 15mg/10mg Arm 2: balcinrenone/dapagliflozin 40mg/10mg Arm 3: dapagliflozin 10mg 	<ul style="list-style-type: none"> Primary endpoint: time to first occurrences of any the components of the composite of CV death, HF hospitalisation and HF event without hospitalisation Secondary endpoints: total occurrences (first and recurrent) of the components of the composite of CV death, HF hospitalisation and HF event without hospitalisation; total occurrences (first and recurrent) of HF hospitalisations; time to CV death; time to death from any cause; change in KCCQ total symptom score from baseline to 24-weeks 	<ul style="list-style-type: none"> FPCD: Q2 2024 Data anticipated: H1 2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



balcinrenone/dapagliflozin (MR antagonist/modulator + SGLT2 inhibitor)

Heart failure, CKD

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase IIb MIRO-CKD <u>NCT06350123</u>	CKD	300	<ul style="list-style-type: none">• Multicentre, randomised, double-blind, dose-finding, parallel group, double-dummy trial• Arm 1: balcinrenone/dapagliflozin 15 mg/10 mg once daily• Arm 2: balcinrenone/dapagliflozin 40 mg/10 mg once daily• Arm 3: dapagliflozin 10 mg once daily	<ul style="list-style-type: none">• Primary endpoint: Relative change in UACR from baseline to Week 12	<ul style="list-style-type: none">• FPCD: Q2 2024• LPCD: Q4 2024• Data readout: Q3 2025• Primary endpoint met
Phase I <u>NCT07754331</u>	Participants with kidney failure on stable intermittent haemodialysis	10	<ul style="list-style-type: none">• Two treatment periods performed in a crossover fashion in order to evaluate the PK of 40 mg/10 mg balcinrenone/dapagliflozin with dosing before and after haemodialysis, with a 7-day washout period between the two treatments	<ul style="list-style-type: none">• Primary endpoints: PK parameters• Secondary endpoints: safety and tolerability	<ul style="list-style-type: none">• FPCD: Q3 2026• Data anticipated: H1 2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



baxdrostat/dapagliflozin (selective ASI/SGLT2)

CKD/Prevention of heart failure

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III BaxDuo-Arctic NCT06268873	CKD and high blood pressure	2500	<ul style="list-style-type: none"> Arm 1: baxdrostat/dapagliflozin QD Arm 2: dapagliflozin/placebo QD 	<ul style="list-style-type: none"> Primary endpoint: change from baseline in eGFR to post-treatment Secondary endpoints: change from baseline in SBP and UACR, kidney HCE and eGFR 	<ul style="list-style-type: none"> FPCD: Q2 2024 Data anticipated: >2027
Phase III BaxDuo-Pacific NCT06742723	CKD and high blood pressure	5000	<ul style="list-style-type: none"> Arm 1: baxdrostat/dapagliflozin QD Arm 2: dapagliflozin/placebo QD 	<ul style="list-style-type: none"> Primary endpoint: Time to the first occurrence of any of the components of the composite of Kidney disease progression ($\geq$ 50% sustained decline in eGFR, Onset of kidney failure), CV events (HF with or without hospitalisation CV death) 	<ul style="list-style-type: none"> FPCD: Q1 2025 Data anticipated: >2027
Phase III PREVENT-HF NCT06677060	T2D, history of hypertension and established CVD and risk factor(s)	11300	<ul style="list-style-type: none"> Arm 1: baxdrostat/dapagliflozin QD Arm 2: dapagliflozin/placebo QD 	<ul style="list-style-type: none"> Primary endpoint: Time to first occurrence of any of the components of the composite of: Hospitalisation for HF, HF without hospitalisation, CV death 	<ul style="list-style-type: none"> FPCD: Q1 2025 Data anticipated: >2027
Phase II BaxDuo-Baltic NCT07222917	CKD and high blood pressure	218	<ul style="list-style-type: none"> Arm 1: baxdrostat/dapagliflozin Arm 2: baxdrostat/Placebo 	<ul style="list-style-type: none"> Primary endpoint: change from baseline in UACR at 12 weeks 	<ul style="list-style-type: none"> FPCD: Q4 2025 LPCD: Q3 2026 Data anticipated: H1 2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



elecglipton (oral GLP-1 RA)

CKD

Trial	Population	Patients	Design	Endpoints	Status
Phase III Elevate-CKD NCT07753993	Chronic kidney disease	7000	<ul style="list-style-type: none">Randomised, double-blind, parallel-group, placebo-controlledArm 1: elecgliptonArm 2: placeboin addition to background dapagliflozin	<ul style="list-style-type: none">Primary endpoint: Time to the first composite event: ≥50% sustained decline in eGFR, ESKD (defined as sustained eGFR < 10 mL/min/1.73 m2, or chronic dialysis treatment, or renal transplant), all-cause mortality	<ul style="list-style-type: none">FPCD: Q3 2026Data anticipated: >2027



elecglipton (oral GLP-1 RA)

HFpEF

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III ELEVATE-HF NCT07761117	HFpEF and HFmrEF	6950	<ul style="list-style-type: none"> Randomised, double-blind, parallel-group, placebo-controlled Arm 1: elecglipton Arm 2: placebo in addition to background dapagliflozin 	<ul style="list-style-type: none"> Primary endpoint: Time to first event of the composite of: CV death, HHF and urgent HF visit 	<ul style="list-style-type: none"> FPCD: Q3 2026 Data anticipated: >2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



elecglipton (oral GLP-1 RA)

Type 2 diabetes

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III Eliminate-1 NCT07662044	Type 2 diabetes	800	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled Arm 1: elecglipton + dapagliflozin Arm 2: elecglipton dose level 1 + placebo Arm 3: elecglipton dose level 2 + placebo Arm 4: placebo 	<ul style="list-style-type: none"> Primary endpoint: change in HbA1c from baseline 	<ul style="list-style-type: none"> FPCD: Q3 2026 Data anticipated: >2027
Phase III Eliminate-2 NCT07662213	Type 2 diabetes	1200	<ul style="list-style-type: none"> Randomised, open-label, active-controlled Arm 1: elecglipton Arm 2: oral semaglutide 	<ul style="list-style-type: none"> Primary endpoint: change in HbA1c from baseline 	<ul style="list-style-type: none"> FPCD: Q3 2026 Data anticipated: >2027
Phase III Eliminate-3 NCT07664553	Type 2 diabetes	600	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled Arm 1: elecglipton dose level 1 Arm 2: elecglipton dose level 2 Arm 3: placebo In addition to background insulin 	<ul style="list-style-type: none"> Primary endpoint: change in HbA1c from baseline 	<ul style="list-style-type: none"> FPCD: Q3 2026 Data anticipated: >2027
Phase III Eliminate-4 NCT07662135	Type 2 diabetes	900	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled Arm 1: elecglipton dose level 1 Arm 2: elecglipton dose level 2 Arm 3: placebo In addition to background dapagliflozin 	<ul style="list-style-type: none"> Primary endpoint: change in HbA1c from baseline 	<ul style="list-style-type: none"> FPCD: Q3 2026 Data anticipated: >2027
Phase III Eliminate-5 NCT07662109	Type 2 diabetes	2000	<ul style="list-style-type: none"> Randomised, double-blind Arm 1: elecglipton dose level 1 + dapagliflozin Arm 2: elecglipton dose level 2 + dapagliflozin Arm 3: elecglipton dose level 1 + placebo Arm 4: elecglipton dose level 2 + placebo Arm 5: placebo + dapagliflozin 	<ul style="list-style-type: none"> Primary endpoint: change in HbA1c from baseline 	<ul style="list-style-type: none"> FPCD: Q3 2026 Data anticipated: >2027
Phase IIb SOLSTICE NCT06579105	Type 2 diabetes	406	<ul style="list-style-type: none"> Arm 1: elecglipton tablet Arm 2: elecglipton tablet Arm 3: elecglipton tablet Arm 4: elecglipton tablet Arm 5: elecglipton tablet Arm 6: elecglipton tablet Arm 7: active comparator semaglutide tablet Arm 8: placebo matching elecglipton tablet 	<ul style="list-style-type: none"> Primary endpoint: change in HbA1c from baseline at 26 weeks Secondary endpoints: change in fasting glucose from baseline, proportion of participants achieving HbA1c ≤6.5% and baseline HbA1c ≥7% and achieving <7.0% and percent change in body weight from baseline 	<ul style="list-style-type: none"> FPCD: Q4 2024 LPCD: Q2 2025 Data readout: Q1 2026 Primary endpoint met

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



elecglipton (oral GLP-1 RA)

Weight management

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III Embold NCT07667803	Obesity or overweight with and without T2D	4500	<ul style="list-style-type: none"> Randomised, parallel-group, double-blind trial Two independent trials (study 1 and study 2) under one master protocol For both trials 1 and 2: Arm 1: elecglipton dose level 1 Arm 2: elecglipton dose level 2 Arm 3: placebo 	<ul style="list-style-type: none"> Primary endpoint: Percent change from baseline to Week 72 in body weight 	<ul style="list-style-type: none"> FPCD: Q3 2026 Data anticipated: >2027
Phase III EMBOLD-Asia NCT07775404 Partnered (Eccogene)	Individuals with obesity or overweight	351	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled Arm 1: elecglipton dose level 1 Arm 2: elecglipton dose level 2 Arm 3: placebo 	<ul style="list-style-type: none"> Primary endpoints: Percent change from baseline to Week 52 in body weight, participants achieving at least 5% body weight loss at Week 52 	<ul style="list-style-type: none"> FPCD: Q3 2026 Data anticipated: >2027
Phase IIb VISTA NCT06579092	Obesity or overweight who have at least one weight-related comorbidity	310	<ul style="list-style-type: none"> Arm 1: elecglipton tablet Arm 2: elecglipton tablet Arm 3: elecglipton tablet Arm 4: elecglipton tablet Arm 5: elecglipton tablet Arm 6: placebo matching elecglipton tablet 	<ul style="list-style-type: none"> Primary endpoints: change in body weight from baseline at 26 weeks and proportion of participants with weight loss ≥5% from baseline weight at 26 weeks Secondary endpoints: change in body weight from baseline at 36 weeks, proportion of participants with weight loss ≥5% and absolute change from baseline in body weight at 26 and 36 weeks 	<ul style="list-style-type: none"> FPCD: Q4 2024 LPCD: Q1 2025 Data readout: Q1 2026 Primary endpoints met
Phase I NCT06555822	Healthy volunteers	31	<ul style="list-style-type: none"> Part A – Arm 1: elecglipton oral tablet Part A – Arm 2: placebo oral tablet Part B: single dose, open label crossover 	<ul style="list-style-type: none"> Primary endpoints (Part A): safety and tolerability Secondary endpoints (Part A): PK and PD parameters Primary endpoint (Part B): PK parameters Secondary endpoints (Part B): safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q3 2024 LPCD: Q1 2025 Data readout: Q2 2025

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



elecglipton (oral GLP-1 RA)

Weight management

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase I NCT06703658	Healthy volunteers or participants with type 2 diabetes mellitus	35	<ul style="list-style-type: none"> SAD: 3 cohorts to receive elexagliptin or placebo tablet MAD: 1 cohort to receive elexagliptin or placebo tablet Japan only 	<ul style="list-style-type: none"> Primary endpoints: safety and tolerability Secondary endpoints: PK and PD parameters 	<ul style="list-style-type: none"> FPCD: Q4 2024 LPCD: Q1 2025 Data readout: Q3 2025
Phase I NCT06742762	Healthy volunteers or participants with renal impairment	16	<ul style="list-style-type: none"> Multi-centre, single-dose, non-randomised, open-label, parallel-group trial, single oral dose of elexagliptin 	<ul style="list-style-type: none"> Primary endpoint: PK parameters Secondary endpoints: safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q1 2025 LPCD: Q2 2025 Data readout: Q3 2025
Phase I NCT06813781	Healthy volunteers or participants with hepatic impairment	33	<ul style="list-style-type: none"> Multi-centre, single-dose, non-randomised, open-label, parallel-group trial, single oral dose of elexagliptin 	<ul style="list-style-type: none"> Primary endpoint: PK parameters Secondary endpoints: safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q1 2025 LPCD: Q3 2025 Data readout: Q1 2026
Phase I NCT06857695	Healthy volunteers	8	<ul style="list-style-type: none"> Part 1: A single dose of elexagliptin film-coated tablet and a single dose of elexagliptin solution for infusion Part 2: A single dose of elexagliptin oral solution 	<ul style="list-style-type: none"> Part 1: absolute bioavailability Part 2: amount of elexagliptin excreted 	<ul style="list-style-type: none"> FPCD: Q1 2025 LPCD: Q1 2025 Data readout: Q3 2025
Phase I NCT06988553 Partnered (Eccogene)	Participants with overweight/obesity with/without T2D	45	<ul style="list-style-type: none"> Randomized, parallel group, double-blind trial elexagliptin or placebo tablet China only 	<ul style="list-style-type: none"> Primary endpoints: safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q2 2025 LPCD: Q3 2025 Data readout: Q1 2026
Phase I NCT06996886	Healthy volunteers	16	<ul style="list-style-type: none"> Open-label, randomised, 4-period, 4-treatment, single-dose crossover trial Different formulations as single dose of elexagliptin 	<ul style="list-style-type: none"> Primary endpoint: PK profile (relative bioavailability) Secondary endpoints: PK profile (food effect) Safety endpoints: safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q2 2025 LPCD: Q2 2025 Data readout: Q4 2025
Phase I NCT06948747	Healthy volunteers	49	<ul style="list-style-type: none"> Open-label, fixed-sequence, single-centre trial Part A: elexagliptin, rosuvastatin and erythromycin tablets Part B: elexagliptin, atorvastatin and simvastatin tablets Part C: elexagliptin and repaglinide tablets 	<ul style="list-style-type: none"> Part A, B and C: Primary endpoints: PK profile Safety endpoints: safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q2 2025 LPCD: Q3 2025 Data readout: Q4 2025
Phase I NCT06942936	Healthy volunteers	51	<ul style="list-style-type: none"> Open-label, fixed-sequence, two-part trial Part A: elexagliptin tablet and itraconazole capsule Part B: elexagliptin and estradiol/ levonorgestrel tablets 	<ul style="list-style-type: none"> Primary endpoint: PK profile Safety endpoints: safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q2 2025 LPCD: Q4 2025 Data readout: Q1 2026

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



elecglipton (oral GLP-1 RA)

Weight management

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase I <u>NCT07455825</u>	Healthy volunteers	65	<ul style="list-style-type: none"> Open-label, randomised, 2 part, 3-period, single-dose trial Different formulations as single dose of elecglipton 	<ul style="list-style-type: none"> Part A and B: Primary endpoint: PK profile (relative bioavailability) Secondary endpoints: PK profile (food effect) Safety endpoints: safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q2 2026 LPCD: Q2 2026 Data readout: Q3 2026
Phase I <u>NCT07444424</u>	Healthy volunteers	32	<ul style="list-style-type: none"> Open-label, fixed-sequence, two-part, single-centre trial Part A and Part B are 2 independent and non-sequential parts in this study Part A: elecglipton + mitiglinide tablets Part B: elecglipton + pioglitazone tablets 	<ul style="list-style-type: none"> Part A and B: Primary endpoint: PK profile Safety endpoints: safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q2 2026 LPCD: Q2 2026 Data readout: Q3 2026
Phase I <u>NCT07534592</u>	Healthy volunteers	48	<ul style="list-style-type: none"> Open-label, fixed-sequence trial Group 1 and Group 2 are independent and non-sequential parts in this study Group 1: atorvastatin administered with and without elecglipton Group 2: rosuvastatin administered with and without elecglipton 	<ul style="list-style-type: none"> Primary endpoint: PK profiles of atorvastatin and elecglipton and rosuvastatin and elecglipton Secondary endpoint: Safety 	<ul style="list-style-type: none"> FPCD: Q2 2026 LPCD: Q2 2026 Data anticipated: H1 2027
Phase I <u>NCT07723833</u>	Healthy volunteers	152	<ul style="list-style-type: none"> Open-label, randomised, 2-period crossover study with 4-cohorts All 4 cohorts are independent and non-sequential parts in this study Different formulations as single dose of elecglipton 	<ul style="list-style-type: none"> Primary endpoint: PK Secondary endpoints: safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q3 2026 LPCD: Q4 2026 Data anticipated: H1 2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



Iaroprovstat (AZD0780, PCSK9 inhibitor)

Dyslipidaemia

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III AZURE-HeFH NCT07000136	Heterozygous familial hypercholesterolemia	473	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled, parallel-group trial Arm 1: Iaroprovstat Arm 2: placebo Global study 24 countries 	<ul style="list-style-type: none"> Primary endpoint: Relative change in LDL-C from baseline to 12 weeks Secondary endpoint: Relative change in LDL-C from baseline to 12 weeks in patients on a statin, indicator for LDL-C < 70 mg/dL (< 1.8 mmol/L) at 12 weeks 	<ul style="list-style-type: none"> FPCD: Q2 2025 LPCD: Q4 2025 Data anticipated: H1 2027
Phase III AZURE-LDL NCT07000123	Patients with dyslipidaemia and history of clinical ASCVD or at risk for a first ASCVD event	3103	<ul style="list-style-type: none"> Randomised, double-Blind, placebo-controlled, parallel-group trial Arm 1: Iaroprovstat Arm 2: placebo Global study 22 countries 	<ul style="list-style-type: none"> Primary endpoint: Relative change in LDL-C from baseline to 12 weeks Secondary endpoints: Relative change in LDL-C from baseline to 12 weeks in patients on statins Indicator for LDL-C < 70 mg/dL (< 1.8 mmol/L) at 12 weeks 	<ul style="list-style-type: none"> FPCD: Q2 2025 LPCD: Q4 2025 Data anticipated: H1 2027
Phase III AZURE-Outcomes NCT07000357	Patients with dyslipidaemia and established ASCVD or at high risk for a first ASCVD event	15100	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled, parallel-group trial Arm 1: Iaroprovstat Arm 2: placebo Global study 34 countries 	<ul style="list-style-type: none"> Primary endpoint: Time to first event of any component of MACE-PLUS Secondary endpoints: Time to first event of any component of 3P MACE, Time to first event of any component of MACE PLUS in patients with a history of ASCVD 	<ul style="list-style-type: none"> FPCD: Q2 2025 Data anticipated: >2027
Phase II/III AZURE-China NCT06834932	Participants with elevated LDL-C	406	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled, multi-centre China only 	<ul style="list-style-type: none"> Primary endpoint (Part A) : PK parameters Secondary endpoint: (Part A) LDL-C at Week 4, To evaluate the effect of treatment with AZD0780 versus placebo on LDL-C at Week 4 Primary endpoint (Part B): To compare the effect of treatment with AZD0780 versus placebo on LDL-C at 12 weeks Secondary endpoint (Part B): To evaluate the effect of treatment with AZD0780 versus placebo on LDL-C at Week 12 	<ul style="list-style-type: none"> FPCD: Q4 2024 LPCD: Q2 2026 Data anticipated: H1 2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



Iaroprovstat (AZD0780, PCSK9 inhibitor)

Dyslipidaemia

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase II PURSUIT <u>NCT06173570</u>	Dyslipidaemia	428	<ul style="list-style-type: none"> Randomised trial with equal distribution across five parallel treatment arms to either placebo or one of four Iaroprovstat doses 	<ul style="list-style-type: none"> Primary endpoint: percent change in LDL-C level from baseline to Week 12 Secondary endpoints: percent change from baseline of LDL-C at Week 12, plasma concentrations summarised by sampling timepoint, percent change from baseline at Week 12 in other lipid parameters and inflammatory markers and safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q1 2024 LPCD: Q2 2025 Data readout: Q1 2025
Phase II <u>NCT06692764</u>	Participants with ASCVD or risk equivalents and LDL-C ≥ 70 mg/dL on stable medication	202	<ul style="list-style-type: none"> Multi-centre, randomised, double-blind, placebo-controlled, crossover trial 	<ul style="list-style-type: none"> Primary endpoint: ambulatory 24-hour average systolic blood pressure at Week 4 Secondary endpoint: ambulatory 24-hour average diastolic blood pressure at Week 4 	<ul style="list-style-type: none"> FPCD: Q4 2024 LPCD: Q1 2025 Data readout: Q2 2026
Phase I <u>NCT06576765</u>	Hepatic impairment and matched healthy controls	16	<ul style="list-style-type: none"> Multi-centre, single-dose, non-randomised, open-label, parallel-group trial 	<ul style="list-style-type: none"> Primary endpoint: PK parameters Secondary endpoints: safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q3 2024 LPCD: Q4 2024 Data readout: Q2 2025
Phase I <u>NCT06592482</u>	Renal impairment and matched healthy controls	30	<ul style="list-style-type: none"> Multi-centre, single-dose, non-randomised, open-label, parallel-group trial 	<ul style="list-style-type: none"> Primary endpoint: PK parameters Secondary endpoints: safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q3 2024 LPCD: Q4 2024 Data readout: Q2 2025

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



laroprovstat (AZD0780, PCSK9 inhibitor)

Dyslipidaemia

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase I <u>NCT06671405</u>	Healthy volunteers	59	<ul style="list-style-type: none"> Open-label, fixed sequence trial to assess the PK of laroprovstat when administered in combination with itraconazole, carbamazepine, and the PK of midazolam and EE/LNG when administered with laroprovstat 	<ul style="list-style-type: none"> Primary endpoint: PK parameters Secondary endpoints: safety and PK parameters 	<ul style="list-style-type: none"> FPCD: Q4 2024 LPCD: Q1 2025 Data readout: Q4 2025
Phase I <u>NCT06742853</u>	Healthy volunteers with elevated LDL-C	81	<ul style="list-style-type: none"> Randomised, single-blind, placebo-controlled trial 	<ul style="list-style-type: none"> Primary endpoints: percent change in LDL-C at Week-4 and safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q4 2024 LPCD: Q3 2025 Data readout: Q4 2025
Phase I <u>NCT07216131</u>	Healthy volunteers	14	<ul style="list-style-type: none"> Fixed-sequence, open-label PK trial of laroprovstat effect on metformin 	<ul style="list-style-type: none"> Primary endpoint: PK measures Secondary endpoint: safety and tolerability measures 	<ul style="list-style-type: none"> FPCD: Q4 2025 LPCD: Q4 2025 Data readout: Q2 2026
Phase I <u>NCT07423598</u>	Healthy volunteers	40	<ul style="list-style-type: none"> Phase I, randomised, single-blind, placebo-controlled study 	<ul style="list-style-type: none"> Primary endpoint: PK measures Secondary endpoint: safety and tolerability measures 	<ul style="list-style-type: none"> FPCD: Q1 2026 LPCD: Q2 2026 Data readout: Q3 2026

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



Iaroprovstat/ezetimibe FDC (PCSK9 inhibitor + NPC1L1 inhibitor)

Dyslipidaemia

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase I <u>NCT07622433</u>	Healthy adults	18	<ul style="list-style-type: none">• Open-label, cross-over trial• Treatment A: Iaroprovstat/ezetimibe FDCP (fasted)• Treatment B: Iaroprovstat + ezetimibe single therapy products (fasted)• Treatment C: Iaroprovstat/ezetimibe FDCP (fed)• Treatment D: Iaroprovstat/ezetimibe FDCP slow variant (fasted)	<ul style="list-style-type: none">• Primary endpoint: relative bioavailability between FDCPs and the STPs of Iaroprovstat and ezetimibe• Secondary endpoint: PK	<ul style="list-style-type: none">• FPCD: Q3 2026• Data anticipated: H2 2026

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



Iaroprovstat/rosuvastatin FDC (PCSK9 inhibitor + HMG-CoA reductase inhibitor)

Approved medicines
Late-stage development
Early development

Dyslipidaemia

Trial	Population	Patients	Design	Endpoints	Status
Phase III reAZURE-NAIVE <u>NCT07619131</u>	Treatment naive patients with elevated LDL-C	600	<ul style="list-style-type: none"> Randomised, double-blind, factorial design trial Arm 1: Iaroprovstat Arm 2: Placebo Arm 3: Iaroprovstat/rosuvastatin dose combination 1 Arm 4: Iaroprovstat/rosuvastatin dose combination 2 Arm 5: Rosuvastatin dose 1 Arm 6: Rosuvastatin dose 2 	<ul style="list-style-type: none"> Primary endpoint: Relative change in LDL-C at 8 weeks Secondary endpoints: Relative change in LDL-C, relative change in Apo B, relative change in non-HDL-C and relative change in total cholesterol 	<ul style="list-style-type: none"> FPCD: Q3 2026 Data anticipated: H2 2027
Phase III reAZURE-PLUS <u>NCT07619118</u>	Patients with dyslipidaemia and established ASCVD or at high risk for a first ASCVD event	200	<ul style="list-style-type: none"> Randomised, double-blind, parallel-group trial Arm 1: Iaroprovstat/rosuvastatin dose 1 vs placebo Arm 2: Rosuvastatin dose 1 vs placebo Arm 3: Iaroprovstat/rosuvastatin dose 2 vs placebo Arm 4: Rosuvastatin dose 2 vs placebo Arm 5: Iaroprovstat/rosuvastatin dose 3 vs placebo Arm 6: Rosuvastatin dose 3 vs placebo Arm 7: Iaroprovstat/rosuvastatin dose 4 vs placebo Arm 8: Rosuvastatin dose 4 vs placebo 	<ul style="list-style-type: none"> Primary endpoint: Relative change in LDL-C at 8 weeks Secondary endpoints: Relative change in Apo B at 8 weeks, relative change in non-HDL-C at 8 weeks and relative change in total cholesterol at 8 weeks 	<ul style="list-style-type: none"> FPCD: Q4 2026 Data anticipated: H1 2027
Phase I <u>NCT07316608</u>	Healthy adults	44	<ul style="list-style-type: none"> Randomised, open-label, 3 or 4-period, single-dose, two-cohort, multi-centre, crossover study with oral dosing US only 	<ul style="list-style-type: none"> Primary: relative bioavailability between FCDP and the STPs Secondary: PK profile 	<ul style="list-style-type: none"> FPCD: Q2 2026 LPCD: Q2 2026 Data readout: Q3 2026

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



lenbelintide (AZD6234, selective amylin receptor agonist)

Obesity with related co-morbidities

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III SELENE-1 NCT07784725	Adults with obesity or overweight with at least one weight-related comorbidity without T2DM	2500	<ul style="list-style-type: none"> Randomised, parallel-group, double-blind trial Arm 1: lenbelintide dose 1 Arm 2: lenbelintide dose 2 Arm 3: placebo 	<ul style="list-style-type: none"> Primary endpoint: Percent change in body weight from baseline at 68 weeks of treatment 	<ul style="list-style-type: none"> FPCD: Q3 2026 Data anticipated: >2027
Phase III SELENE-2 NCT07784270	Adults with Type 2 Diabetes Mellitus (T2DM) and obesity or overweight	1500	<ul style="list-style-type: none"> Randomised, parallel-group, double-blind trial Arm 1: lenbelintide dose 1 Arm 2: lenbelintide dose 2 Arm 3: placebo 	<ul style="list-style-type: none"> Primary endpoint: Percent change in body weight from baseline at 68 weeks of treatment. 	<ul style="list-style-type: none"> FPCD: Q3 2026 Data anticipated: >2027
Phase III SELENE-3 NCT07776509	Adults with obesity or overweight with at least one weight-related comorbidity and with or without Type 2 Diabetes Mellitus (T2DM) currently receiving a stable dose of incretin-based medications	500	<ul style="list-style-type: none"> Randomised, parallel-group, double-blind trial Arm A: lenbelintide Arm B: placebo 	<ul style="list-style-type: none"> Primary endpoint: Percent change in body weight from baseline at 68 weeks of treatment 	<ul style="list-style-type: none"> FPCD: Q3 2026 Data anticipated: >2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



zibotentan/dapagliflozin (ETA receptor antagonist/SGLT2 inhibitor)

Chronic kidney disease

Trial	Population	Patients	Design	Endpoints	Status
Phase III ZENITH High Proteinuria <u>NCT06087835</u>	CKD and high proteinuria	1835	<ul style="list-style-type: none">Randomised, parallel, multi-centre, double-blind trialArm 1: zibotentan/dapagliflozin dose A or dose BArm 2: dapagliflozin	<ul style="list-style-type: none">Primary endpoint: change in eGFR from baselineSecondary endpoints: Change in Urine Albumin to Creatinine Ratio (UACR) from baseline; Time to the first occurrence of any of the components of the renal composite endpoint of 40% sustained decline in eGFR or End Stage Kidney Disease (ESKD) or renal death; Change in Urine Protein to Creatinine Ratio (UPCR) from baseline in the biopsy-confirmed IgAN subgroup	<ul style="list-style-type: none">FPCD: Q4 2023LPCD: Q4 2024Data anticipated: H1 2027



AZD4144 (NLRP3)

Cardiorenal disease

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase I NCT07783308	Partipants with hepatic impairment and match controls	30	<ul style="list-style-type: none">Phase I, open-label, parallel group study	<ul style="list-style-type: none">Primary endpoint: PK	<ul style="list-style-type: none">FPCD: Q3 2026Data anticipated: H2 2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



Airsupra (PT027, SABA/ICS, pMDI)

Asthma

Trial	Population	Patients	Design	Endpoints	Status
Phase IIIb ACADIA NCT06307665	Adolescents with asthma	440	<ul style="list-style-type: none"> Randomised, double-blind, multi-centre, parallel-group Arm 1: BDA MDI 160/180µg prn Arm 2: AS MDI 180µg prn 	<ul style="list-style-type: none"> Primary endpoint: severe asthma exacerbation rate (annualised) Secondary endpoints: time to first severe exacerbation, annualised total systemic corticosteroid exposure, safety (AEs and SAEs), PK sub-study (including Cmax, AUClast and AUCinf) 	<ul style="list-style-type: none"> FPCD: Q2 2024 Data anticipated: H2 2027
Phase III BAIYUN NCT06471257	Adult patients with asthma	790	<ul style="list-style-type: none"> Randomised, double-blind, multi-centre, event-driven, parallel-group Arm 1: BDA MDI 160/180µg prn Arm 2: AS MDI 180µg prn China only 	<ul style="list-style-type: none"> Primary endpoint: time to first severe exacerbation Secondary endpoints: severe exacerbation rate (annualised), total systemic corticosteroid exposure, ACQ-5 responder, AQLQ+12 responder 	<ul style="list-style-type: none"> FPCD: Q3 2024 Data anticipated: H2 2027
Phase II MITCHELL NCT06644924	Adults with asthma	102	<ul style="list-style-type: none"> Randomised, single-dose, double-blind, placebo-controlled, 3-period, 3-treatment, crossover, multicentre Arm 1: AS MDI 180µg (double-blind) Arm 2: placebo MDI (double-blind) Arm 3: Ventolin Evohaler 200µg (open-label) US Only 	<ul style="list-style-type: none"> Primary endpoint: Mean change from baseline in FEV1 AUC0-6 (Non-inferiority of AS MDI relative to Ventolin Evohaler) Secondary endpoints: FEV1 AUC0-6, Mean change from baseline in FEV1 AUC0-4, Safety (AEs and SAEs) 	<ul style="list-style-type: none"> FPCD: Q1 2025 LPCD: Q2 2025 Data readout: Q3 2025 Primary endpoint met



Breztri, Trixeo (LAMA/LABA/ICS)

Asthma

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III KALOS NCT04609878	Uncontrolled asthma	2266	<ul style="list-style-type: none"> Randomised, double-blind, double-dummy, parallel group and multi-centre trial Treatments (24- to 52-week variable length) Arm 1: BGF 320/28.8/9.6µg BID MDI Arm 2: BGF 320/14.4/9.6µg BID MDI Arm 3: <i>Symbicort</i> Aerosphere 320/9.6µg BID MDI Arm 4: <i>Symbicort</i> 320/9µg BID pMDI 	<ul style="list-style-type: none"> Primary endpoint: change from baseline in FEV1 AUC0-3 at Week 24 Secondary endpoint: change from baseline in morning pre-dose trough FEV1 at Week 24 	<ul style="list-style-type: none"> FPCD: Q1 2021 Data readout: Q2 2025 Primary endpoint met
Phase III LOGOS NCT04609904	Uncontrolled asthma	2182	<ul style="list-style-type: none"> Randomised, double-blind, double dummy, parallel group and multi-centre trial Treatments (24- to 52-week variable length) Arm 1: BGF 320/28.8/9.6µg BID MDI Arm 2: BGF 320/14.4/9.6µg BID MDI Arm 3: <i>Symbicort</i> Aerosphere 320/9.6µg BID MDI Arm 4: <i>Symbicort</i> 320/9µg BID pMDI 	<ul style="list-style-type: none"> Primary endpoint: change from baseline in FEV1 AUC0-3 at Week 24 Secondary endpoint: change from baseline in morning pre-dose trough FEV1 at Week 24 	<ul style="list-style-type: none"> FPCD: Q1 2021 Data readout: Q2 2025 Primary endpoint met
Phase III VATHOS NCT05202262	Inadequately controlled asthma despite treatment with medium dose ICS or ICS/LABA	645	<ul style="list-style-type: none"> Randomised, double-blind, parallel group, multi-centre trial Treatments (24-week) Arm 1: <i>Symbicort</i> Aerosphere 320/9.6µg BID MDI Arm 2: PT009 160/9.6µg BID MDI Arm 3: BD 320µg BID MDI Arm 4: open-label <i>Symbicort</i> Turbuhaler 320/9µg BID 	<ul style="list-style-type: none"> Primary endpoint: change from baseline in FEV1 AUC0-3 at Week 24 	<ul style="list-style-type: none"> FPCD: Q1 2022 Data readout: Q2 2025 Primary endpoint met

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



Breztri, Trixeo (LAMA/LABA/ICS)

COPD

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III ATHLOS NCT06067828	COPD	180	<ul style="list-style-type: none"> Randomised, double-blind, three-treatment, three-period, crossover trial Treatments (2-week treatment periods, 2-week washout between treatments) Arm 1: <i>Breztri</i> 320/14.4/9.6µg BID MDI Arm 2: <i>Symbicort</i> Aerosphere 320/9.6µg BID MDI Arm 3: placebo BID MDI 	<ul style="list-style-type: none"> Primary endpoint: change from baseline in isotime IC Secondary endpoint: change from baseline in constant work rate cycle ergometry endurance time 	<ul style="list-style-type: none"> FPCD: Q4 2023 Data readout: Q1 2026 Primary endpoint met
Phase III THARROS NCT06283966	COPD who are at risk of cardiopulmonary event	5250	<ul style="list-style-type: none"> Randomised, double blind, event-driven trial Arm 1: BGF MDI 320/14.4/9.6µg BID Arm 2: GFF MDI 14.4/9.6µg BID 	<ul style="list-style-type: none"> Primary endpoint: time to first severe cardiac or COPD event Secondary endpoints: time to first severe COPD exacerbation event, time to first severe cardiac event, time to cardiopulmonary death, moderate/severe COPD exacerbation rate, time to MI hospitalisation or cardiac death and time to HF acute healthcare visit/hospitalisation or cardiac death 	<ul style="list-style-type: none"> FPCD: Q1 2024 Data anticipated: >2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



Fasenra (IL-5R mAb)

Other eosinophilic diseases

Trial	Population	Patients	Design	Endpoints	Status
Phase III NATRON <u>NCT04191304</u>	Patients with HES (history of persistent eosinophilia >1500 cells/μL with evidence of end organ manifestations attributable to eosinophilia) and signs or symptoms of HES worsening/flare at Visit 1; age 12 years and older	134	<ul style="list-style-type: none">Randomised, double-blind, placebo controlledArm 1: <i>Fasenra</i> 30mg Q4W s.c.Arm 2: placebo Q4W s.c.24-week trial with a minimum 1-year open label extension	<ul style="list-style-type: none">Primary endpoint: time to first HES worsening/flare	<ul style="list-style-type: none">FPCD: Q3 2020LPCD: Q4 2024Data readout: Q2 2025Primary endpoint met



Saphnelo (type I interferon receptor mAb)

Lupus (SLE/LN)

Trial	Population	Patients	Design	Endpoints	Status
Phase III AZALEA-SLE NCT04931563 Partnered (BMS)	Moderate to severe SLE	276	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled Arm 1: 300mg <i>Saphnelo</i> i.v. Q4W Arm 2: placebo i.v. Q4W Asia only 	<ul style="list-style-type: none"> Primary endpoint: BICLA at Week 52 	<ul style="list-style-type: none"> FPCD: Q4 2021 LPCD: Q2 2024 Data readout: Q2 2025 Primary endpoint met
Phase III IRIS NCT05138133 Partnered (BMS)	Active, proliferative LN	363	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled Arm 1: <i>Saphnelo</i> i.v. Arm 2: placebo i.v. 	<ul style="list-style-type: none"> Primary endpoint: CRR at Week 52 	<ul style="list-style-type: none"> FPCD: Q2 2022 LPCD: Q1 2026 Data anticipated: H1 2027
Phase III LAVENDER NCT06015737 Partnered (BMS)	Chronic and/or subacute CLE	339	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled Arm 1: <i>Saphnelo</i> s.c. Arm 2: placebo s.c. 	<ul style="list-style-type: none"> Primary endpoint: Clinical response based on CLASI-70 at week 24 	<ul style="list-style-type: none"> FPCD: Q4 2024 LPCD: Q2 2026 Data anticipated: H1 2027
Phase III TULIP-SC NCT04877691 Partnered (BMS)	Moderate to severe SLE	367	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled Arm 1: <i>Saphnelo</i> s.c. Arm 2: placebo s.c. 	<ul style="list-style-type: none"> Primary endpoint: BICLA at Week 52 	<ul style="list-style-type: none"> FPCD: Q3 2021 LPCD: Q3 2024 Data readout: Q3 2025 Primary endpoint met



Saphnelo (type I interferon receptor mAb)

Sclerosis and other myopathies

Trial	Population	Patients	Design	Endpoints	Status
Phase III DAISY NCT05925803 Partnered (BMS)	Systemic sclerosis	314	<ul style="list-style-type: none">Randomised, double-blind, placebo-controlledArm 1: <i>Saphnelo</i> s.c.Arm 2: placebo s.c.	<ul style="list-style-type: none">Primary endpoint: CRIS-25 at Week 52	<ul style="list-style-type: none">FPCD: Q4 2023LPCD: Q1 2026Data anticipated: H1 2027
Phase III JASMINE NCT06455449 Partnered (BMS)	Idiopathic inflammatory myopathies	240	<ul style="list-style-type: none">Randomised, double-blind, placebo-controlledArm 1: <i>Saphnelo</i> s.c.Arm 2: placebo s.c.	<ul style="list-style-type: none">Primary endpoint: Total Improvement Score $\geq$40 at Week 52	<ul style="list-style-type: none">FPCD: Q4 2024Data anticipated: >2027



Tezspire (TSLP mAb)

CRSwNP, COPD and EoE

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III CROSSING NCT05583227 Partnered (Amgen)	Adult and paediatric aged 12 years and older with eosinophilic esophagitis	360	<ul style="list-style-type: none"> Arm 1: <i>Tezspire</i> s.c. low dose Arm 2: <i>Tezspire</i> s.c. high dose Arm 3: placebo 52-week trial 	<ul style="list-style-type: none"> Co-primary endpoints: histologic response of peak esophageal eosinophil per HPF count of ≤ 6 across all available esophageal levels and change from baseline in Dysphagia Symptom Questionnaire score 	<ul style="list-style-type: none"> FPCD: Q1 2023 LPCD: Q3 2025 Data readout: Q3 2026 Co-primary endpoints met
Phase III EMBARK NCT06883305 Partnered (Amgen)	Adults with moderate to very severe COPD	990	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled Arm 1: <i>Tezspire</i> s.c. dose 1 Arm 2: <i>Tezspire</i> s.c. dose 2 Arm 3: placebo 52-week treatment minimum 	<ul style="list-style-type: none"> Primary endpoint: Annualized moderate to severe COPD exacerbations. 	<ul style="list-style-type: none"> FPCD: Q2 2025 Data anticipated: >2027
Phase III JOURNEY NCT06878261 Partnered (Amgen)	Adults with moderate to very severe COPD	990	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled Arm 1: <i>Tezspire</i> s.c. dose 1 Arm 2: <i>Tezspire</i> s.c. dose 2 Arm 3: placebo 52-week treatment minimum 	<ul style="list-style-type: none"> Primary endpoint: Annualized moderate to severe COPD exacerbations 	<ul style="list-style-type: none"> FPCD: Q2 2025 Data anticipated: >2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



Next-generation propellant

pMDI

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III <u>NCT05573464</u>	Moderate to very severe COPD	542	<ul style="list-style-type: none"> Randomised, double-blind, 12-week (with an extension to 52 weeks in a subset of participants), parallel-group, multi-centre trial Arm 1: <i>Breztri</i> MDI NGP 160/7.2/4.8µg (2 inhalations BID) Arm 2: <i>Breztri</i> MDI HFA 160/7.2/4.8µg (2 inhalations BID) 	<ul style="list-style-type: none"> Primary endpoints: number of participants with AEs/SAEs and potentially clinically significant changes in Digital 12-lead Holter ECG, laboratory values, blood pressure, pulse rate, respiratory rate and body temperature 	<ul style="list-style-type: none"> FPCD: Q3 2022 Data readout: Q4 2024
Phase III <u>NCT05755932</u>	Mucociliary clearance in healthy volunteers	30	<ul style="list-style-type: none"> Randomised, double-blind, multi-site, two-way crossover trial with propellant only Arm 1: NGP pMDI; 6 inhalations BID for 7 days Arm 2: HFA pMDI; 6 inhalations BID for 7 days 	<ul style="list-style-type: none"> Primary endpoint: change from baseline in MCC through 60 minutes following inhalation of 99m technetium sulfur colloid and gamma camera imaging Secondary endpoint: change from baseline in MCC at 3 hours following inhalation of 99m technetium sulfur colloid and gamma camera imaging 	<ul style="list-style-type: none"> FPCD: Q2 2023 Data readout: Q4 2024
Phase III <u>NCT05850494</u>	Well-controlled or partially-controlled asthma	52	<ul style="list-style-type: none"> Randomised, multi-centre double-blind, single-dose crossover trial Arm 1: NGP propellant only pMDI; 4 inhalations per dose Arm 2: HFA propellant only pMDI; 4 inhalations per dose 	<ul style="list-style-type: none"> Primary endpoints: change from baseline FEV1 0 to 15 minutes post-dose, cumulative incidence of bronchospasm events and safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q2 2023 Data readout: Q1 2024 Primary endpoint met
Phase III <u>NCT06075095</u>	COPD	300	<ul style="list-style-type: none"> Randomised, placebo-controlled, double-blind, multi-centre, 4-week, 3-way crossover pharmacodynamic trial to assess the equivalence of <i>Breztri</i> delivered by pMDI NGP vs. with <i>Breztri</i> delivered by MDI HFA Arm 1: <i>Breztri</i> pMDI NGP 320/14.4/9.6µg Arm 2: <i>Breztri</i> pMDI HFA 320/14.4/9.6µg Placebo: MDI HFA 	<ul style="list-style-type: none"> Primary endpoints: changes in FEV1 AUC (0-4) and change in morning pre-dose trough FEV1 Secondary endpoints: safety and efficacy 	<ul style="list-style-type: none"> FPCD: Q1 2024 Data readout: Q3 2025 Primary endpoint met
Phase III <u>NCT06502366</u>	Asthma	398	<ul style="list-style-type: none"> Randomised, placebo-controlled, double-blind, multi-centre, 12-week, 3-way, partial-replicate crossover trial BDA MDI NGP 160/180µg BDA MDI HFA 160/180µg Placebo: MDI HFA 	<ul style="list-style-type: none"> Primary endpoint: change from baseline in peak FEV1 in 0-60 minutes after dosing at Day 29 Secondary endpoint: change from baseline in morning pre-dose trough FEV1 	<ul style="list-style-type: none"> FPCD: Q3 2024 Data readout: Q2 2026 Primary endpoint met

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



Next-generation propellant

pMDI

Trial	Population	Patients	Design	Endpoints	Status
Phase I NCT06723756	Healthy volunteers	105	<ul style="list-style-type: none">Randomised, double-blind, single-dose, single-centre, 3-way crossover trialArm 1: <i>Breztri</i> pMDI NGP 160/14.4/4.8µg (single dose of 2 inhalations)Arm 2: <i>Breztri</i> pMDI HFA 160/14.4/4.8µg (single dose of 2 inhalations)	<ul style="list-style-type: none">Primary endpoints: AUClast and Cmax	<ul style="list-style-type: none">FPCD: Q1 2025Data readout: Q3 2025



tozorakimab (IL-33 ligand mAb)

COPD

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III MIRANDA NCT06040086	Adults with symptomatic COPD with a history of exacerbations	1454	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled, parallel group Arm 1: tozorakimab dose s.c. + SoC Arm 2: placebo s.c. + SoC 	<ul style="list-style-type: none"> Primary endpoint: annualised rate of moderate to severe COPD exacerbations (former smokers) Secondary endpoints: annualised rate of moderate to severe COPD exacerbations (former or current smokers), annualised rate of severe COPD exacerbations (former and former or current smokers), COPD exacerbations requiring hospitalisation and/or Emergency Room (ER)/ Emergency Department (ED) visits and change in pre/post-BD FEV1, E-RS:COPD and SGRQ 	<ul style="list-style-type: none"> FPCD: Q4 2023 Data readout: Q1 2026 Primary endpoint met
Phase III OBERON NCT05166889	Adults with symptomatic COPD with a history of exacerbations	1132	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled, parallel-group Treatment: 52-week Arm 1: tozorakimab dose 1 s.c. + SoC Arm 2: tozorakimab dose 2 s.c. + SoC Arm 3: placebo s.c. + SoC 	<ul style="list-style-type: none"> Primary endpoint: annualised rate of moderate to severe COPD exacerbations (former smokers) Secondary endpoints: annualised rate of moderate to severe COPD exacerbations (former or current smokers), annualised rate of COPD exacerbations requiring hospitalisation and/or ER/ED visits and change in pre/post-BD FEV1, E-RS:COPD and SGRQ 	<ul style="list-style-type: none"> FPCD: Q1 2022 Data readout: Q1 2026 Primary endpoint met

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



tozorakimab (IL-33 ligand mAb)

COPD

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III PROSPERO NCT05742802	Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent (adults with symptomatic COPD with a history of exacerbations)	1713	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled, parallel-group, long-term extension trial Treatment: 52-weeks Arm 1: tozorakimab dose 1 s.c. + SoC Arm 2: tozorakimab dose 2 s.c. + SoC Arm 3: placebo s.c. + SoC 	<ul style="list-style-type: none"> Primary endpoint: annualised rate of severe COPD exacerbation in primary population of former smokers over the treatment period incorporating both the predecessor studies and PROSPERO Secondary endpoint: annualised rate of severe COPD exacerbation in the overall population of current and former smokers, time to first severe COPD exacerbation in former smokers, annualised rate of COPD exacerbations requiring hospitalisation and/or ER/ED visits in former smokers. 	<ul style="list-style-type: none"> FPCD: Q1 2023 Data readout: Q1 2026 Primary endpoint not met
Phase III TITANIA NCT05158387	Adults with symptomatic COPD with a history of exacerbations	1174	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled, parallel-group Treatment: 52-week Arm 1: tozorakimab dose 1 s.c. + SoC Arm 2: tozorakimab dose 2 s.c. + SoC Arm 3: placebo s.c. + SoC 	<ul style="list-style-type: none"> Primary endpoint: annualised rate of moderate to severe COPD exacerbations (former smokers) Secondary endpoints: annualised rate of moderate to severe COPD exacerbations (former or current smokers), annualized COPD exacerbations requiring hospitalisation and/or Emergency Room/Emergency Department and change in pre/post-BD FEV1, E-RS: COPD and SGRQ 	<ul style="list-style-type: none"> FPCD: Q1 2022 Data readout: Q1 2026 Primary endpoint met

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



tozorakimab (IL-33 ligand mAb)

Severe viral LRTD, asthma

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III TILIA NCT05624450	Adults hospitalised for viral lung infection requiring supplemental oxygen	3527	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled, parallel group Arm 1: tozorakimab dose i.v. + SoC Arm 2: placebo i.v. + SoC 	<ul style="list-style-type: none"> Primary endpoint: progression to death or to invasive mechanical ventilation/extracorporeal membrane oxygenation Secondary endpoints: safety and other efficacy measures 	<ul style="list-style-type: none"> FPCD: Q4 2022 Data anticipated: H2 2027
Phase II UMBRIEL NCT06932263	Adult participants with uncontrolled asthma on medium-to-high dose inhaled corticosteroids	540	<ul style="list-style-type: none"> Multi-centre, double-blind, placebo-controlled dose range finding Arm 1: tozorakimab dose 1 s.c. Arm 2: tozorakimab dose 2 s.c. Arm 3: placebo s.c. 	<ul style="list-style-type: none"> Primary endpoint: annualised rate of severe asthma exacerbations Secondary endpoints: annualised rate of severe asthma exacerbations, time-to-first severe asthma exacerbation; pre and post BD FEV1, change in baseline ACQ- 6 and AQLQ(S), safety and other efficacy measures 	<ul style="list-style-type: none"> FPCD: Q2 2025 Data anticipated: H2 2027

Oncology


CVRM

R&I

Infectious Diseases

Rare Disease





BioPharmaceuticals

Early-stage development



lenbelintide (AZD6234, selective amylin receptor agonist)

Obesity with related co-morbidities

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase II APRICUS NCT06595238	Participants living with obesity or overweight with co-morbidity	231	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled trial 	<ul style="list-style-type: none"> Primary endpoints: percent change in body weight from baseline to Week 26 and weight loss $\geq 5\%$ from baseline weight to Week 26 	<ul style="list-style-type: none"> FPCD: Q4 2024 LPCD: Q4 2025 Data readout: Q2 2026
Phase II ARAY NCT06851858	Adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy	69	<ul style="list-style-type: none"> Randomised, parallel-group, double-blind, placebo-controlled trial 	<ul style="list-style-type: none"> Primary endpoints: Percent change in body weight from baseline at Study Week 2; Weight loss $\geq 5\%$ from baseline at Study Week 26 Secondary endpoints: Weight loss, HbA1c, PK measures 	<ul style="list-style-type: none"> FPCD: Q2 2025 LPCD: Q3 2025 Data readout: Q3 2026
Phase I/II AGLOW NCT07017179	Chinese participants with obesity/overweight	48	<ul style="list-style-type: none"> Sub study 1: lenbelintide vs placebo, 16 weeks Sub study 2 cohort A: AZD9550 vs placebo, 28 weeks Sub study 2 cohort B: AZD6234 + AZD9550 vs placebo, 28 weeks China only 	<ul style="list-style-type: none"> Primary endpoint: Safety and tolerability in each cohort Secondary endpoints: PK, efficacy and immunogenicity in cohorts 	<ul style="list-style-type: none"> FPCD: Q2 2022 LPCD: Q1 2026 Data anticipated: H1 2027
Phase I NCT05511025	Healthy participants who are overweight or obese	64	<ul style="list-style-type: none"> SAD trial 	<ul style="list-style-type: none"> Primary endpoint: safety 	<ul style="list-style-type: none"> FPCD: Q4 2022 LPCD: Q4 2023 Data readout: Q1 2024
Phase I NCT06132841	Overweight or obese participants	142	<ul style="list-style-type: none"> Randomised, single-blind, placebo-controlled trial with repeated doses of lenbelintide or placebo via s.c. injection 	<ul style="list-style-type: none"> Primary endpoints: safety and tolerability of repeat doses 	<ul style="list-style-type: none"> FPCD: Q4 2023 Data anticipated: H1 2027
Phase I NCT06845813	Participants include those with end-stage renal disease (ESRD) on intermittent haemodialysis (HD), severe renal impairment not on dialysis, and optional groups for moderate and mild renal impairment.	48	<ul style="list-style-type: none"> Phase I multicentre, single-dose, non-randomised, open-label, parallel-group study aims to examine the pharmacokinetics, safety, and tolerability of lenbelintide in both male and female participants. 	<ul style="list-style-type: none"> Compare the plasma PK of a single SC dose of lenbelintide in participants with ESRD on HD, severe renal impairment (not on dialysis), moderate (optional), and mild (optional) renal impairment to those with normal renal function 	<ul style="list-style-type: none"> FPCD: Q1 2025 LPCD: Q3 2025 Data readout: Q1 2026
Phase I NCT07013643	Healthy females of childbearing and non-childbearing potential	50	<ul style="list-style-type: none"> Open-label, single-sequence, multiple-cohort study 	<ul style="list-style-type: none"> To assess the effect of multiple doses of lenbelintide (cohort 1) and AZD6234 and AZD9550 in combination (cohort 2) on the PK of single doses of combined oral contraceptive EE/LEVO 	<ul style="list-style-type: none"> FPCD: Q3 2025 Data anticipated: H2 2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



opemalirsen (AZD2373, APOL1)

Chronic kidney disease

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase IIb APPRECIATE <u>NCT06824987</u> Partnered (Ionis Pharmaceuticals Inc)	Participants diagnosed with APOL1 mediated kidney disease (AMKD), proteinuria	96	<ul style="list-style-type: none">Randomised, multi-centre, double-blind trial in US and UK followed by OLEArm 1: opemalirsen dose AArm 2: opemalirsen dose BArm 3: placebo	<ul style="list-style-type: none">Primary endpoint: Dose-response effect of AZD2373 on placebo corrected percentage change in uACR from baseline to Week 30Secondary endpoints: Safety and tolerability, proportion of patients achieving a 45% or greater reduction in uACR	<ul style="list-style-type: none">FPCD: Q2 2025Data anticipated: H2 2027
Phase I <u>NCT07154901</u> Partnered (Ionis Pharmaceuticals Inc)	Healthy participants/renal impairment	35	<ul style="list-style-type: none">Multicentre, single-dose, non-randomised, open-label, parallel-group	<ul style="list-style-type: none">Primary endpoints: PK measuresSecondary endpoints: PK/PD, safety measures	<ul style="list-style-type: none">FPCD: Q3 2025LPCD: Q2 2026Data anticipated: H2 2026

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



surovatamig (CD19/CD3 T-cell engager)

Antibody-mediated kidney disease

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase II CLEAR-AbKD NCT07571746	Primary membranous nephropathy	25	<ul style="list-style-type: none">Part A: Multiple ascending with sentinel dosingPart B: Multiple ascending doses	<ul style="list-style-type: none">Primary endpoint: safety and tolerabilitySecondary endpoints: efficacy, PK	<ul style="list-style-type: none">FPCD: Q3 2026Data anticipated: >2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



AZD1043 (ActRII mAb)

Weight management

Trial	Population	Patients	Design	Endpoints	Status
Phase I D9740C00001 <u>NCT07511205</u>	Healthy participants living with overweight and/or obesity	104	<ul style="list-style-type: none">Randomised, single-blind, placebo-controlled trialPart A (single ascending doses):<ul style="list-style-type: none">Part A1 (Global SAD, 6 cohorts): AZD1043Part A2 (Japanese SAD, 2 cohorts): AZD1043Part A1 (Chinese SAD, 1 cohort): AZD1043Part B (multiple ascending doses):<ul style="list-style-type: none">Part B1 (Global MAD, 3 cohorts): AZD1043Part B2 (Japanese MAD, 1 cohort): AZD1043	<ul style="list-style-type: none">Primary endpoints: Adverse events and serious adverse eventsSecondary endpoints: PK and ADA	<ul style="list-style-type: none">Data anticipated: H2 2027Initiating



AZD1613 (PAPPA-1 mAb)

ADPKD

Trial	Population	Patients	Design	Endpoints	Status
Phase I PIONEER-PKD NCT07228364	Autosomal dominant polycystic kidney disease	40	<ul style="list-style-type: none">Randomised, single-blind, placebo-controlled study with sequential MAD design	<ul style="list-style-type: none">Primary endpoint: Safety and tolerabilitySecondary endpoints: PK, PD	<ul style="list-style-type: none">FPCD: Q1 2026Data anticipated: H2 2027
Phase I NCT06995820	Healthy volunteers	136	<ul style="list-style-type: none">Randomised, single-blind, placebo-controlled single and multiple ascending dose	<ul style="list-style-type: none">Primary endpoint: safety and tolerabilitySecondary endpoints: PK parameters, changes in plasma PD biomarkers	<ul style="list-style-type: none">FPCD: Q2 2025Data anticipated: H1 2027



AZD2389 (anti-fibrotic mechanism)

MASH

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase II BORANA NCT06750276	Participants with liver fibrosis and compensated cirrhosis	40	<ul style="list-style-type: none"> Randomised, single-blind, placebo-controlled trial 	<ul style="list-style-type: none"> Primary endpoints: safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q4 2024 LPCD: Q3 2025 Data readout: Q4 2025
Phase II BRAVO NCT07610837	SLD and advanced fibrosis	104	<ul style="list-style-type: none"> Arm A: oral AZD2389 for 24 weeks Arm B: oral placebo for 24 weeks 	<ul style="list-style-type: none"> Primary endpoint: Absolute change in Enhanced Liver Fibrosis (ELF) score from baseline to week 24; safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q2 2026 Data anticipated: H2 2027
Phase I NCT06138795	Healthy volunteers	128	<ul style="list-style-type: none"> Randomised, placebo-controlled SAD/MAD trial 	<ul style="list-style-type: none"> Primary endpoints: safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q4 2023 LPCD: Q2 2025 Data readout: Q4 2025
Phase I NCT06812780	Healthy volunteers or participants with hepatic impairment	36	<ul style="list-style-type: none"> Multi-centre, single-dose, non-randomised, open-label, parallel-group trial 	<ul style="list-style-type: none"> Primary endpoint: PK parameters Secondary endpoints: safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q1 2025 LPCD: Q3 2025 Data readout: Q1 2026
Phase I NCT06846528	Healthy volunteers	16	<ul style="list-style-type: none"> Open-label, fixed-sequence trial AZD2389 AZD2389 + itraconazole 	<ul style="list-style-type: none"> Primary endpoints: PK parameters, safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q1 2025 LPCD: Q2 2025 Data readout: Q3 2025
Phase I NCT06974565	Healthy volunteers	24	<ul style="list-style-type: none"> Open-label, randomised, single dose, 2-way crossover 	<ul style="list-style-type: none"> Pharmacokinetics, safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q2 2025 LPCD: Q3 2025 Data readout: Q4 2025
Phase I NCT06973005	Healthy volunteers	8	<ul style="list-style-type: none"> Open label, fixed sequence, 3 period 	<ul style="list-style-type: none"> Pharmacokinetics, safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q2 2025 LPCD: Q3 2025 Data readout: Q4 2025

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



AZD3974 (anti-inflammatory and anti-fibrotic mechanism)

cirrhosis

Trial	Population	Patients	Design	Endpoints	Status
Phase I NCT07290283	Healthy volunteers	176	<ul style="list-style-type: none">Single-blind, placebo-controlled, randomised	<ul style="list-style-type: none">Primary endpoints: Safety/tolerability, PK	<ul style="list-style-type: none">FPCD: Q1 2026Data anticipated: H1 2027



AZD4063 (PLN siRNA)

Dilated cardiomyopathy

Trial	Population	Patients	Design	Endpoints	Status
Phase I PULSE NCT07241104 Partnered (Ionis Pharmaceuticals Inc)	R14del dilated cardiomyopathy	31	<ul style="list-style-type: none">Unblinded, SAD/MAD with 3 cohorts	<ul style="list-style-type: none">Primary endpoints: Safety and tolerability measures	<ul style="list-style-type: none">FPCD: Q4 2025Data anticipated: H2 2027



AZD4144 (NLRP3)

Cardiorenal disease

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase IIa SERENIA <u>NCT07215702</u>	Sepsis-associated acute kidney injury	124	<ul style="list-style-type: none"> Phase IIa, randomised, double-blind, placebo-controlled study 	<ul style="list-style-type: none"> Primary endpoint: AUC 24-hour CrCl Secondary endpoints: Days alive and free of KRT up to Day 30, Days alive and free of modified KDIGO AKI Stage 2 or 3 up to Days 7, 15, and 30, AUC(D1-7): Serum creatinine, PK/PD measures, safety and tolerability measures 	<ul style="list-style-type: none"> FPCD: Q1 2026 Data anticipated: H1 2027
Phase I <u>NCT06122714</u>	Healthy participants	95	<ul style="list-style-type: none"> Randomised, single-blind, placebo-controlled, SAD/MAD sequential group trial 	<ul style="list-style-type: none"> Primary endpoints: safety and tolerability Secondary endpoints: PK parameters 	<ul style="list-style-type: none"> FPCD: Q4 2023 LPCD: Q4 2024 Data readout: Q1 2025
Phase I <u>NCT06491550</u>	Healthy participants	92	<ul style="list-style-type: none"> Randomised, single-blind, placebo-controlled, SAD/MAD sequential group trial 	<ul style="list-style-type: none"> Primary endpoints: safety and tolerability Secondary endpoints: PK parameters 	<ul style="list-style-type: none"> FPCD: Q3 2024 LPCD: Q2 2025 Data readout: Q3 2025
Phase I <u>NCT06693765</u>	Participants with renal impairment, end-stage kidney disease and healthy volunteers	41	<ul style="list-style-type: none"> Single-dose, non-randomised, open-label, parallel-group trial 	<ul style="list-style-type: none"> Primary endpoints: safety, tolerability and PK parameters 	<ul style="list-style-type: none"> FPCD: Q4 2024 LPCD: Q2 2025 Data readout: Q4 2025
Phase I <u>NCT06675175</u>	Participants with established ASCVD	28	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled, parallel group trial 	<ul style="list-style-type: none"> Primary endpoints: safety, tolerability and PD parameters Secondary endpoints: PK and PD parameters 	<ul style="list-style-type: none"> FPCD: Q1 2025 LPCD: Q4 2025 Data readout: Q1 2026
Phase I <u>NCT06948006</u>	Healthy participants	32	<ul style="list-style-type: none"> Open-label, randomized, single-dose, crossover trial 	<ul style="list-style-type: none"> Primary endpoints: PK and safety 	<ul style="list-style-type: none"> FPCD: Q2 2025 LPCD: Q2 2025 Data readout: Q3 2025

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



AZD4144 (NLRP3)

Cardiorenal disease

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase I <u>NCT06925854</u>	Healthy participants	12	<ul style="list-style-type: none"> Open-label, 2-period, 2-sequence cross over trial Treatment A: single dose of rosuvastatin Treatment B: single dose of rosuvastatin in combination with AZD4144 Participants will be randomized 1:1 ratio to receive treatment sequence AB or BA. 	<ul style="list-style-type: none"> Primary endpoints: PK and safety 	<ul style="list-style-type: none"> FPCD: Q2 2025 LPCD: Q2 2025 Data readout: Q3 2025
Phase I <u>NCT06942923</u>	Healthy participants with obesity	28	<ul style="list-style-type: none"> Placebo-controlled, parallel group study 	<ul style="list-style-type: none"> Primary endpoints: safety, tolerability and PD parameters Secondary endpoints: PK and PD parameters 	<ul style="list-style-type: none"> FPCD: Q2 2025 LPCD: Q3 2025 Data readout: Q4 2025
Phase I <u>NCT07518459</u>	Healthy participants	16	<ul style="list-style-type: none"> Open-label, non-randomised, single dose study 	<ul style="list-style-type: none"> Mass balance recovery, rates and routes of elimination Metabolite profiling PK 	<ul style="list-style-type: none"> FPCD: Q1 2026 LPCD: Q2 2026 Data readout: Q3 2026
Phase I <u>NCT07685600</u>	Healthy participants	32	<ul style="list-style-type: none"> Open-label, randomised, two arm, fixed sequence trial Arm 1: sequence and combination of oral AZD4144 and itraconazole Arm 2: sequence and combination of i.v. AZD4144 and itraconazole 	<ul style="list-style-type: none"> Primary endpoint: PK 	<ul style="list-style-type: none"> FPCD: Q3 2026 Data anticipated: H1 2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



AZD4248 (NNMT)

CKD

Trial	Population	Patients	Design	Endpoints	Status
Phase I NCT07024823	Healthy volunteers	164	<ul style="list-style-type: none">Randomised, single-blind, placebo-controlledPart A: SAD in healthy volunteersPart B: MAD in healthy volunteersPart C: multiple dosing DKDPart D: observational cohort	<ul style="list-style-type: none">Primary endpoints: Safety and tolerability measuresSecondary endpoints: PK parameters	<ul style="list-style-type: none">FPCD: Q3 2025Data anticipated: H1 2027



AZD4954 (Lp(a) inhibitor)

Dyslipidaemia

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase I <u>NCT06980428</u>	Healthy volunteers	120	<ul style="list-style-type: none">Randomised, placebo-controlled SAD/MAD trial	<ul style="list-style-type: none">Primary endpoints: safety and tolerability	<ul style="list-style-type: none">FPCD: Q2 2025Data anticipated: H1 2027
Phase I <u>NCT07513571</u>	Healthy participants	32	<ul style="list-style-type: none">Treatment A: single dose of AZD4954 aloneTreatment B: single dose of laroprovstat aloneTreatment C: single doses of laroprovstat + AZD4954Cohort 1: Treatment A followed by Treatment C.Cohort 2: Treatment B followed by Treatment C	<ul style="list-style-type: none">To assess the effect of a single dose of oral laroprovstat on the PK of a single dose of oral AZD4954 in healthy participants.	<ul style="list-style-type: none">FPCD: Q2 2026LPCD: Q2 2026Data readout: Q3 2026

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



AZD5462 (oral relaxin)

Heart failure

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase IIb LUMINARA NCT06299826	Stable patients with chronic heart failure	375	<ul style="list-style-type: none"> Two cohort, randomised, double-blind, placebo-controlled, multi-centre trial Arm 1: AZD5462 (high dose) Arm 2: AZD5462 (medium dose) Arm 3: AZD5462 (low dose) Arm 4: placebo 	<ul style="list-style-type: none"> Primary endpoint: change in heart function from baseline to Week 25 compared to placebo 	<ul style="list-style-type: none"> FPCD: Q3 2024 LPCD: Q3 2025 Data readout: Q2 2026
Phase Ib AURORA NCT06639087	Stable patients with heart failure and moderately impaired renal function	8	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled, multi-centre mechanistic trial Arm 1: AZD5462 + dapagliflozin Arm 2: placebo + dapagliflozin 	<ul style="list-style-type: none"> Primary endpoint: change in fractional excretion of sodium from baseline to Day 1 	<ul style="list-style-type: none"> FPCD: Q4 2024 LPCD: Q2 2025 Data readout: Q1 2026
Phase I GLITTER NCT06661733	Participants with severe renal impairment and participants with normal renal function	16	<ul style="list-style-type: none"> Single centre, non-randomised, open-label, parallel group trial Cohort 1: AZD5462 Cohort 2: AZD5462 	<ul style="list-style-type: none"> Primary endpoints: PK parameters, safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q4 2024 LPCD: Q4 2024 Data readout: Q3 2025
Phase I PHOTON NCT06989983	Healthy volunteers	8	<ul style="list-style-type: none"> Open-label, two-part sequential human ADME trial 	<ul style="list-style-type: none"> Primary endpoints: mass balance recovery, absorption, metabolism, excretion of [14C]AZD5462 and absolute bioavailability of AZD5462 Secondary endpoints: safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q2 2025 LPCD: Q2 2025 Data readout: Q1 2026

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



AZD9550 (GLP-1-glucagon receptor agonist)

MASH, Obesity

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II CONTEMPO NCT06151964	Overweight and obese participants with T2DM or without T2DM	118	<ul style="list-style-type: none"> Randomised, single-blind, placebo-controlled, MAD trial with 4 parts (A to D) Part A: multiple repeat doses of AZD9550 or placebo given as 4 QW s.c. doses for 4 weeks to 2 sequential cohorts evaluating 2 low dose levels of AZD9550 or placebo Part B: QW up-titration over 5 doses of AZD9550 or placebo Part C: bi-weekly/monthly up-titration of AZD9550 or placebo for 24 weeks Part D: bi-weekly/monthly up-titration of AZD9550 or placebo for 24 weeks (Japan only) Part E: bi-weekly/monthly up-titration of AZD9550 and AZD6234 or placebo for 24 weeks 	<ul style="list-style-type: none"> Primary endpoints: safety, tolerability and PK parameters 	<ul style="list-style-type: none"> FPCD: Q4 2023 Data anticipated: H1 2027
Phase I NCT05848440	Healthy volunteers	64	<ul style="list-style-type: none"> SAD trial 	<ul style="list-style-type: none"> Primary endpoints: safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q2 2023 LPCD: Q4 2023 Data readout: Q2 2024

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



AZD9550+AZD6234 (GLP-1-glucagon receptor agonist + selective amylin receptor agonist)

Obesity

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase IIb ASCEND NCT06862791	Adults who are living with obesity or overweight with at least one of the following weight-related co-morbidities: hypertension, dyslipidemia or obstructive sleep apnoea	360	<ul style="list-style-type: none"> Randomised, parallel-group, double-blind, placebo-controlled, multi-centre, reduced factorial design IMP injected subcutaneous, once weekly Arm 1: AZD9550 low dose + AZD6234 low dose or placebos Arm 2: AZD9550 medium dose + AZD6234 medium dose or placebos Arm 3: AZD9550 high dose + AZD6234 high dose or placebos Arm 4: AZD9550 low dose + AZD6234 medium dose or placebos Arm 5: AZD9550 medium dose + AZD6234 low dose or placebos Arm 6: AZD9550 high dose + AZD6234 medium dose or placebos Arm 7: AZD9550 medium dose + AZD6234 high dose or placebos Arm 8: AZD9550 high dose or placebo Arm 9: AZD6234 high dose or placebo 	<ul style="list-style-type: none"> Primary endpoints: percent change in body weight from baseline after 36 weeks of treatment, weight loss $\geq 5\%$ from baseline after 36 weeks of treatment Secondary endpoints: absolute body weight change, weight loss $\geq 5\%/10\%/15\%$ from baseline, ADA incidence/prevalence/titres 	<ul style="list-style-type: none"> FPCD: Q1 2025 LPCD: Q2 2025 Data readout: Q3 2026
Phase I NCT07546760	Severe and moderate hepatic impairment and healthy volunteers	28	<ul style="list-style-type: none"> Open-label, parallel group trial 	<ul style="list-style-type: none"> AEs, SAEs and PK 	<ul style="list-style-type: none"> FPCD: Q2 2026 Data anticipated: H1 2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



sunakiment (AZD8630, inhaled TSLP)

Asthma

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase II LEVANTE NCT06529419 Partnered (AMGEN)	Adults with uncontrolled asthma at risk of exacerbations	516	<ul style="list-style-type: none"> Randomised, placebo-controlled, double-blind, dose range-finding, multi-centre trial Arm 1: AZD8630 Dose A Arm 2: AZD8630 Dose B Arm 3: AZD8630 Dose C Arm 4: placebo 	<ul style="list-style-type: none"> Primary endpoint: time to first CompEx asthma event Secondary endpoints: change from baseline in pre-bronchodilator forced expiratory volume in 1 second and safety and tolerability 	<ul style="list-style-type: none"> FPCD: Q3 2024 LPCD: Q4 2025 Data readout: Q2 2026
Phase I APkITA NCT07065331 Partnered (AMGEN)	Adolescent participants with asthma aged 11 to 17	22	<ul style="list-style-type: none"> Phase 1, open label, single dose study in adolescent participants with asthma where the participants will receive AZD8630 administered via dry powder inhaler 	<ul style="list-style-type: none"> Area under the serum concentration-time curve from time zero to 24 hours (AUC0-24) Maximum observed drug concentration (C_{max}) Time to reach peak or maximum observed concentration (T_{max}) 	<ul style="list-style-type: none"> FPCD: Q2 2025 LPCD: Q3 2025 Data readout: Q1 2026
Phase I NCT05110976 Partnered (AMGEN)	Healthy volunteers and patients with asthma	232	<ul style="list-style-type: none"> SAD and MAD trial 	<ul style="list-style-type: none"> Primary endpoints: safety and tolerability Secondary endpoints: PK parameters and FENO 	<ul style="list-style-type: none"> FPCD: Q1 2022 LPCD: Q3 2023 Data readout: Q4 2023
Phase I NCT06531811 Partnered (AMGEN)	Healthy volunteers	32	<ul style="list-style-type: none"> Randomised, open-label, 2-treatment, 2-period trial 	<ul style="list-style-type: none"> Primary endpoints: safety and tolerability Secondary endpoint: PK parameters 	<ul style="list-style-type: none"> FPCD: Q3 2024 LPCD: Q3 2024 Data readout: Q2 2025
Phase I NCT06795906 Partnered (AMGEN)	Adults with asthma on medium-to-high dose inhaled corticosteroids and long-acting beta-agonists	24	<ul style="list-style-type: none"> Randomised, placebo-controlled, double-blind, parallel design 	<ul style="list-style-type: none"> Primary endpoints: safety and tolerability, pharmacokinetic parameter Secondary endpoint : change from baseline in FeNO at weeks 1 and 2 	<ul style="list-style-type: none"> FPCD: Q1 2025 LPCD: Q2 2025 Data readout: Q4 2025

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



surovatamig (CD19/CD3 T-cell engager)

RA, SLE

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase I NCT07201558	Adult participants with rheumatoid arthritis or systemic lupus erythematosus	48	<ul style="list-style-type: none">Open-label, multicentrePart 1: SADPart 2: SUD	<ul style="list-style-type: none">Primary endpoints: safety and tolerability measures	<ul style="list-style-type: none">FPCD: Q1 2026Data anticipated: >2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



AZD0120 (autologous anti-CD19 and anti-BCMA CAR-T)

Autoimmune conditions, neurology and SLE

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase Ib/II PHOENIX NCT06897930	Refractory systemic lupus erythematosus (SLE)	24	<ul style="list-style-type: none"> Single-arm, open-label, multi-centre trial 	<ul style="list-style-type: none"> Primary endpoints (Phase I): safety and tolerability, determination of recommended dose for expansion phase Secondary endpoints (Phase I): SRI-4, DORIS, LLDAS, BICLA, time from infusion to disease flare, PK parameters, LN-specific responses, disease related biomarker assessments, AZD0120 immunogenicity, RCL presence 	<ul style="list-style-type: none"> FPCD: Q3 2025 Data anticipated: >2027
Phase Ib ZENITH NCT07224373	Adults with refractory active relapsing or progressive multiple sclerosis	24	<ul style="list-style-type: none"> Open-label, randomised Group 1 (RMS): Regimen 1 of AZD0120 Group 1 (RMS): Regimen 2 of AZD0120 Group 2 (PMS): Regimen 1 of AZD0120 Group 2 (PMS): Regimen 2 of AZD0120 	<ul style="list-style-type: none"> Primary: Incidence and severity of DLTs, AEs, SAEs, and TEAEs Secondary: B-cell counts, Cellular Kinetics, ARR, CDP-12, CDP-24, CDI, 9HPT, T25FW, EDSS, SDMT, NEDA-3, PIRA, MRI parameters, SF-36v2, Neuro-QoL, RCL, ADA 	<ul style="list-style-type: none"> FPCD: Q1 2026 Data anticipated: >2027
Phase I/IIb AURORA NCT07295847	Adult participants with systemic sclerosis, idiopathic inflammatory myopathies or difficult-to-treat rheumatoid arthritis	27	<ul style="list-style-type: none"> Open label multi-centre, multi-cohort trial Arm A: AZD0120 regimen 1 Arm B: AZD0120 regimen 2 	<ul style="list-style-type: none"> Primary: DLTs, TEAEs, RP2D Secondaries: PK, anti-drug antibodies, detectable replication competent lentivirus, disease activity score, modified Rodnan Skin Score, total improvement score 	<ul style="list-style-type: none"> FPCD: Q1 2026 Data anticipated: >2027
Phase I/II NCT06530849	Refractory systemic lupus erythematosus	21	<ul style="list-style-type: none"> Single-arm, open label, multi-centre trial 	<ul style="list-style-type: none"> Primary endpoint (Phase I): safety at 28 days Primary endpoint (Phase II): efficacy (SRI-4 response) at Week 48 	<ul style="list-style-type: none"> FPCD: Q3 2024 LPCD: Q2 2026 Data anticipated: H1 2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



AZD1163 (anti-PAD2/4 bispecific antibody)

Rheumatoid arthritis

Trial	Population	Patients	Design	Endpoints	Status
Phase IIb LaunchPAD-RA <u>NCT07276581</u>	Moderate-to-severely active RA	320	<ul style="list-style-type: none">• Double-blind, 4-arm study• Arm 1: s.c. injection of AZD1163 Dose 1 + SoC (csDMARDs or TNFi +/- csDMARD)• Arm 2: s.c. injection of AZD1163 Dose 2 + SoC (csDMARDs or TNFi +/- csDMARD)• Arm 3: s.c. injection of AZD1163 Dose 3 + SoC (csDMARDs or TNFi +/- csDMARD)• Arm 4: placebo + SoC (csDMARDs or TNFi +/- csDMARD)	<ul style="list-style-type: none">• Primary endpoint: Change from baseline in DAS28-CRP at Week 12• Key secondary endpoint: Percentage of participants achieving ACR20, ACR50, CDAI and SDAI at Week 12.	<ul style="list-style-type: none">• FPCD: Q1 2026• Data anticipated: H2 2027



AZD4916

Respiratory

Approved medicines

Late-stage development

Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase I NCT06951880	Healthy volunteers	178	<ul style="list-style-type: none">Randomised, single-blind, placebo controlled SAD/MAD trial	<ul style="list-style-type: none">Primary endpoints: Safety and tolerability; Secondary endpoints: PK parameters	<ul style="list-style-type: none">FPCD: Q3 2026Data anticipated: >2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



AZD5492 (CD20 TITAN TCE)

SLE

Trial	Population	Patients	Design	Endpoints	Status
Phase I TITAN NCT06916806	Systemic lupus erythematosus, idiopathic inflammatory myopathies, rheumatoid arthritis	70	<ul style="list-style-type: none">Open-label, multi-centrePart 1: Single ascending dose with AZD5492Part 2: Step-up dosing with AZD5492	<ul style="list-style-type: none">Primary endpoints: safety and tolerabilitySecondary endpoints: PK parameters	<ul style="list-style-type: none">Data anticipated: H1 2027



AZD6793 (IRAK4)

COPD

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase II PRESTO <u>NCT07082738</u>	Moderate to very severe COPD	987	<ul style="list-style-type: none"> Randomised, double-blind, placebo controlled 3 arm 24 week study AZD6793 (dose 1) AZD6793 (dose 2) Placebo 	<ul style="list-style-type: none"> Primary endpoint: annualised rate of moderate or severe COPD exacerbations Secondary endpoints: time to first exacerbations, annualised rate of severe exacerbations, CompEx, pre-BD FEV1, post-BD FEV1, BCSS, CAT, SGRQ 	<ul style="list-style-type: none"> FPCD: Q3 2025 Data anticipated: >2027
Phase I <u>NCT05662033</u>	Healthy volunteers	133	<ul style="list-style-type: none"> Single-blind, randomised, placebo-controlled trial 	<ul style="list-style-type: none"> Primary endpoints: safety and tolerability Secondary endpoint: PK parameters 	<ul style="list-style-type: none"> FPCD: Q4 2022 LPCD: Q4 2024 Data readout: Q3 2025
Phase I <u>NCT06368440</u>	Healthy volunteers	40	<ul style="list-style-type: none"> Single-blind, randomised, placebo-controlled trial Japanese and Chinese healthy participants 	<ul style="list-style-type: none"> Primary endpoint: safety Secondary endpoints: PK parameters 	<ul style="list-style-type: none"> FPCD: Q2 2024 LPCD: Q4 2024 Data readout: Q2 2025
Phase I <u>NCT06494644</u>	Healthy participants	17	<ul style="list-style-type: none"> A single-group trial with a duration of up to 8 weeks (maximum of 53 days) including Screening, Period 1, Period 2, Period 3 and Follow-up to assess the pharmacokinetics of AZD6793 when administered alone and in combination with itraconazole in healthy participants 	<ul style="list-style-type: none"> Primary endpoint: PK parameters (C_{max}, AUC, CL/F, t_{1/2}, t_{max}, V_z/F, RAUC) Secondary endpoint: safety 	<ul style="list-style-type: none"> FPCD: Q3 2024 LPCD: Q4 2024 Data readout: Q2 2025
Phase I <u>NCT07433062</u>	Participants with Type 2 diabetes mellitus (T2DM)	35	<ul style="list-style-type: none"> Double blind, 2-period cross over study to evaluate the effect of steady-state AZD6793 on the steady-state pharmacokinetics/pharmacodynamics of metformin in participants with Type 2 diabetes mellitus 	<ul style="list-style-type: none"> Mean glucose levels on Day 7 of each treatment period as assessed by CGM metrics (time in range, time in tight range, time below range, time above range, AUC(0-24)) 	<ul style="list-style-type: none"> FPCD: Q1 2026 Data anticipated: H2 2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



AZD7798 (humanised mAb)

Crohn's disease

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase IIa AMALTHEA <u>NCT06450197</u>	Moderate to severe Crohn's disease	120	<ul style="list-style-type: none">Randomised, double-blind, placebo-controlled trialArm 1: AZD7798Arm 2: placebo	<ul style="list-style-type: none">Primary endpoint: Crohn's Disease Activity Index (CDAI) remissionSecondary endpoints: endoscopic response, endoscopic remission, endoscopic score change from baseline, CDAI response, CDAI score change from baseline, symptomatic remission, PK parameters and ADA	<ul style="list-style-type: none">FPCD: Q4 2024Data anticipated: H2 2026
Phase II CALLISTO <u>NCT06681324</u>	Patients with active ileal Crohn's disease and an ileostomy	24	<ul style="list-style-type: none">Participant- and investigator-blind, randomised, placebo-controlled Phase II studyArm 1: AZD7798Arm 2: Placebo	<ul style="list-style-type: none">Primary endpoint: safetySecondary endpoints: Simple Endoscopic Score for Crohn's Disease (SES-CD) , endoscopic response and remission, PK parameters, ADA	<ul style="list-style-type: none">FPCD: Q1 2025Data anticipated: H2 2026

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



AZD8965 (arginase enzyme inhibitor)

IPF

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase IIb ARGiNAUT <u>NCT07652658</u>	Participants with IPF	359	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled, parallel-group 24-week, multi-centre study Arm 1: AZD8965 low dose Arm 2: AZD8965 medium dose Arm 3: AZD8965 high dose Arm 4: Placebo 	<ul style="list-style-type: none"> Primary endpoint: Absolute change from baseline in FVC at Week 24 Secondary endpoints: Change from baseline in FVC, change from baseline in percentage predicted FVC, change in rate of decline in FVC, safety and tolerability, PK 	<ul style="list-style-type: none"> FPCD: Q3 2026 Data anticipated: >2027
Phase I <u>NCT06502379</u>	Healthy volunteers	163	<ul style="list-style-type: none"> Randomised, single-blind, SAD/MAD, placebo-controlled, AZD8965/placebo administered orally PART 1: SAD cohorts PART 2: MAD cohorts PART 3a: Japanese and Chinese participants SAD cohorts PART 3b: Japanese and Chinese participants SMAD cohorts PART 4: food effect cohort 	<ul style="list-style-type: none"> Primary endpoints (Part 1, 2, 3): safety and tolerability measures Primary endpoint (Part 4): PK parameters Secondary endpoint (Part 1, 2, 3): PK parameters Secondary endpoints (Part 4): safety and tolerability measures under fasted and fed condition 	<ul style="list-style-type: none"> FPCD: Q3 2024 LPCD: Q4 2025 Data readout: Q1 2026

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



AZD0292 (Psl-PcrV N3Y-bispecific mAb)

Bronchiectasis

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase IIb BREEZE NCT07774403	Bronchiectasis and chronic pseudomonas aeruginosa colonisation	84	<ul style="list-style-type: none"> Randomized, double-blind, placebo-controlled, parallel trial Arm A: AZD0292 i.v. Arm B: Placebo i.v. China only 	<ul style="list-style-type: none"> Primary: Annualised rate of exacerbations over a variable follow-up time Secondary: Other efficacy measures, safety, PK 	<ul style="list-style-type: none"> FPCD: Q3 2026 Data anticipated: >2027
Phase IIb CLEAR NCT07088926	Bronchiectasis patients ≥ 12 years of age, chronically colonized with PsA	435	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled, parallel, multidose 2 dosage regimens (high dose, low dose) of AZD0292 i.v. vs placebo i.v. 	<ul style="list-style-type: none"> Primary: efficacy Secondary: safety, PK 	<ul style="list-style-type: none"> FPCD: Q4 2025 Data anticipated: >2027
Phase I NCT06311760	Healthy volunteers	32	<ul style="list-style-type: none"> Randomised, single-blind, placebo-controlled trial Arm 1: AZD0292 Dose 1 administered via i.v. infusion Arm 2: AZD0292 Dose 2 administered via i.v. infusion Arm 3: AZD0292 Dose 3 administered via i.v. infusion Arm 4: AZD0292 Dose 4 administered via i.v. infusion Arm 5: placebo administered via i.v. infusion 	<ul style="list-style-type: none"> Primary endpoints: AEs and participants with AESI Secondary endpoints: Cmax, AUClast, AUCinfinity and ADA 	<ul style="list-style-type: none"> FPCD: Q2 2024 LPCD: Q3 2024 Data readout: Q2 2025

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



AZD0543 (hMPV long-acting neutralising antibody)

Prevention of hMPV respiratory illness

Trial	Population	Patients	Design	Endpoints	Status
Phase I NCT07824622	Healthy volunteers	144	<ul style="list-style-type: none">Randomised, double-blind, placebo-controlled trialCohort 1: low dose AZD0543 vs placeboCohort 2: medium dose AZD0543 vs placeboCohort 3: high dose AZD0543 vs placebo	<ul style="list-style-type: none">Primary endpoint: Safety and tolerabilitySecondary endpoints: PK	<ul style="list-style-type: none">FPCD: Q3 2026Data anticipated: H1 2027



AZD5148 (anti-TcdB mAb)

Clostridium difficile

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase IIb PRISM <u>NCT07285213</u>	Adults with qualifying C. difficile infection episode	230	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled AZD5148 or placebo 	<ul style="list-style-type: none"> Primary endpoint: efficacy Secondary endpoint: safety, PK 	<ul style="list-style-type: none"> FPCD: Q4 2025 Data anticipated: >2027
Phase I <u>NCT06469151</u>	Healthy volunteers	84	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled, dose escalation Cohort 1: AZD5148 (dose 1, i.m.) or placebo Cohort 2a: AZD5148 (dose 2, i.m.) or placebo Cohort 2b: AZD5148 (dose 2, i.m., Chinese participants) or placebo Cohort 3: AZD5148 (dose 2, i.v.) or placebo Cohort 4a: AZD5148 (dose 3, i.v.) or placebo Cohort 4b: AZD5148 (dose 3, i.v., Chinese participants) or placebo Cohort 5: AZD5148 (dose 4, i.v.) or placebo 	<ul style="list-style-type: none"> Primary endpoint: safety Secondary endpoint: PK parameters 	<ul style="list-style-type: none"> FPCD: Q2 2024 LPCD: Q4 2024 Data readout: Q1 2026

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease




AZD7760 (mAb combination targeting S aureus virulence factors)

Prevention of Staph aureus infection

Trial	Population	Patients	Design	Endpoints	Status
Phase I/IIa NCT06749457	Phase I: healthy volunteers male and female participants aged 18 to 55 years Phase IIa: patients with ESKD receiving haemodialysis through a central venous catheter	231	<ul style="list-style-type: none"> Phase I: randomised, double-blind, placebo-controlled, dose escalation trial to evaluate the safety and PK of AZD7760 to evaluate 3 doses Phase IIa: randomised, double-blind, placebo-controlled trial to evaluate the safety and PK of AZD7760 	<ul style="list-style-type: none"> Primary endpoint (Phase I): safety Primary endpoint (Phase IIa): safety Secondary endpoints (Phase I): PK parameters and ADA Secondary endpoints (Phase IIa): PK parameters, ADA and D451 safety 	<ul style="list-style-type: none"> FPCD: Q1 2025 LPCD: Q3 2026 Data anticipated: H1 2027





Rare Disease

Approved medicines
and late-stage pipeline



Ultomiris (anti-C5 mAb)

Haematology, nephrology, transplant

Trial	Population	Patients	Design	Endpoints	Status
Phase III AWAKE NCT06830798	Delayed graft function in high risk donor kidneys	450	<ul style="list-style-type: none"> Arm1: Placebo Arm2: <i>Ultomiris</i> 	<ul style="list-style-type: none"> Primary endpoint: time to freedom from dialysis Secondary endpoints: DGF incidence, number of dialysis sessions, time to first occurrence of eGFR $\Rightarrow$ 30 mL/min/1.73m². 	<ul style="list-style-type: none"> FPCD: Q2 2025 Trial discontinued due to efficacy
Phase III I CAN NCT06291376	Immunoglobulin A nephropathy	510	<ul style="list-style-type: none"> Arm 1: <i>Ultomiris</i> via weight-based i.v. infusion Arm 2: placebo via weight-based i.v. infusion 	<ul style="list-style-type: none"> Primary endpoints: change from baseline in proteinuria based on 24-hour UPCR at Week 34 and eGFR over 106 weeks Secondary endpoints: reduction in UPCR$\geq$50%, change in proteinuria at week 10, time to sustained $\geq$30% eGFR decline, composite kidney endpoint 	<ul style="list-style-type: none"> FPCD: Q2 2024 LPCD: Q3 2026 Data readout: Q1 2026 Primary endpoint met
Phase III TMA-314 NCT04557735	Paediatric thrombotic microangiopathy-associated haematopoietic stem cell transplant	41	<ul style="list-style-type: none"> Arm 1: <i>Ultomiris</i> administered once every 4 to 8 weeks 	<ul style="list-style-type: none"> Primary endpoint: proportion of participants with TMA response Secondary endpoints: time to TMA response, proportion of participants with TMA relapse 	<ul style="list-style-type: none"> FPCD: Q4 2020 LPCD: Q2 2024 Data readout: Q1 2025 Positive high-level results
Phase II SANCTUARY NCT04564339	Proliferative lupus nephritis or immunoglobulin A nephropathy	123	<ul style="list-style-type: none"> Arm 1: LN cohort, <i>Ultomiris</i> Arm 2: LN cohort, placebo Arm 3: IgAN cohort, <i>Ultomiris</i> Arm 4: IgAN cohort, placebo 	<ul style="list-style-type: none"> Primary endpoint: percentage change in proteinuria from baseline to Week 26 Secondary endpoints: percentage change in proteinuria from baseline to Week 50 	<ul style="list-style-type: none"> FPCD: Q1 2021 LPCD: Q2 2025 Data readout: Q2 2025



Ultomiris (anti-C5 mAb)

Neurology

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase II/III ALXN1210-MG-319 NCT05644561	Paediatric patients (6 to < 18 years of age) with documented AChR-Ab (+) Myasthenia Gravis (MG)	12	<ul style="list-style-type: none">Single ArmUltomiris Q4W (<20 kg) or Q8W (≥20 Kg)	<ul style="list-style-type: none">PK, PD, Safety, Efficacy at Week 18	<ul style="list-style-type: none">FPCD: Q3 2023LPCD: Q4 2025Data readout: Q3 2026Primary endpoint met
Phase II/III ALXN1210-NMO-317 NCT05346354	Paediatric patients with NMOSD	12	<ul style="list-style-type: none">Arm 1: Ultomiris q8w	<ul style="list-style-type: none">Primary endpoint: change from baseline in annualised relapse rate at Week 50	<ul style="list-style-type: none">FPCD: Q3 2022LPCD: Q2 2026Data anticipated: H2 2027

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



Amlypave (fibril-reactive mAb)

AL amyloidosis

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III CARES-301 NCT04504825	AL amyloidosis (Mayo Stage IIIb)	124	<ul style="list-style-type: none"> Arm 1: <i>Amlypave</i> combined with SoC for PCD Arm 2: placebo combined with SoC for PCD 	<ul style="list-style-type: none"> Primary endpoint: a hierarchical combination of time to all-cause mortality and frequency of cardiovascular hospitalisation, safety (TEAEs) Secondary endpoint: quality of life measures 	<ul style="list-style-type: none"> FPCD: Q1 2021 LPCD: Q4 2023 Data readout: Q3 2025 Primary endpoint not met
Phase III CARES-302 NCT04512235	AL amyloidosis (Mayo Stage IIIa)	267	<ul style="list-style-type: none"> Arm 1: <i>Amlypave</i> combined with SoC for PCD Arm 2: placebo combined with SoC for PCD 	<ul style="list-style-type: none"> Primary endpoint: Hierarchical combination of time to all-cause mortality and frequency of cardiovascular hospitalisation, safety (TEAEs) Secondary endpoint: quality of life measures 	<ul style="list-style-type: none"> FPCD: Q4 2020 LPCD: Q4 2023 Data readout: Q3 2025 Primary endpoint not met

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



clirimitug (TTR depleter)

Amyloidosis

Trial	Population	Patients	Design	Endpoints	Status
Phase III DepleTTR-CM NCT06183931	ATTR-CM (wild-type and variant)	1180	<ul style="list-style-type: none">Arm 1: clirimitug via i.v. infusion Q4W for at least 30 months up to a maximum of 48 monthsArm 2: placebo via i.v. infusion Q4W for at least 30 months up to a maximum of 48 months	<ul style="list-style-type: none">Primary endpoint: composite all-cause mortality and total CV events.Secondary endpoints: KCCQ, 6MWT, all-cause mortality, CV mortality, CV events	<ul style="list-style-type: none">FPCD: Q1 2024LPCD: Q2 2025Data anticipated: >2027



efzimfotase alfa (ALXN1850, next-generation asfotase alfa)

Hypophosphatasia

Approved medicines
Late-stage development
Early development

Trial	Population	Patients	Design	Endpoints	Status
Phase III CHESTNUT NCT06079372	Hypophosphatasia	40	<ul style="list-style-type: none"> Arm 1: bodyweight-dependent doses of either 20mg, 35mg or 50mg of efzimfotase alfa Q2W via s.c. for 24 weeks Arm 2: 6mg/kg/week of Strensiq via s.c. injection as either 2mg/kg 3 times per week or 1mg/kg 6 times per week for 24 weeks 	<ul style="list-style-type: none"> Primary endpoint: incidence of TEAEs 	<ul style="list-style-type: none"> FPCD: Q2 2024 LPCD: Q1 2025 Data readout: Q1 2026 Primary endpoint met
Phase III HICKORY NCT06079281	Hypophosphatasia	114	<ul style="list-style-type: none"> Arm 1: placebo on Day 1 followed by Q2W via s.c. injection for 24 weeks Arm 2: bodyweight-dependent doses of either 20mg, 35mg or 50mg of efzimfotase alfa Q2W via s.c. injection for 24 weeks 	<ul style="list-style-type: none"> Primary endpoint: change from baseline in 6MWT at Day 169 	<ul style="list-style-type: none"> FPCD: Q2 2024 LPCD: Q1 2025 Data readout: Q1 2026 Primary endpoint not met
Phase III MULBERRY NCT06079359	Hypophosphatasia	30	<ul style="list-style-type: none"> Arm 1: bodyweight-dependent doses of either 25mg, 35mg, or 50mg of efzimfotase Q2W via s.c. injection for 24 weeks Arm 2: placebo Q2W for 24 weeks 	<ul style="list-style-type: none"> Primary endpoint: Radiographic Global Impression of Change (RGI-C) Score at Day 169 	<ul style="list-style-type: none"> FPCD: Q3 2024 LPCD: Q3 2025 Data readout: Q1 2026 Primary endpoint met

Oncology

CVRM

R&I

Infectious Diseases

Rare Disease



eneboparatide (parathyroid hormone receptor 1 agonist)

Hypoparathyroidism

Trial	Population	Patients	Design	Endpoints	Status
Phase III CALYPSO NCT05778071	Chronic hypoparathyroidism	165	<ul style="list-style-type: none">Arm 1: 20mcg eneboparatide administered once daily via s.c. injectionArm 2: placebo administered once daily via s.c. injection	<ul style="list-style-type: none">Primary endpoint: complete independence from active vitamin D, independence from therapeutic doses of oral calcium (i.e. taking oral elemental calcium supplements ≤600mg/day) and albumin-adjusted serum calcium within the normal range (8.3 to 10.6mg/dL) vs. placebo after 24 weeks of treatment	<ul style="list-style-type: none">FPCD: Q3 2023Data readout: Q1 2025Primary endpoint met




Klygefa (anti-C5 dual-binding nanobody)

Neurology

Trial	Population	Patients	Design	Endpoints	Status
Phase III PREVAIL NCT05556096	Generalised myasthenia gravis	260	<ul style="list-style-type: none">Arm 1: weight-based maintenance treatment with <i>Klygefa</i> on Day 1, followed by weight-based maintenance treatment of <i>Klygefa</i> on Week 1 (Day 8) and Q1W thereafter for a total of 26 weeksArm 2: placebo	<ul style="list-style-type: none">Primary endpoint: change from baseline in MG-ADL total score at Week 26Key Secondary endpoints: Change from baseline in QMG total score, Change from baseline in the MGC total score	<ul style="list-style-type: none">FPCD: Q4 2022LPCD: Q4 2024Data readout: Q3 2025Primary endpoint met





Rare Disease

Early-stage development



tarperprumig (ALXN1820, anti-properdin)

Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis

Trial	Population	Patients	Design	Endpoints	Status
Phase II I-TRANSCEND NCT07160608	Newly diagnosed or relapsing ANCA (Anti-Neutrophil Cytoplasmic Antibody)-associated vasculitis patients	75	<ul style="list-style-type: none"> Randomised, double-blind, placebo-controlled, parallel group tarperprumig (dose regimen 1 or 2) placebo 	<ul style="list-style-type: none"> Primary endpoint: safety and tolerability Secondary endpoints: Remission at Week 26; Sustained Remission at Week 52; Change from baseline in eGFR, uPCR, uACR and hematuria; Number of participants achieving BVAS of 0 through week 52; Time to first relapse 	<ul style="list-style-type: none"> FPCD: Q4 2025 Data anticipated: >2027



ALXN1920 (kidney-targeted factor H fusion protein)

Nephrology

Trial	Population	Patients	Design	Endpoints	Status
Phase II AUTUMN NCT07157787	Primary membranous nephropathy (PMN)	30	<ul style="list-style-type: none">Randomised, double-blind, placebo-controlledALXN1920 SC infusionPlacebo SC infusion	<ul style="list-style-type: none">Primary Endpoint: Change From Baseline in Proteinuria Based on 24-hour UPCR at Week 26Secondary endpoints: Change From Baseline in Proteinuria Based on 24-hour UPCR, Change From Baseline in Proteinuria Based on Spot UPCR at Week 26, Change From Baseline in Serum Albumin at Week 26, Change From Baseline in Anti-phospholipase A2 Receptor (anti-PLA2R) Antibody Level at Week 26, Change From Baseline in Peripheral Cluster of Differentiation 20 (CD20+) B Cell Count at Week 4, Week 8, and Week 26, Change From Baseline biomarker level at Week 26	<ul style="list-style-type: none">FPCD: Q1 2026Data anticipated: H2 2027
Phase I ALXN1920-HV-101 NCT05751642	Healthy adults	48	<ul style="list-style-type: none">Randomised, double-blind, placebo-controlled SAD trial	<ul style="list-style-type: none">Primary endpoints: safety and tolerabilitySecondary endpoints: PK/PD parameters	<ul style="list-style-type: none">FPCD: Q2 2023LPCD: Q4 2023Data readout: Q2 2024



cevolisiran (ALXN2030, siRNA targeting complement C3)

Transplant

Trial	Population	Patients	Design	Endpoints	Status
Phase II CONCORD NCT06744647	Kidney transplant recipients with late active or chronic active antibody-mediated rejection (AMR)	45	<ul style="list-style-type: none">Randomised, controlled, double-blindcevolisiran Dose Acevolisiran Dose BPlacebo	<ul style="list-style-type: none">Primary endpoint: Biopsy-proven histologic resolution at 52 weeksSecondary endpoints: Biopsy-proven histologic resolution at 28 weeks, change from baseline in biopsy-proven histologic scores at 28 and 52 weeks, eGFR, TEAEs, PK measures	<ul style="list-style-type: none">FPCD: Q4 2025Data anticipated: H2 2027
Phase I ALXN2030-HV-101 NCT05501717	Healthy volunteers	48	<ul style="list-style-type: none">Randomised, placebo-controlled SAD trial	<ul style="list-style-type: none">Primary endpoint: safety	<ul style="list-style-type: none">FPCD: Q4 2022LPCD: Q2 2025Data anticipated: H2 2026



ALXN2230

Neurology and haematology

Trial	Population	Patients	Design	Endpoints	Status
Phase I NCT07352423	Healthy participants	48	<ul style="list-style-type: none">Randomised, double-blind, placebo controlled trialSingle ascending dose of ALXN2230	<ul style="list-style-type: none">Primary endpoint: Safety and tolerabilitySecondary endpoints: PK/PD	<ul style="list-style-type: none">FPCD: Q2 2026Data anticipated: H2 2027



ALXN2350 (AAV gene therapy)

BAG3-associated dilated cardiomyopathy (DCM)

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II DCMRestore NCT07218887	BAG3 mutation associated dilated cardiomyopathy	18	<ul style="list-style-type: none">Open-label, dose finding and dose expansion studyALXN2350 one of three doses as single IV infusion	<ul style="list-style-type: none">Primary endpoint: Part A TEAEs, SAEs up to week 78Secondary endpoints: Part B TEAEs, SAEs, cardiac events, time to first event of death, heart transplant, mechanical circulatory support or aborted sudden cardiac death, up to week 78	<ul style="list-style-type: none">FPCD: Q2 2026Data anticipated: H2 2027



AZD0120 (autologous anti-CD19 and anti-BCMA CAR-T)

AL amyloidosis

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II ALACRITY NCT07081646	Relapsed or Refractory AL Amyloidosis	91	<ul style="list-style-type: none">Open-label, multicentre, non-randomised trial	<ul style="list-style-type: none">Primary endpoint: % of pts achieving complete hematologic response (CR) through 6 monthsSecondary endpoints: % of patients achieving modified hematologic response (CR+VGPR+low dFLC response) through 6 months, MRD negativity through 6 months, OS, EFS	<ul style="list-style-type: none">FPCD: Q3 2025Data anticipated: >2027



AZD1390 (ATM inhibitor)

Solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase I NCT03423628	Recurrent glioblastoma eligible for re-irradiation, brain metastases and leptomeningeal disease, newly-diagnosed glioblastoma patients	180	<ul style="list-style-type: none">Open-label trialArm 1: recurrent GBM, AZD1390 + RT in dose escalation cohorts (Japan safety/PK cohorts added); optional food effectArm 3: primary GBM, AZD1390 + RT in dose escalation cohorts	<ul style="list-style-type: none">Primary endpoints: safety, tolerability and MTDSecondary endpoints: PK parameters and preliminary assessment of anti-tumour activity	<ul style="list-style-type: none">FPCD: Q2 2018Data anticipated: H2 2026



Glossary – 1 of 5

14C	Carbon 14
1L, 2L, 3L	1st-, 2nd- or 3rd-line
5-FU	5-fluorouracil
6MWT	6-minute walk test
A2AR	Adenosine A2A receptor
AAV	Adeno-associated virus
ACE	Angiotensin-converting enzyme
AChR+	Acetylcholine receptor-positive
ACQ	Asthma Control Questionnaire
ACR	American College of Rheumatology Response Scoring System
ActRII	Activin type II receptor
ADA	Anti-drug antibody
ADC	Antibody-drug conjugate
ADP	Adenosine diphosphate
ADsCa	Albumin-adjusted serum calcium
ADT	Androgen deprivation therapy
AE	Adverse event
AER	Annual exacerbation rate
AEs	Adverse events
AESI	Adverse event of special interest
AGA	Actionable genomic alteration
aHUS	Atypical haemolytic uraemic syndrome
AI	Aromatase inhibitor
AI	Auto-injector
AKT	Protein kinase B
AL amyloidosis	Light-chain amyloidosis
ALK	Anaplastic lymphoma kinase
ALL	Acute lymphocytic leukaemia
alloSCT	Allogeneic stem cell transplantation
ALSFRS-R	Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised
AMKD	APOL1-mediated kidney disease
AML	Acute myeloid leukaemia
AMR	Antibody mediated rejection
ANCA	Anti-neutrophil cytoplasmic antibody
anti-FRα	Anti-folate receptor alpha
anti-PCD	Anti-plasma cell dyscrasia
APFS	Accessorised pre-filled syringe
APOL1	Apolipoprotein L1
APOL1 G0/G1/G2	Sequences of the G0, G1, and G2 APOL1 variants from amino acids 339–398
AQLQ	Asthma Quality of Life Questionnaire
AQP4+	Aquaporin-4 antibody positive
ARB	Angiotensin receptor blockers
ARPI	Androgen receptor pathway inhibitor

AS	Albuterol sulfate
ASCO	American Society of Clinical Oncology
ASCVD	Atherosclerotic cardiovascular disease
ASI	Aldosterone synthase inhibitor
ASO	Antisense oligonucleotide
ATM	Ataxia telangiectasia mutated kinase
ATR	Ataxia telangiectasia and Rad3-related protein
ATTR	Transthyretin amyloidosis
ATTR-CM	Transthyretin amyloid cardiomyopathy
ATTR-PN	Transthyretin amyloid polyneuropathy
ATTRv-PN	Hereditary transthyretin-mediated amyloid polyneuropathy
AUC	Area under curve
AUC0-24	Area under the curve from 0 to 24 hours
AUC0-3	Area under the curve from 0 to 3 hours
AUC0-6	Area under the curve from 0 to 6 hours
AUCinf	Area under plasma concentration time curve from zero to infinity
AUClast	Area under plasma concentration curve from zero to the last quantifiable concentration
AUCt	Area under concentration-time curve
AUEC	Area under the effect-time curve
Avb8	Alpha v beta 8
B-ALL	B cell acute lymphoblastic leukaemia
B7H4	B7 homolog 4
BA	Bioavailability
BAFF	B-cell activating factor
BAG3	BCL2-associated athanogene 3
BBB	Blood-brain barrier
BCG	Bacillus Calmette-Guérin
BCL2	B-cell leukemia/lymphoma 2 protein
BCMA	B-cell maturation antigen
BCSS	Breathlessness, Cough and Sputum Scale
BD	Budesonide
BDA	Budesonide albuterol
BFF	Budesonide and formoterol fumarate
BGF	Budesonide, glycopyrronium and formoterol fumarate
BICLA	British Isles Lupus Assessment Group-based Composite Lupus Assessment
BICR	Blinded independent central review
BID	Twice per day
BIG	Big Ten Cancer Research Consortium
BM	Biomarker
BMD	Bone mineral density
BMTI	Bone metastasis-free interval
BMI	Body mass index
BOR	Best overall response rate

BR	Bendamustine and rituximab
BRCA	BReast CANcer gene
BRCAm	BReast CANcer gene-mutated
BRCAwt	BReast CANcer wild-type gene
BRD4	Bromodomain-containing protein 4
BTC	Biliary tract cancer
BTC	Biliary tract carcinoma
BTk	Bruton's tyrosine kinase
BTkI	Bruton's tyrosine kinase
BVAS	Birmingham Vasculitis Activity Score
C3	Complement component 3
C5	Complement component 5
CA-125	Cancer antigen-125
CAAT	Chronic Airways Assessment Test
CAD	Coronary artery disease
cAMR	Chronic antibody-medicated rejection
CAPOX	Capecitabine and oxaliplatin
CAR-T	Chimeric antigen receptor T-cell therapy
CAT	COPD Assessment Test
CBP	Cardiopulmonary bypass
CBR	Clinical benefit rate
CD	Cluster of differentiation
CD123	Interleukin 3 receptor a
CD19	Cluster of differentiation 19
CD20	Cluster of differentiation 20
CD3	Cluster of differentiation 3
CD39	Cluster of differentiation 39
CD73	Cluster of differentiation 73
CD8	Cluster of differentiation 8
CDAI	Clinical Disease Activity Index
CDK	Cyclin-dependent kinase
CDK2	Cyclin-dependent kinase 2
CDK4/6i	Cyclin-dependent kinase 4/6 inhibitor
CE	Clinically evaluable
CHD	Coronary heart disease
Chemo	Chemotherapy
CHF	Chronic heart failure
cHL	Classic Hodgkin lymphoma
CHOP	Cyclophosphamide, doxorubicin, vincristine and prednisone
CI	Confidence interval
CK	Creatine kinase
CKD	Chronic kidney disease
CLD	Chronic lung disease



Glossary – 2 of 5

[BACK](#)
[NEXT](#)

CLDN18.2	Claudin 18.2
CLL	Chronic lymphocytic leukaemia
CM	Cardiomyopathy
cm	Centimetre
CMAx	Maximum observed plasma concentration
cMET	C-mesenchymal epithelial transition factor
CMML	Chronic myelomonocytic leukaemia
CNS	Central nervous system
CNS-PFS	Central nervous system progression-free survival
CompEx	Composite endpoint for exacerbations
COPD	Chronic obstructive pulmonary disease
CPB	Cardiopulmonary bypass
CPI	Checkpoint inhibitor
CPI-experienced	Checkpoint inhibitor-experienced
CPI-naïve	Checkpoint inhibitor-naïve
cPR	Central pathological review
CPS	Combined positive score
CR	Complete response
CRC	Colorectal cancer
CrCl	Creatinine clearance
CRR	Complete renal response
CRR	Complete response rate
CRSwNP	Chronic rhinosinusitis with nasal polyps
CRT	Chemoradiotherapy
CRwNP	Chronic rhinosinusitis with nasal polyps
CSA-AKI	Cardiac surgery-associated acute kidney injury
CSPC	Castration-sensitive prostate cancer
CTC	Circulating tumour cell
CTCAE	Common Terminology Criteria for Adverse Events
ctDNA	Circulating tumor DNA
CTLA-4	Cytotoxic T-lymphocyte-associated antigen-4
CTLA4	Cytotoxic T-lymphocyte associated protein 4
CTx	Chemotherapy
CV	Cardiovascular
CVOT	Cardiovascular outcomes trial
CVRM	Cardiovascular, Renal and Metabolism
CXCR2	C-X-C Motif chemokine receptor 2
CyBorD	Cyclophosphamide, bortezomib and dexamethasone
D2T RA	Difficult-to-treat rheumatoid arthritis
DAS28-CRP	Disease Activity Score in 28 joints using C-reactive protein
Dato-DXd	Datopotamab deruxtecan
DCM	Dilated cardiomyopathy
DCR	Disease control rate

DDFS	Distant disease-free survival
DDI	Drug-drug Interaction
DDR	DNA damage response
dECG	Differentiated electrocardiogram
DFS	Disease-free survival
DGF	Delayed graft function
DLBCL	Diffuse large B-cell lymphoma
DLT	Dose-limiting toxicity
DMARDs	Disease-modifying antirheumatic drugs
DNA	Deoxyribonucleic acid
dNCC	Directly measured non-ceruloplasmin-bound copper
dnTGFb	Dominant-negative transforming growth factor-beta
DoCR	Durability of complete response
DoR	Duration of response
DPB	Disease progression in bone
DPI	Dry powder inhaler
dPTEN	Phosphatase and tensin homolog deficient
DRFI	Disease recurrence-free interval
DRR	Disease response rate
DSQ	Dysphagia Symptom Questionnaire
DXA	Dual energy X-ray absorptiometry
E-RS: COPD	Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease
eBC	Early breast cancer
EBRT	External beam radiation therapy
ECG	Electrocardiogram
ED	Emergency department
EFS	Event-free survival
EG	Eosinophilic gastritis
EGE	Eosinophilic gastroenteritis
eGFR	Estimated glomerular filtration rate
EGFRi	Epidermal growth factor receptor inhibitor
EGFRm	Epidermal growth factor receptor-mutated
EGPA	Eosinophilic granulomatosis with polyangiitis
ELF	Enhanced Liver Fibrosis
EM	Emerging Markets
EoE	Eosinophilic oesophagitis
EOS	Eosinophil
EPI	Epigenetics
ER	Estrogen receptor
ER+	Estrogen receptor-positive
ERK	Extracellular signal-regulated kinase
ERT	Enzyme replacement therapy
ESAI	Eczema Area and Severity Index

ESCC	Esophageal squamous cell carcinoma
ESKD	End-stage kidney disease
ESR1	Estrogen receptor 1
ESRD	End-stage renal disease
ET	Endocrine therapy
ETA	Endothelin A
ETA RA	Endothelin receptor A antagonist
EU	European Union
EVH	Extravascular haemolysis
FAF	Fundus autofluorescence
FCDP	Fixed-dose combination product
FCR	Fludarabine, cyclophosphamide and rituximab
FDC	Fixed-dose combination
FeNO	Fractional nitric oxide concentration in exhaled breath
FEV	Forced-expiratory volume
FEV1	Forced expiratory volume in 1 second
FGFR	Fibroblast growth factor receptor
FL	Follicular lymphoma
FLAP	5-lipoxygenase activating protein
FLOT	Fluorouracil, leucovorin, oxaliplatin and docetaxel
FOLFIRI	Folinic acid, fluorouracil and irinotecan
FOLFOX	Folinic acid, fluorouracil and oxaliplatin
FOXP3	Forkhead box P3
FP	5-fluorouracil/cisplatin
FPCD	First patient commenced dosing
FPG	Fasting plasma glucose
FRα	Folate receptor alpha
FVC	Forced vital capacity
GA	Geographic atrophy
GBM	Glioblastoma
gBRCAm	Germline BRCA-mutated
GC	Gastric cancer
GCB	Germinal center B-cell
GEJ	Gastric/gastroesophageal junction
GEJC	Gastroesophageal junction cancer
GFF	Glycopyrronium and formoterol fumarate
GI	Gastrointestinal
GLP-1	Glucagon-like peptide-1
GLP-1/glu	Glucagon-like peptide 1 receptor/glucagon dual peptide agonist
GLP-1RA	Glucagon-like peptide 1 receptor agonist
GMFR	Geometric mean fold rise
gMG	Generalised myasthenia gravis
GMT	Geometric mean titer



Glossary – 3 of 5

BACK

NEXT

GN	Glomerulonephritis
GPC3	Glypican-3
GPC3-positive	Glypican 3-positive
GPCR5D	G protein-coupled receptor, class C, group 5, member D
GU	Genitourinary
GYN	Gynaecologic
H1	H1-antihistamine
hADME	Human mass balance
HbA1c	Glycated haemoglobin
HCC	Hepatocellular carcinoma
HD	High dose
HDL-C	High-density lipoprotein cholesterol
HER2	Human epidermal growth factor receptor 2
HER2-low	Human epidermal growth factor receptor 2-low
HER2-negative	Human epidermal growth factor receptor 2-negative
HER2-positive	Human epidermal growth factor receptor 2-positive
HES	Hyper eosinophilic syndrome
HF	Heart failure
HFA	Hydrofluoroalkane
HFO	Hydrofluoro-olefins
HFpEF	Heart failure with preserved ejection fraction
HFrEF	Heart failure with reduced ejection fraction
HGFR	Met/hepatocyte growth factor receptor
HGSC	High-grade serous carcinoma
hHF	Hospitalisation for heart failure
HIF-PH	Hypoxia inducible factor-prolyl hydroxylase
HK	Hyperkalaemia
HLA-A*02:01	Human leukocyte antigen serotype within the HLA-A serotype group
HLR	High-level results
hMPV	Human metapneumovirus
HNSCC	Head and neck squamous-cell carcinoma
HPD	Hyperprogressive disease
HPDD	Highest protocol-defined dose
HPF	High-power field
HPP	Hypophosphatasia
HR	Hazard ratio
HR+	Hormone receptor-positive
HR-low	Hormone receptor-low
HRD	Homologous recombination deficiency
HRD+	Homologous recombination deficiency-positive
HRQoL	Health-related quality of life
HRR	homologous recombination repair
HRRm	Homologous recombination repair-mutated

HSCT-TMA	hematopoietic stem cell transplantation-associated thrombotic microangiopathy
HSD17B13	Hydroxysteroid 17-beta dehydrogenase 13
HVPG	Hepatic venous pressure gradient
i	Inhibitor
i.m.	Intramuscular
i.v.	Intravenous
IA	Investigator-assessed
IBD	Inflammatory bowel disease
ICR	Independent central review
ICS	Inhaled corticosteroid
ICS-LABA	Inhaled corticosteroid long-acting beta-agonists
ICU	Intensive care unit
IDFS	Invasive disease-free survival
IgAN	Immunoglobulin A nephropathy
IHC	Immunohistochemistry
IHF	Impaired hepatic function
IIM	Idiopathic inflammatory myopathies
IIT	Investigated initiated trial
iJAK1	Inhaled Janus kinase
IL	Interleukin
IL-12	Interleukin-12
IL-33	Interleukin-33
IL-5	Interleukin-5
IL-5R	Interleukin-5 receptor
IMAC-TIS	International Myositis Assessment And Clinical Studies-Total Improvement Score
IND	Investigational new drug
INV	Investigator review
IO	Immuno-oncology
IPF	Idiopathic pulmonary fibrosis
IPFS	Invasive progression-free survival
IRA	Inflation Reduction Act
IRAK4	Interleukin-1 receptor-associated kinase 4
IRC	Independent review committee
ISS	Investigator-sponsored studies
ISS7	Itch-severity score (weekly)
iTSLP	Inhaled thymic stromal lymphopoietin
ITT	Intent-to-treat
IVIg	Intravenous immunoglobulin
JAK-1	Janus kinase 1
K+	Potassium
KCCQ	Kansas City Cardiomyopathy Questionnaire
kg	Kilogram
Ki67	Antigen Ki67

LA amylin	Long-acting amylin
LAAB	Long-acting antibody
LABA	Long-acting beta agonist
LAMA	Long-acting muscarinic agonist
LAMA/LABA/ICS	Long-acting muscarinic antagonist/long-acting beta agonist/inhaled corticosteroid
LCAT	Lecithin-cholesterol acyltransferase
LCM	Lifecycle management
LDH	Lactate dehydrogenase
LDL-C	Low-density lipoprotein cholesterol
LICA	Ligand-conjugated ASO
LIF	Low-density lipoprotein cholesterol
LN	Lupus nephritis
LOS	Length of stay
LPCD	Last patient commenced dosing
LRTD	Lower respiratory tract disease
LS-SCLC	Limited stage small-cell lung cancer
LSD	Last subject dosed
LV	Left ventricle
m	Mutation
mAb	Monoclonal antibody
MABA	Muscarinic antagonist-beta2 agonist
MACE	Major adverse cardiac events
MAD	Multiple ascending dose
MAKE	Major adverse kidney events
MASH	Metabolic dysfunction-associated steatohepatitis
MASLD	Metabolic dysfunction-associated steatotic liver disease
mBC	Metastatic breast cancer
MCC	Mucociliary clearance
MCL	Mantle cell lymphoma
mCRPC	Metastatic castrate-resistant prostate cancer
MDI	Metered-dose inhaler
mDOR	Median duration of response
MDS	Myelodysplastic syndrome
MEK	Mitogen-activated protein kinase
MET	Mesenchymal epithelial transition factor
mFOLFOX	Modified folinic acid, fluorouracil and oxaliplatin
mg	Milligram
MG	Myasthenia gravis
MG-ADL	Myasthenia Gravis-Activities of Daily Living
mg/dL	Milligrams per decilitre
MGFA	Myasthenia Gravis Foundation of America
mHSPC	Metastatic hormone sensitive prostate cancer
MI	Myocardial infarction

Glossary – 4 of 5

[BACK](#)[NEXT](#)

mL	Millilitre
MM	Multiple myeloma
MMAE	Monomethyl auristatin E
MMT	Mixed meal test
mNIS+7	Modified Neuropathy Impairment Score +7
mNSCLC	Metastatic non-small cell lung cancer
MoA	Mechanism of action
mPFS	Median progression-free survival
MPO	Myeloperoxidase
mPR	Major pathological response
MR	Mineralocorticoid receptor
MRA	Mineralocorticoid receptor antagonist
MRD	Minimal residual disease
MRD-negative	Minimal residual disease-negative
MRI	Magnetic resonance imaging
MRM	Mineralocorticoid receptor modulator
mRNA	Messenger ribonucleic acid
MSA	Multiple system atrophy
MTAP-deficient	Methylthioadenosine phosphorylase-deficient
MTD	Maximum tolerated dose
mTNBC	Metastatic triple-negative breast cancer
MZL	Marginal zone lymphoma
nAb	Neutralising antibody
NaC	Sodium channel
NAFLD	Non-alcoholic fatty liver disease
NASH	Non-alcoholic fatty liver disease
NCFB	Non-cystic fibrosis bronchiectasis
NCI	National Cancer Institute
NCPV	Noncalcified plaque volume
Neo-adj	Neoadjuvant
NF1	Neurofibromatosis type 1
NF1-PN	Neurofibromatosis type 1 with plexiform neurofibromas
ng	Next-generation
NGF	Nerve growth factor
NGP	Next-generation propellant
ngSERD	Next-generation oral selective estrogen receptor degrader
NHA	Novel hormonal agent
NHL	Non-Hodgkin's lymphoma
NIH	National Institute of Health
NKTCL	Extranodal natural killer T-cell lymphoma
NLRP3	NLR family pyrin domain-containing protein 3
NME	New molecular entity
NMOSD	Neuromyelitis optica spectrum disorder

NMR+	Normalised membrane ratio-positive
NNMT	Nicotinamide N-methyltransferase
NP	Nasal polyps
NSCLC	Non-small cell lung cancer
NSQ	Non-squamous
NST	Neoadjuvant systemic treatment
NT-proBNP	N-terminal pro-B-type natriuretic peptide
NYHA	New York Heart Association
OBID	Optimal biological dose
OCS	Oral corticosteroid
OD	Once daily
oGLP1	Oral glucagon-like receptor peptide 1
OGTT	Oral glucose tolerance test
oPCSK9	Oral protein convertase subtilisin/kexin type 9
OR	Objective response
ORR	Overall response rate
oRXFP1	Oral relaxin family peptide receptor 1
OS	Overall survival
PA	Primary aldosteronism
PALB2m	Partner and localizer of BRCA2-mutated
PAPPA-1	Pregnancy-associated plasma protein-A1
PAR2	Protease-activated receptor 2
PARP	Poly ADP ribose polymerase
PARP-1sel	Poly ADP ribose polymerase-1 selective
PARP1	poly(ADP-ribose) polymerase-1
PARPi	poly-ADP ribose polymerase inhibitor
PASI	Psoriasis area severity index
PBD	Pyrrolobenzodiazepine
PCD	Plasma cell dyscrasia
pCR	Pathological complete response
PCSK9	Proprotein convertase subtilisin/kexin type 9
PCWG3	Prostate Cancer Clinical Trials Working Group 3
PD	Pharmacodynamics
PD-1	Programmed cell death protein-1
PD-L1	Programmed death-ligand 1
PD-L1-high	Programmed death-ligand 1-high
PD1	Programmed cell death protein 1
PDAC	Pancreatic ductal adenocarcinoma
PDE4	Phosphodiesterase type 4
Peak	Maximum
PET	Positron-emission tomography
PFS	Progression-free survival
PFS2	Time to second disease progression or death

PFS6	Progression-free survival at 6 months
PgR	Progesterone receptor
PI3K	Phosphoinositide 3 kinase
PIK3CA	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit
PK	Pharmacokinetic
PK/PD	Pharmacokinetic/pharmacodynamic
PLEX	Plasma exchange
PLL	Prolymphocytic leukaemia
PLN	Phospholamban
pMDI	Pressurised metered-dose inhaler
PMN	Primary membranous nephropathy
PN	Plexiform neurofibroma
PN	Polyneuropathy
PNH	Paroxysmal nocturnal haemoglobinuria
PNH-EVH	PNH with extravascular haemolysis
PNPLA3	Phospholipase domain-containing protein 3
POC	Proof-of-concept
POLO	DNA polymerase theta
POM	Proof-of-mechanism
post-BD	Post-bronchodilator
PP	Plasmapheresis
pPCI	Primary percutaneous coronary intervention
PR	Partial response
pre-BD	Pre-bronchodilator
PRMT5	Protein arginine methyltransferase 5
PRO	Patient reported outcome
PROTAC	Proteolysis-targeting chimera
PRR	Recurrent platinum resistant
PS	Propensity score
PSA	Prostate-specific antigen
PSA50	Prostate-specific antigen 50
PSA90	Prostate-specific antigen decline of ≥90%
PSC	Pulmonary sarcomatoid carcinoma
PSMA	Prostate-specific membrane antigen
PSR	Platinum-sensitive relapsed
PTCL	Peripheral T-cell lymphoma
PTEN	Phosphatase and tensin homolog gene
PTH	Parathyroid hormone
PVR	Pulmonary vascular resistance
Q1W	Every one week
Q2W	Every two weeks
Q4W	Every four weeks
Q8W	Every eight weeks

Glossary – 5 of 5

[BACK](#)

QCS	Quantitative continuous scoring
QD	Once daily
QID	Four times per day
QOD	Every other day
QoL	Quality of life
QoL-DN	Norfolk Quality of Life-Diabetic Neuropathy
QT	Duration of ventricular electrical systole
QTcF	Corrected QT interval by Fredericia
R&I	Respiratory and Immunology
r-CRISS	Revised Combined Response Index in Systemic Sclerosis
R/R	Relapsed/refractory
r/r	Relapsed/refractory
RA	Rheumatoid arthritis
RAAS	Renin-angiotensin-aldosterone system
RAGE	Receptor for advanced glycation end products
RC	Radioconjugates
RCL	Replication-competent lentivirus
RECIST	Response Evaluation Criteria in Solid Tumours
REiNS	Response Evaluation in Neurofibromatosis and Schwannomatosis
RET	Rearranged during transfection
RFS	Relapse-free survival
RGI-C	Radiographic Global Impression of Change
rhLCAT	Recombinant human lecithin-cholesterol acyltransferase
RMS	Relapsing multiple sclerosis
rNDV	Recombinant Newcastle disease virus
RORγ	Related orphan receptor gamma
RP2D	Recommended Phase II dose
rPFS	Radiographic progression-free survival
RR	Response rate
RSV	Respiratory syncytial virus
RT	Radiation therapy
S-1	Tegafur, gimeracil and oteracil
s. asthma	Severe asthma
s.c.	Subcutaneous
SABA	Short-acting beta2-agonist
SAD	Single ascending dose
SAE	Serious adverse event
SARS-CoV-2	Severe-acute-respiratory-syndrome-related coronavirus-19
SBP	Systolic blood pressure
SBRT	Stereotactic body radiation therapy
SCCHN	Squamous-cell carcinoma of the head and neck
SCD	Sickle cell disease
SCLC	Small cell lung cancer

SD	Stable disease
SERD	Selective estrogen receptor degrader
SES-CD	Simple Endoscopic Score for Crohn's Disease
SGLT2	Sodium-glucose transport protein 2
SGLT2i	Sodium/glucose cotransporter 2 inhibitor
SGRM	Selective glucocorticoid receptor modulator
SGRQ	Saint George Respiratory Questionnaire
siRNA	Small interfering ribonucleic acid
SJC	Swollen joint count
sK	Serum potassium
SLE	Systemic lupus erythematosus
SLE/LN	Systemic lupus erythematosus/lupus nephritis
SLL	Small lymphocytic lymphoma
SMAD	Single and multiple ascending dose trial
SoC	Standard-of-care
sPGA	Static Physician's Global Assessment Score
SRI-4	Systemic Lupus Erythematosus Responder Index-4
SS	Steady state
SSc	Systemic sclerosis
SSE-FS	Symptomatic skeletal event-free survival
ST2	Suppression of tumorigenicity 2
STAT3	Signal transducer and activator of transcription 3
STEAP2	Six-transmembrane epithelial antigen of the prostate 2
Stg. I/II/III	Stage I/II/III
STP	Single therapy product
sUA	Serum uric acid
T2D	Type-2 diabetes
T2DM	Type-2 diabetes mellitus
T300	Imfinzi plus Imjudo
T790M	Threonine 790 substitution with methionine
TACE	Transarterial chemoembolization
tBRCAm	Tumour (somatic) BRCA-mutated
TC	Tumour cell
TCE	T-cell engager
TCR	T-cell receptor
TCR-T	T-cell receptor therapy
TDR	Tumour drivers and resistance
TDT	Time to discontinuation of treatment
TEAE	Treatment-emergent adverse event
TESAE	Treatment-emergent serious adverse event
TFST	Time to first subsequent therapy or death
TGFβRIIDN	Transforming growth factor-beta RIIDN
THP	Paclitaxel, trastuzumab and pertuzumab

TID	Three times per day
TIGIT	T-cell immunoreceptor with Ig and ITIM domains
TIM-3	T-cell immunoglobulin and mucin domain-containing protein
TIM3	T-cell immunoglobulin and mucin domain 3
TIS	Total Improvement Score
TJC	Tender joint count
TKI	Tyrosine kinase Inhibitor
Tlast	Time of last quantifiable concentration
TLR	Toll-like receptor 9
TMA	Thrombotic microangiopathy
Tmax	Time to reach maximum observed plasma concentration
TNBC	Triple negative breast cancer
TNF	Tumour necrosis factor
TNFi	Tumour necrosis factor inhibitor
TNSALP	Tissue-nonspecific alkaline phosphatase
TOP1i	Topoisomerase 1 inhibitor
TP53	Tumour protein 53
TP53 R175H	Tumour protein p53 with arginine at position 175 is replaced with histidine
TPS	Tumour proportion score
Treg	Regulatory T-cell
TROP2	Trophoblast cell surface antigen 2
TSLP	Thymic stromal lymphopoietin
TSST	Time to second subsequent therapy
TTD	Time to treatment discontinuation
TTf	Time to treatment failure
TTNT	Time to next therapy
TTP	Time to tumour progression
TTR	Time to treatment response
TTR	Transthyretin
u-LTE4	Urinary leukotriene E4
u/r HTN	Uncontrolled or treatment resistant hypertension
UACR	Urinary albumin/creatinine ratio
UEC	Universal effector cell
UK	United Kingdom
ULN	Upper limit of normal
UMEC	Umedidinium
UPCR	Urine protein creatinine ratio
URAT1	Uric acid transporter 1
US	United States
VEGF	Vascular endothelial growth factor
VHH	Single domain antibody
VLP	Virus-like particle
XELOX	Oxaliplatin and capecitabine